10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from             to             

Commission file number 001-08895

Healthpeak Properties, Inc.

(Exact name of registrant as specified in its charter)

Maryland	33-0091377
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

5050 South Syracuse Street, Suite 800

Denver, CO 80237

(Address of principal executive offices) (Zip Code)

(720) 428-5050

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	PEAK	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

As of August 1, 2022, there were 539,581,438 shares of the registrant’s $1.00 par value common stock outstanding.

HEALTHPEAK PROPERTIES, INC.

INDEX

PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited):	3
	Consolidated Balance Sheets	3
	Consolidated Statements of Operations	4
	Consolidated Statements of Comprehensive Income (Loss)	5
	Consolidated Statements of Equity and Redeemable Noncontrolling Interests	6
	Consolidated Statements of Cash Flows	8
	Notes to the Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	61
Item 4.	Controls and Procedures	62
PART II. OTHER INFORMATION
Item 1A.	Risk Factors	63
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	63
Item 5.	Other Information	63
Item 6.	Exhibits	65
Signatures		66

2

PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited)

Healthpeak Properties, Inc.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

	June 30, 2022		December 31, 2021
ASSETS
Real estate:
Buildings and improvements	$	12,590,403	$	12,025,271
Development costs and construction in progress	675,713		877,423
Land	2,705,260		2,603,964
Accumulated depreciation and amortization	(3,097,748)		(2,839,229)
Net real estate	12,873,628		12,667,429
Net investment in direct financing leases	—		44,706
Loans receivable, net of reserves of $2,015 and $1,813	413,962		415,811
Investments in and advances to unconsolidated joint ventures	402,154		403,634
Accounts receivable, net of allowance of $2,122 and $1,870	47,340		48,691
Cash and cash equivalents	73,013		158,287
Restricted cash	54,815		53,454
Intangible assets, net	470,865		519,760
Assets held for sale and discontinued operations, net	66,647		37,190
Right-of-use asset, net	233,391		233,942
Other assets, net	682,388		674,615
Total assets	$	15,318,203	$	15,257,519
LIABILITIES AND EQUITY
Bank line of credit and commercial paper	$	1,448,569	$	1,165,975
Senior unsecured notes	4,655,852		4,651,933
Mortgage debt	349,329		352,081
Intangible liabilities, net	169,622		177,232
Liabilities related to assets held for sale and discontinued operations, net	15,869		15,056
Lease liability	201,124		204,547
Accounts payable, accrued liabilities, and other liabilities	706,819		755,384
Deferred revenue	814,754		789,207
Total liabilities	8,361,938		8,111,415
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	115,877		87,344
Common stock, $1.00 par value: 750,000,000 shares authorized; 539,580,161 and 539,096,879 shares issued and outstanding	539,580		539,097
Additional paid-in capital	10,073,712		10,100,294
Cumulative dividends in excess of earnings	(4,306,762)		(4,120,774)
Accumulated other comprehensive income (loss)	(1,318)		(3,147)
Total stockholders’ equity	6,305,212		6,515,470
Joint venture partners	334,120		342,234
Non-managing member unitholders	201,056		201,056
Total noncontrolling interests	535,176		543,290
Total equity	6,840,388		7,058,760
Total liabilities and equity	$	15,318,203	$	15,257,519

See accompanying Notes to the Unaudited Consolidated Financial Statements.

3

Healthpeak Properties, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues:
Rental and related revenues	$	387,079	$	340,642	$	757,229	$	668,614
Resident fees and services	125,360		117,308		246,920		233,436
Income from direct financing leases	—		2,180		1,168		4,343
Interest income	5,493		16,108		10,987		25,121
Total revenues	517,932		476,238		1,016,304		931,514
Costs and expenses:
Interest expense	41,867		38,681		79,453		85,524
Depreciation and amortization	180,489		171,459		358,222		328,997
Operating	215,044		190,132		422,291		371,893
General and administrative	24,781		24,088		48,612		48,990
Transaction costs	612		619		908		1,417
Impairments and loan loss reserves (recoveries), net	139		931		271		4,173
Total costs and expenses	462,932		425,910		909,757		840,994
Other income (expense):
Gain (loss) on sales of real estate, net	10,340		175,238		14,196		175,238
Gain (loss) on debt extinguishments	—		(60,865)		—		(225,157)
Other income (expense), net	2,861		1,734		21,177		3,934
Total other income (expense), net	13,201		116,107		35,373		(45,985)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	68,201		166,435		141,920		44,535
Income tax benefit (expense)	718		763		(59)		755
Equity income (loss) from unconsolidated joint ventures	382		867		2,466		2,190
Income (loss) from continuing operations	69,301		168,065		144,327		47,480
Income (loss) from discontinued operations	2,992		113,960		3,309		383,968
Net income (loss)	72,293		282,025		147,636		431,448
Noncontrolling interests’ share in continuing operations	(3,955)		(3,535)		(7,685)		(6,841)
Noncontrolling interests’ share in discontinued operations	—		(2,210)		—		(2,539)
Net income (loss) attributable to Healthpeak Properties, Inc.	68,338		276,280		139,951		422,068
Participating securities’ share in earnings	(281)		(287)		(2,258)		(2,732)
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Basic earnings (loss) per common share:
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78
Diluted earnings (loss) per common share:
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78
Weighted average shares outstanding:
Basic	539,558		538,929		539,456		538,805
Diluted	539,815		544,694		539,701		539,081

See accompanying Notes to the Unaudited Consolidated Financial Statements.

4

Healthpeak Properties, Inc.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net income (loss)	$	72,293	$	282,025	$	147,636	$	431,448
Other comprehensive income (loss):
Net unrealized gains (losses) on derivatives	1,629		—		1,629		332
Change in Supplemental Executive Retirement Plan obligation and other	100		108		200		215
Reclassification adjustment realized in net income (loss)	—		—		—		(251)
Total other comprehensive income (loss)	1,729		108		1,829		296
Total comprehensive income (loss)	74,022		282,133		149,465		431,744
Total comprehensive (income) loss attributable to noncontrolling interests’ share in continuing operations	(3,955)		(3,535)		(7,685)		(6,841)
Total comprehensive (income) loss attributable to noncontrolling interests’ share in discontinued operations	—		(2,210)		—		(2,539)
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.	$	70,067	$	276,388	$	141,780	$	422,364

See accompanying Notes to the Unaudited Consolidated Financial Statements.

5

Healthpeak Properties, Inc.

CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS

(In thousands, except per share data)

(Unaudited)

For the three months ended June 30, 2022:

	Common Stock			Additional Paid-In Capital		Cumulative Dividends In Excess Of Earnings		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Total Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests
	Shares	Amount
April 1, 2022	539,524	$	539,524	$	10,084,687	$	(4,212,941)	$	(3,047)	$	6,408,223	$	539,499	$	6,947,722	$	97,890
Net income (loss)	—	—		—		68,338		—		68,338		3,942		72,280		13
Other comprehensive income (loss)	—	—		—		—		1,729		1,729		—		1,729		—
Issuance of common stock, net	65	65		262		—		—		327		—		327		—
Repurchase of common stock	(9)	(9)		(254)		—		—		(263)		—		(263)		—
Amortization of stock-based compensation	—	—		6,721		—		—		6,721		—		6,721		—
Common dividends ($0.30 per share)	—	—		—		(162,159)		—		(162,159)		—		(162,159)		—
Distributions to noncontrolling interests	—	—		—		—		—		—		(8,265)		(8,265)		(85)
Contributions from noncontrolling interests	—	—		—		—		—		—		—		—		355
Adjustments to redemption value of redeemable noncontrolling interests	—	—		(17,704)		—		—		(17,704)		—		(17,704)		17,704
June 30, 2022	539,580	$	539,580	$	10,073,712	$	(4,306,762)	$	(1,318)	$	6,305,212	$	535,176	$	6,840,388	$	115,877

For the three months ended June 30, 2021:

	Common Stock			Additional Paid-In Capital		Cumulative Dividends In Excess Of Earnings		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Total Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests
	Shares	Amount
April 1, 2021	538,886	$	538,886	$	10,148,168	$	(3,994,562)	$	(3,497)	$	6,688,995	$	552,144	$	7,241,139	$	78,413
Net income (loss)	—	—		—		276,280		—		276,280		5,745		282,025		—
Other comprehensive income (loss)	—	—		—		—		108		108		—		108		—
Issuance of common stock, net	75	75		(118)		—		—		(43)		—		(43)		—
Repurchase of common stock	(10)	(10)		(305)		—		—		(315)		—		(315)		—
Exercise of stock options	4	4		122		—		—		126		—		126		—
Amortization of stock-based compensation	—	—		6,144		—		—		6,144		—		6,144		—
Common dividends ($0.30 per share)	—	—		—		(161,971)		—		(161,971)		—		(161,971)		—
Distributions to noncontrolling interests	—	—		—		—		—		—		(8,957)		(8,957)		—
Purchase of noncontrolling interests	—	—		(5)		—		—		(5)		(65)		(70)		—
Contributions from noncontrolling interests	—	—		—		—		—		—		—		—		178
Adjustments to redemption value of redeemable noncontrolling interests	—	—		(6,776)		—		—		(6,776)		—		(6,776)		6,776
June 30, 2021	538,955	$	538,955	$	10,147,230	$	(3,880,253)	$	(3,389)	$	6,802,543	$	548,867	$	7,351,410	$	85,367

6

For the six months ended June 30, 2022:

	Common Stock			Additional Paid-In Capital		Cumulative Dividends In Excess Of Earnings		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Total Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests
	Shares	Amount
January 1, 2022	539,097	$	539,097	$	10,100,294	$	(4,120,774)	$	(3,147)	$	6,515,470	$	543,290	$	7,058,760	$	87,344
Net income (loss)	—	—		—		139,951		—		139,951		7,660		147,611		25
Other comprehensive income (loss)	—	—		—		—		1,829		1,829		—		1,829		—
Issuance of common stock, net	831	831		(175)		—		—		656		—		656		—
Repurchase of common stock	(348)	(348)		(11,267)		—		—		(11,615)		—		(11,615)		—
Amortization of stock-based compensation	—	—		12,865		—		—		12,865		—		12,865		—
Common dividends ($0.60 per share)	—	—		—		(325,939)		—		(325,939)		—		(325,939)		—
Distributions to noncontrolling interests	—	—		—		—		—		—		(15,774)		(15,774)		(85)
Contributions from noncontrolling interests	—	—		—		—		—		—		—		—		588
Adjustments to redemption value of redeemable noncontrolling interests	—	—		(28,005)		—		—		(28,005)		—		(28,005)		28,005
June 30, 2022	539,580	$	539,580	$	10,073,712	$	(4,306,762)	$	(1,318)	$	6,305,212	$	535,176	$	6,840,388	$	115,877

For the six months ended June 30, 2021:

	Common Stock			Additional Paid-In Capital		Cumulative Dividends In Excess Of Earnings		Accumulated Other Comprehensive Income (Loss)		Total Stockholders’ Equity		Total Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests
	Shares	Amount
January 1, 2021	538,405	$	538,405	$	10,175,235	$	(3,976,232)	$	(3,685)	$	6,733,723	$	556,227	$	7,289,950	$	57,396
Net income (loss)	—	—		—		422,068		—		422,068		9,380		431,448		—
Other comprehensive income (loss)	—	—		—		—		296		296		—		296		—
Issuance of common stock, net	954	954		90		—		—		1,044		—		1,044		—
Repurchase of common stock	(408)	(408)		(12,072)		—		—		(12,480)		—		(12,480)		—
Exercise of stock options	4	4		122		—		—		126		—		126		—
Amortization of stock-based compensation	—	—		11,557		—		—		11,557		—		11,557		—
Common dividends ($0.60 per share)	—	—		—		(326,089)		—		(326,089)		—		(326,089)		—
Distributions to noncontrolling interests	—	—		—		—		—		—		(16,675)		(16,675)		(52)
Purchase of noncontrolling interests	—	—		(5)		—		—		(5)		(65)		(70)		—
Contributions from noncontrolling interests	—	—		—		—		—		—		—		—		326
Adjustments to redemption value of redeemable noncontrolling interests	—	—		(27,697)		—		—		(27,697)		—		(27,697)		27,697
June 30, 2021	538,955	$	538,955	$	10,147,230	$	(3,880,253)	$	(3,389)	$	6,802,543	$	548,867	$	7,351,410	$	85,367

_______________________________________

See accompanying Notes to the Unaudited Consolidated Financial Statements.

7

Healthpeak Properties, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended June 30,
	2022		2021
Cash flows from operating activities:
Net income (loss)	$	147,636	$	431,448
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of real estate, in-place lease, and other intangibles	358,222		328,997
Amortization of stock-based compensation	10,021		9,459
Amortization of deferred financing costs	5,377		4,334
Straight-line rents	(23,872)		(15,336)
Amortization of nonrefundable entrance fees and above/below market lease intangibles	(50,054)		(45,842)
Equity loss (income) from unconsolidated joint ventures	(2,530)		(7,100)
Distributions of earnings from unconsolidated joint ventures	476		4,015
Loss (gain) on sale of real estate under direct financing leases	(22,693)		—
Deferred income tax expense (benefit)	(1,038)		(2,538)
Impairments and loan loss reserves (recoveries), net	271		15,168
Loss (gain) on debt extinguishments	—		225,157
Loss (gain) on sales of real estate, net	(16,688)		(557,138)
Loss (gain) upon change of control, net	—		(1,042)
Casualty-related loss (recoveries), net	78		1,061
Other non-cash items	(1,187)		(8,057)
Changes in:
Decrease (increase) in accounts receivable and other assets, net	10,714		32,928
Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue	34,935		(55,920)
Net cash provided by (used in) operating activities	449,668		359,594
Cash flows from investing activities:
Acquisitions of real estate	(159,206)		(498,142)
Development, redevelopment, and other major improvements of real estate	(366,404)		(281,829)
Leasing costs, tenant improvements, and recurring capital expenditures	(50,745)		(43,132)
Proceeds from sales of real estate, net	37,719		2,253,889
Contributions to unconsolidated joint ventures	(1,971)		(10,168)
Distributions in excess of earnings from unconsolidated joint ventures	5,496		34,586
Proceeds from sales/principal repayments on loans receivable and direct financing leases	77,685		265,934
Investments in loans receivable and other	(3,710)		(8,842)
Net cash provided by (used in) investing activities	(461,136)		1,712,296
Cash flows from financing activities:
Borrowings under bank line of credit and commercial paper	8,242,327		8,177,450
Repayments under bank line of credit and commercial paper	(7,959,733)		(7,587,040)
Issuance and borrowings of debt, excluding bank line of credit and commercial paper	—		142,100
Repayments and repurchase of debt, excluding bank line of credit and commercial paper	(2,507)		(2,170,170)
Payments for debt extinguishment and deferred financing costs	—		(217,468)
Issuance of common stock and exercise of options, net of offering costs	(7)		1,170
Repurchase of common stock	(11,615)		(12,480)
Dividends paid on common stock	(325,276)		(326,089)
Distributions to and purchase of noncontrolling interests	(15,859)		(16,745)
Contributions from and issuance of noncontrolling interests	588		—
Net cash provided by (used in) financing activities	(72,082)		(2,009,272)
Net increase (decrease) in cash, cash equivalents and restricted cash	(83,550)		62,618
Cash, cash equivalents and restricted cash, beginning of period	219,448		181,685
Cash, cash equivalents and restricted cash, end of period	$	135,898	$	244,303

See accompanying Notes to the Unaudited Consolidated Financial Statements.

8

Healthpeak Properties, Inc.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited) 

NOTE 1.  Business

Overview

Healthpeak Properties, Inc., a Standard & Poor’s 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) that, together with its consolidated entities (collectively, “Healthpeak” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). Healthpeak® acquires, develops, owns, leases, and manages healthcare real estate. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) life science; (ii) medical office; and (iii) continuing care retirement community (“CCRC”).

The Company’s corporate headquarters are in Denver, Colorado and it has additional offices in California, Tennessee, and Massachusetts.

NOTE 2.  Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”), and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (“SEC”).

Revision to Additional Paid-In Capital and Redeemable Noncontrolling Interests

During the third quarter of 2021, the Company identified and corrected immaterial errors in the classification and redemption value of redeemable noncontrolling interests of consolidated joint ventures in its life science segment. The Company corrected the classification of its redeemable noncontrolling interests and increased the balance to its estimated redemption value, with a corresponding decrease to additional paid-in capital (“APIC”) in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity.

The increase in the unrealized value of the redeemable noncontrolling interests was largely attributable to rapidly rising rents and compressing capitalization rates in the market in which the entities operate, and was identified and corrected by management. The Company determined the impact of the adjustments to be immaterial, individually and in the aggregate, based on consideration of quantitative and qualitative factors. As such, these adjustments are reflected in this Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021.

These adjustments had no impact on the Consolidated Statements of Cash Flows, Consolidated Statements of Operations, or any per share amounts. The Company made changes (all amounts in thousands) to the Consolidated Statements of Equity and Redeemable Noncontrolling Interests to decrease APIC, total stockholders’ equity, and total equity as of June 30, 2021 by $82,319 with a corresponding increase to redeemable noncontrolling interests of $85,367 and a decrease to accounts payable, accrued liabilities, and other liabilities as of June 30, 2021 of $3,048 on the Consolidated Balance Sheet.

9

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide financial aid to individuals, businesses, and state and local governments. During the three and six months ended June 30, 2022 and 2021, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenue during the coronavirus (“Covid”) pandemic. Grant income is recognized when there is reasonable assurance that the grant will be received and the Company will comply with all conditions attached to the grant. Additionally, grants are recognized over the periods in which the Company recognizes the increased expenses and lost revenue the grants are intended to defray. As of June 30, 2022, the amount of qualifying expenditures and lost revenue exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture.

The following table summarizes information related to government grant income received and recognized by the Company (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Government grant income recorded in other income (expense), net	$	209	$	87	$	6,762	$	1,397
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	—		584		648		1,010
Government grant income recorded in income (loss) from discontinued operations	—		428		206		3,660
Total government grants received	$	209	$	1,099	$	7,616	$	6,067

Discontinued Operations

Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

During 2020, the Company established and began executing a plan to dispose of its senior housing triple-net and Senior Housing Operating Property (“SHOP”) properties and concluded that the planned dispositions represented a strategic shift that had and will have a major effect on the Company’s operations and financial results. Therefore, senior housing triple-net and SHOP assets meeting the held for sale criteria are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 4 for further information.

Recent Accounting Pronouncements

Adopted

Government Assistance. In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which increases the transparency of government assistance including the disclosure of the types of assistance, an entity’s accounting for assistance, and the effect of the assistance on an entity’s financial statements. The adoption of ASU 2021-10 on January 1, 2022 did not have a material impact on the Company’s consolidated financial position, results of operations, cash flows, or disclosures.

Not Yet Adopted

Reference Rate Reform. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional guidance for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on financial reporting. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”), which amends the scope of ASU 2020-04 to include derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. The amendments in ASU 2020-04 and ASU 2021-01 were effective immediately and may be applied through December 31, 2022. The Company is evaluating whether the optional relief provided by ASU 2020-04 or ASU 2021-01 will be adopted but does not expect the adoption of these standards to have a material impact on its consolidated financial position, results of operations, cash flows, or disclosures.

10

NOTE 3.  Real Estate Transactions

2022 Real Estate Investment Acquisitions

67 Smith Place

In January 2022, the Company closed a life science acquisition in Cambridge, Massachusetts for $72 million.

Vista Sorrento Phase II

In January 2022, the Company closed a life science acquisition in San Diego, California for $24 million.

Webster MOB Portfolio

In March 2022, the Company acquired a portfolio of two medical office buildings (“MOBs”) in Houston, Texas for $43 million.

Northwest Medical Plaza

In May 2022, the Company acquired one MOB in Bentonville, Arkansas for $26 million.

2021 Real Estate Investment Acquisitions

In 2021, the Company closed the following life science acquisitions: (i) eight acquisitions in Cambridge, Massachusetts for $498 million, (ii) one life science acquisition in San Diego, California for $20 million, and (iii) 12 acres of land for $128 million in South San Francisco, California.

Also during 2021, the Company closed the following MOB acquisitions: (i) one MOB in Nashville, Tennessee for $13 million, (ii) one MOB in Denver, Colorado for $38 million, (iii) a portfolio of 14 MOBs for $371 million (the “MOB Portfolio”), (iv) one MOB in Fort Lauderdale, Florida for $16 million; (v) one MOB in Wichita, Kansas for $50 million, (vi) three MOBs in Morristown, New Jersey for $155 million, (vii) two MOBs in Dallas, Texas for $60 million, (viii) one MOB in Seattle, Washington for $43 million, (ix) one MOB in New Orleans, Louisiana for $34 million, and (x) one MOB in Cambridge, Massachusetts for $55 million. In conjunction with the acquisition of the MOB Portfolio, the Company originated $142 million of secured mortgage debt.

Development Activities

The Company’s commitments, which are primarily related to development and redevelopment projects and tenant improvements, decreased by $16 million, to $454 million at June 30, 2022, when compared to December 31, 2021, primarily as a result of construction spend on existing projects in the first half of 2022 thereby decreasing the remaining commitment.

NOTE 4.  Dispositions of Real Estate and Discontinued Operations

2022 Dispositions of Real Estate

In January 2022, the Company sold one life science facility in Salt Lake City, Utah for $14 million, resulting in a gain on sale of $4 million.

During the three months ended June 30, 2022, the Company sold three MOBs and one MOB land parcel for $27 million, resulting in total gain on sales of $10 million.

In July 2022, the Company completed two MOB sales for aggregate proceeds of $9 million.

2021 Dispositions of Real Estate

Sunrise Senior Housing Portfolio

In January 2021, the Company sold a portfolio of 32 SHOP assets (the “Sunrise Senior Housing Portfolio”) for $664 million, resulting in an immaterial loss on sale, which is recognized in income (loss) from discontinued operations, and provided the buyer with: (i) financing of $410 million (see Note 6) and (ii) a commitment to finance up to $92 million of additional debt for capital expenditures. The commitment to finance additional debt for capital expenditures was subsequently reduced to $56 million in June 2021, $47 million in February 2022, and $40 million in July 2022 (see Note 6). As of June 30, 2022, $0.4 million of the additional financing has been funded. Upon completion of the license transfer process in June 2021, the Company sold the two remaining Sunrise senior housing triple-net assets for $80 million, resulting in a gain on sale of $22 million, which is recognized in income (loss) from discontinued operations.

11

Brookdale Triple-Net Portfolio

In January 2021, the Company sold 24 senior housing assets in a triple-net lease with Brookdale Senior Living Inc. for $510 million, resulting in total gain on sale of $169 million, which is recognized in income (loss) from discontinued operations.

Additional SHOP Portfolio

In January 2021, the Company sold a portfolio of 16 SHOP assets for $230 million, resulting in total gain on sale of $59 million, which is recognized in income (loss) from discontinued operations. The Company provided the buyer with financing of $150 million (see Note 6).

HRA Triple-Net Portfolio

In February 2021, the Company sold eight senior housing assets in a triple-net lease with Harbor Retirement Associates for $132 million, resulting in total gain on sale of $33 million, which is recognized in income (loss) from discontinued operations.

Oakmont SHOP Portfolio

In April 2021, the Company sold a portfolio of 12 SHOP assets for $564 million. In conjunction with the sale, mortgage debt held on two properties with a carrying value of $64 million was repaid and the remaining mortgage debt held on four properties with a carrying value of $107 million was assumed by the buyer. The transaction resulted in total gain on sale of $80 million, which is recognized in income (loss) from discontinued operations.

Discovery SHOP Portfolio

In April 2021, the Company sold a portfolio of 10 SHOP assets for $334 million, resulting in total gain on sale of $9 million, which is recognized in income (loss) from discontinued operations. Also included in this transaction was the sale of two mezzanine loans and two preferred equity investments for $21 million, resulting in no gain or loss on sale of the investments (collectively, the “Discovery SHOP Portfolio”).

Sonata SHOP Portfolio

In April 2021, the Company sold a portfolio of five SHOP assets for $64 million, resulting in total gain on sale of $3 million, which is recognized in income (loss) from discontinued operations.

SLC SHOP Portfolio

In May 2021, the Company sold seven SHOP assets for $113 million and repaid $70 million of mortgage debt that was held on six of the assets, resulting in total gain on sale of $1 million, which is recognized in income (loss) from discontinued operations.

Hoag Hospital

In May 2021, the Company sold one hospital for $226 million through the exercise of a purchase option by a tenant, resulting in gain on sale of $172 million.

2021 Other Dispositions

In addition to the portfolio and individual sales discussed above, the Company sold the following during the three months ended June 30, 2021: (i) six SHOP assets for $44 million, (ii) three senior housing triple-net assets for $12 million, and (iii) four MOBs for $21 million, resulting in total gain on sales of $10 million ($7 million of which is recognized in income (loss) from discontinued operations). Additionally, during the three months ended March 31, 2021, the Company sold one SHOP asset for $5 million resulting in an immaterial gain on sale, which is recognized in income (loss) from discontinued operations.

During the second half of 2021, the Company sold the following: (i) eight SHOP assets for $120 million, (ii) four senior housing triple-net assets for $12 million, and (iii) six MOBs and a portion of one MOB land parcel for $47 million, resulting in total gain on sales of $48 million ($32 million of which is recognized in income (loss) from discontinued operations). In conjunction with one of the SHOP asset sales, mortgage debt held on the property with a carrying value of $36 million was assumed by the buyer.

Held for Sale and Discontinued Operations

During 2020, the Company established and began executing a plan to dispose of its senior housing triple-net and SHOP properties. As of December 31, 2020, the Company concluded that the planned dispositions represented a strategic shift that had and will have a major effect on the Company’s operations and financial results. Therefore, senior housing triple-net and SHOP assets meeting the held for sale criteria are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties.

12

The following summarizes the assets and liabilities classified as held for sale or as discontinued operations at June 30, 2022 and December 31, 2021, which are included in assets held for sale and discontinued operations, net and liabilities related to assets held for sale and discontinued operations, net, respectively, on the Consolidated Balance Sheets (in thousands):

	June 30, 2022		December 31, 2021
ASSETS
Accounts receivable, net of allowance of $990 and $4,138	$	761	$	2,446
Cash and cash equivalents	8,070		7,707
Right-of-use asset, net	19		26
Other assets, net	1,400		3,237
Total assets of discontinued operations, net	10,250		13,416
Assets held for sale, net(1)	56,397		23,774
Assets held for sale and discontinued operations, net	$	66,647	$	37,190
LIABILITIES
Lease liability	$	19	$	26
Accounts payable, accrued liabilities, and other liabilities	11,479		14,843
Deferred revenue	102		92
Total liabilities of discontinued operations, net	11,600		14,961
Liabilities related to assets held for sale, net(1)	4,269		95
Liabilities related to assets held for sale and discontinued operations, net	$	15,869	$	15,056

_______________________________________

(1)As of June 30, 2022, includes two life science assets and two MOBs primarily comprised of net real estate assets of $51 million. As of December 31, 2021, includes four MOBs and one life science facility primarily comprised of net real estate assets of $23 million.

13

The results of discontinued operations during the three and six months ended June 30, 2022 and 2021, or through the disposal date of each asset or portfolio of assets held within discontinued operations if sold during such periods, as applicable, are included in the consolidated results of operations for the three and six months ended June 30, 2022 and 2021. Summarized financial information for discontinued operations for the three and six months ended June 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues:
Rental and related revenues	$	—	$	1,613	$	—	$	6,841
Resident fees and services	2,825		30,273		5,480		103,270
Total revenues	2,825		31,886		5,480		110,111
Costs and expenses:
Interest expense	—		1,177		—		3,853
Operating	2,442		33,647		5,116		105,165
Transaction costs	—		—		—		76
Impairments and loan loss reserves (recoveries), net	—		10,995		—		10,995
Total costs and expenses	2,442		45,819		5,116		120,089
Other income (expense):
Gain (loss) on sales of real estate, net	2,563		122,238		2,492		381,900
Other income (expense), net	16		128		19		6,012
Total other income (expense), net	2,579		122,366		2,511		387,912
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	2,962		108,433		2,875		377,934
Income tax benefit (expense)	30		302		370		1,124
Equity income (loss) from unconsolidated joint ventures	—		5,225		64		4,910
Income (loss) from discontinued operations	$	2,992	$	113,960	$	3,309	$	383,968

Impairments of Real Estate

2022

During the three and six months ended June 30, 2022, the Company did not recognize any impairment charges.

2021

During the three and six months ended June 30, 2021, the Company recognized an impairment charge of $4 million related to one SHOP asset classified as held for sale, which is reported in income (loss) from discontinued operations. Following a reduction in the expected sales price of the asset occurring in the second quarter of 2021, the Company wrote down its carrying value of $20 million to its fair value, less estimated costs to sell, of $16 million.

The fair value of the impaired asset was based on a forecasted sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. The Company’s forecasted sales prices are typically determined using an income approach and/or a market approach (comparable sales model), which rely on certain assumptions by management, including: (i) market capitalization rates, (ii) comparable market transactions, (iii) estimated prices per unit, (iv) negotiations with prospective buyers, and (v) forecasted cash flow streams (lease revenue rates, expense rates, growth rates, etc.). There are inherent uncertainties in making these assumptions. For the Company’s impairment calculation as of June 30, 2021, the Company’s fair value estimate primarily relied on a market approach and utilized comparable market transactions and negotiations with prospective buyers.

14

Goodwill Impairment

When testing goodwill for impairment, if the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company recognizes an impairment charge for the amount by which the carrying value, including goodwill, exceeds the reporting unit’s fair value. Following the senior housing triple-net and SHOP dispositions, the Company performed an impairment assessment to evaluate the fair value of its reporting units as of June 30, 2021. These fair value estimates primarily relied on a market approach, utilizing comparable market transactions, forecasted sales prices, and negotiations with prospective buyers. These estimates are considered to be a Level 3 measurement within the fair value hierarchy, and are subject to inherent uncertainties.

As a result of this assessment, during the three and six months ended June 30, 2021, the Company recognized a $7 million goodwill impairment charge reported in income (loss) from discontinued operations as the fair value of the remaining assets based on forecasted sales prices was less than the carrying value of the assets, including the related goodwill. The fair value was greater than the carrying value of the assets and related goodwill of all other reporting units, and as a result, no impairment charge was recognized.

Other Losses

During the first quarter of 2022, the Company recognized $14 million of expenses for tenant relocation and other costs associated with a planned MOB demolition. These expenses are included in other income (expense), net on the Consolidated Statements of Operations for the six months ended June 30, 2022.

NOTE 5.  Leases

Lease Income

The following table summarizes the Company’s lease income, excluding discontinued operations (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Fixed income from operating leases	$	296,729	$	268,290	$	584,020	$	531,246
Variable income from operating leases	90,350		72,352		173,209		137,368
Interest income from direct financing leases	—		2,180		1,168		4,343

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital classified as a direct financing lease (“DFL”) for $68 million and recognized a gain on sale of $23 million, which is included in other income (expense), net.

Net investment in DFLs consists of the following (in thousands):

	June 30, 2022		December 31, 2021
Present value of minimum lease payments receivable	$	—	$	1,220
Present value of estimated residual value	—		44,706
Less deferred selling profits	—		(1,220)
Net investment in direct financing leases	$	—	$	44,706

Direct Financing Lease Internal Ratings

At June 30, 2022, the Company had no properties classified as a DFL. At December 31, 2021, the Company had one hospital classified as a DFL with a carrying amount of $45 million and an internal rating of “performing”.

15

NOTE 6.  Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

	June 30, 2022		December 31, 2021
Secured loans(1)	$	387,447	$	396,281
Mezzanine and other	31,098		25,529
Unamortized discounts, fees, and costs	(2,568)		(4,186)
Reserve for loan losses	(2,015)		(1,813)
Loans receivable, net	$	413,962	$	415,811

_______________________________________

(1)At June 30, 2022, the Company had $48 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects. At December 31, 2021, the Company had $58 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects.

SHOP Seller Financing

In conjunction with the sale of 32 SHOP facilities in the Sunrise Senior Housing Portfolio for $664 million in January 2021 (see Note 4), the Company provided the buyer with initial financing of $410 million. The remainder of the sales price was received in cash at the time of sale. Additionally, the Company agreed to provide up to $92 million of additional financing for capital expenditures (up to 65% of the estimated cost of capital expenditures). The additional financing was subsequently reduced to $56 million in June 2021, $47 million in February 2022, and $40 million in July 2022 in conjunction with the principal repayments discussed below. Through June 30, 2022, $0.4 million of the additional financing had been funded. The initial and additional financing is secured by the buyer's equity ownership in each property.

In June 2021, the Company received principal repayments of $246 million on the initial financing provided in conjunction with the sale of the Sunrise Senior Housing Portfolio. In connection with the June 2021 principal repayment, the Company accelerated recognition of $7 million of the related mark-to-market discount, which is included in interest income in the Consolidated Statements of Operations. Additionally, in February 2022, the Company received principal repayments of $8 million in conjunction with the disposition of the underlying collateral. As of June 30, 2022 and December 31, 2021, this secured loan had an outstanding balance of $157 million and $165 million, respectively. In July 2022, the Company received principal repayments of $27 million in conjunction with the disposition of the underlying collateral, resulting in a $7 million reduction in the Company’s remaining commitment to provide additional financing for capital expenditures.

In conjunction with the sale of 16 additional SHOP facilities for $230 million in January 2021 (see Note 4), the Company provided the buyer with financing of $150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer's equity ownership in each property.

During the first quarter of 2021, the Company reduced the consideration and reported gain on sales of real estate and recognized a mark-to-market discount of $16 million for certain transactions with seller financing. The Company’s discount is based on the difference between the stated interest rates (ranging from 3.50% to 4.50%) and corresponding prevailing market rates of approximately 5.25% as of the transaction dates. The discount is recognized as interest income over the term of the discounted loans (ranging from one to three years) using the effective interest rate method. During the three and six months ended June 30, 2022, the Company recognized $1 million and $2 million, respectively, of non-cash interest income related to the amortization of its mark-to-market discounts. During the three and six months ended June 30, 2021, the Company recognized $9 million and $10 million, respectively, of non-cash interest income related to the amortization of its mark-to-market discounts, of which $7 million was recognized as a result of the accelerated recognition discussed above related to the Sunrise Senior Housing Portfolio.

2022 Other Loans Receivable Transactions

In May 2022, the Company received full repayment of the outstanding balance of a $2 million secured loan.

16

2021 Other Loans Receivable Transactions

The Company classifies a loan receivable as held for sale when management no longer has the intent or ability to hold the loan receivable for the foreseeable future or until maturity. If a loan receivable is classified as held for sale, previously recorded reserves for loan losses are reversed and the loan is reported at the lower of amortized cost or fair value. During the second quarter of 2021, two loans receivable with a total amortized cost of $64 million were classified as held for sale. Upon the transfer of these two loans to held for sale, the carrying value was decreased by $11 million to an estimated fair value of $53 million, $8 million of which was previously recognized as a reserve for loan losses. As a result, a $3 million net loss was recognized in impairments and loan loss reserves (recoveries), net during the three and six months ended June 30, 2021. In the second half of 2021, the Company sold these two loans receivable previously classified as held for sale for their aggregate carrying value of $53 million.

These fair value estimates were made for each individual loan classified as held for sale and primarily relied on a market approach, utilizing comparable market transactions, forecasted sales prices, and negotiations with prospective buyers. These estimates are considered to be a Level 3 measurement within the fair value hierarchy, and are subject to inherent uncertainties.

Additionally, in April 2021, the Company sold two mezzanine loans as part of the Discovery SHOP Portfolio disposition (see Note 4), resulting in no gain or loss on sale of the mezzanine loans.

In May 2021, the Company received a $10 million principal repayment related to one of its secured loans. In September 2021, the Company received repayment of the remaining $15 million balance.

In July 2021, the Company received full repayment of the outstanding balance of an $8 million secured loan.

CCRC Resident Loans

For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the previous residence. At June 30, 2022 and December 31, 2021, the Company held $30 million and $24 million, respectively, of such notes receivable, which are included in mezzanine and other in the table above.

Loans Receivable Internal Ratings

In connection with the Company’s quarterly review process or upon the occurrence of a significant event, loans receivable are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Loans that are deemed Performing meet all present contractual obligations, and collection and timing of all amounts owed is reasonably assured. Watch List Loans are defined as loans that do not meet the definition of Performing or Workout. Workout Loans are defined as loans in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.

17

The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of June 30, 2022 (in thousands):

Investment Type	Year of Origination												Total
	2022		2021		2020		2019		2018		Prior
Secured loans
Risk rating:
Performing loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total secured loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Mezzanine and other
Risk rating:
Performing loans	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total mezzanine and other	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092

Reserve for Loan Losses

The Company evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. The determination of loan losses also considers concentration of credit risk associated with the senior housing industry to which its loans receivable relate. The Company’s borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis, which the Company utilizes to calculate the debt service coverages used in its assessment of internal ratings, which is a primary credit quality indicator. Debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, NOI, occupancy, rental rates, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures.

In its assessment of current expected credit losses for loans receivable and unfunded loan commitments, the Company utilizes past payment history of its borrowers, current economic conditions, and forecasted economic conditions through the maturity date of each loan to estimate a probability of default and a resulting loss for each loan receivable. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends.

The following table summarizes the Company’s reserve for loan losses (in thousands):

	June 30, 2022						December 31, 2021
	Secured Loans		Mezzanine and Other		Total		Secured Loans		Mezzanine and Other		Total
Reserve for loan losses, beginning of period	$	1,804	$	9	$	1,813	$	3,152	$	7,128	$	10,280
Provision for expected loan losses	256		(3)		253		793		896		1,689
Expected loan losses related to loans sold or repaid(1)	(51)		—		(51)		(2,141)		(8,015)		(10,156)
Reserve for loan losses, end of period	$	2,009	$	6	$	2,015	$	1,804	$	9	$	1,813

_______________________________________

(1)Includes one loan repaid during the six months ended June 30, 2022 and six loans sold or repaid during the year ended December 31, 2021.

Additionally, at June 30, 2022 and December 31, 2021, a liability of $0.4 million and $0.3 million, respectively, related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.

18

NOTE 7.  Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method, excluding investments classified as discontinued operations (dollars in thousands): 

				Carrying Amount
				June 30,		December 31,
Entity(1)	Segment	Property Count(2)	Ownership %(2)	2022		2021
SWF SH JV	Other	19	54	$	351,686	$	355,394
Life Science JV	Life science	1	49	26,719		25,605
Needham Land Parcel JV(3)	Life science	—	38	14,831		13,566
Medical Office JVs(4)	Medical office	3	20 - 67	8,918		9,069
				$	402,154	$	403,634

_______________________________________

(1)These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

(2)Property counts and ownership percentages are as of June 30, 2022.

(3)In December 2021, the Company acquired a 38% interest in a life science development joint venture in Needham, Massachusetts for $13 million. Land held for development is excluded from the property count as of June 30, 2022.

(4)Includes two unconsolidated medical office joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). During 2021, the Company also held a 30% interest in Ventures III, which issued its final distribution and was dissolved.

In April 2021, the Company sold its two preferred equity investments for their carrying value as part of the Discovery SHOP Portfolio disposition (see Note 4). Prior to the sale, the Company’s ownership percentage in these two unconsolidated joint ventures was as follows: (i) Discovery Naples JV (41%) and (ii) Discovery Sarasota JV (47%).

In May 2021, the two remaining CCRCs in the CCRC JV were sold for $38 million, $19 million of which represents the Company’s 49% interest, resulting in an immaterial gain on sale recorded within equity income (loss) from unconsolidated joint ventures during the year ended December 31, 2021.

South San Francisco Joint Ventures

On August 1, 2022, the Company entered into a master equity transaction agreement with a sovereign wealth fund (“SWF Partner”) that provides the Company the opportunity to sell up to 30% interests in certain redevelopment and future development projects owned by the Company.

Concurrently, the Company executed definitive agreements with the SWF Partner to sell a 30% interest in seven life science assets in South San Francisco, California for gross proceeds of $126 million. The Company and the SWF Partner will share in key decisions related to the planned redevelopment and operation of the assets, resulting in the Company deconsolidating the previously wholly-owned assets and recognizing its 70% share as an equity method investment.

19

NOTE 8.  Intangibles

Intangible assets primarily consist of lease-up intangibles and above market tenant lease intangibles. The following table summarizes the Company’s intangible lease assets (dollars in thousands):

Intangible lease assets	June 30, 2022		December 31, 2021
Gross intangible lease assets	$	802,180	$	797,675
Accumulated depreciation and amortization	(331,315)		(277,915)
Intangible assets, net(1)	$	470,865	$	519,760
Weighted average remaining amortization period in years	6		6

_______________________________________

(1)Excludes intangible assets reported in assets held for sale and discontinued operations, net of $2 million and zero as of June 30, 2022 and December 31, 2021, respectively.

Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (dollars in thousands):

Intangible lease liabilities	June 30, 2022		December 31, 2021
Gross intangible lease liabilities	$	240,733	$	234,917
Accumulated depreciation and amortization	(71,111)		(57,685)
Intangible liabilities, net	$	169,622	$	177,232
Weighted average remaining amortization period in years	8		8

During the six months ended June 30, 2022, in conjunction with the Company’s acquisitions of real estate, the Company acquired intangible assets of $7 million and intangible liabilities of $6 million. The intangible assets and liabilities acquired had a weighted average amortization period at acquisition of 7 years and 11 years, respectively.

During the year ended December 31, 2021, in conjunction with the Company’s acquisitions of real estate, the Company acquired intangible assets of $109 million and intangible liabilities of $57 million. The intangible assets and intangible liabilities acquired each had a weighted average amortization period at acquisition of 9 years.

NOTE 9.  Debt

Bank Line of Credit and Term Loan

On May 23, 2019, the Company executed a $2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. Also in May 2019, the Company entered into a $250 million unsecured term loan facility, with a maturity date of May 23, 2024 (the “2019 Term Loan”). In July 2021, the Company repaid the $250 million 2019 Term Loan.

In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $2.5 billion to $3.0 billion and extend the maturity date to January 20, 2026. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at LIBOR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at June 30, 2022, the margin on the Revolving Facility was 0.78% and the facility fee was 0.15%. At June 30, 2022 and December 31, 2021, the Company had no balance outstanding under the Revolving Facility.

The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million, subject to securing additional commitments. Further, the Revolving Facility includes customary LIBOR replacement language, including, but not limited to, the use of rates based on the secured overnight financing rate administered by the Federal Reserve Bank of New York. The Revolving Facility also includes a sustainability-linked pricing component whereby the applicable margin may be reduced by up to 0.025% based on the Company’s achievement of specified sustainability-linked metrics, subject to certain conditions.

20

The Revolving Facility also contains certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreement: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of $7.7 billion. The Company believes it was in compliance with each of these covenants at June 30, 2022.

Commercial Paper Program

In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, unsecured short-term debt securities with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At June 30, 2022 and December 31, 2021, the maximum aggregate face or principal amount that can be outstanding at any one time was $1.5 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of unsecured short-term debt securities issued under the Commercial Paper Program. At June 30, 2022, the Company had $1.45 billion of securities outstanding under the Commercial Paper Program, with original maturities of approximately 45 days and a weighted average interest rate of 1.95%. At December 31, 2021, the Company had $1.17 billion of securities outstanding under the Commercial Paper Program, with original maturities of approximately two months and a weighted average interest rate of 0.32%.

In July 2022, the Company increased the maximum aggregate face or principal amount that can be outstanding at any one time from $1.5 billion to $2.0 billion.

Senior Unsecured Notes

At each of June 30, 2022 and December 31, 2021, the Company had senior unsecured notes outstanding with an aggregate principal balance of $4.7 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at June 30, 2022.

During the three and six months ended June 30, 2022, the Company did not issue, repurchase, or redeem any senior unsecured notes.

The following table summarizes the Company’s senior unsecured notes repurchases and redemptions during the year ended December 31, 2021 (dollars in thousands):

Payoff Date	Amount		Coupon Rate		Maturity Year
May 19, 2021(1)	$	251,806	3.40	%	2025
May 19, 2021(1)	298,194		4.00	%	2025
February 26, 2021(2)	188,000		4.25	%	2023
February 26, 2021(2)	149,000		4.20	%	2024
February 26, 2021(2)	331,000		3.88	%	2024
January 28, 2021(2)	112,000		4.25	%	2023
January 28, 2021(2)	201,000		4.20	%	2024
January 28, 2021(2)	469,000		3.88	%	2024

_______________________________________

(1)Upon repurchasing a portion of the 3.40% and 4.00% senior unsecured notes due 2025, the Company recognized a $61 million loss on debt extinguishment during the three and six months ended June 30, 2021.

(2)Upon completing the repurchases and redemptions of all outstanding 4.25%, 4.20%, and 3.88% senior unsecured notes due 2023 and 2024, the Company recognized a $164 million loss on debt extinguishment during the six months ended June 30, 2021.

21

In 2021, the Company completed two green bond offerings. The net proceeds from both green bonds have been allocated to eligible green projects, and the Company may choose to re-allocate net proceeds from such offerings to one or more other eligible green projects. The following table summarizes these senior unsecured note issuances for the year ended December 31, 2021 (dollars in thousands):

Issue Date	Amount		Coupon Rate		Maturity Year
November 24, 2021	$	500,000	2.13	%	2028
July 12, 2021	450,000		1.35	%	2027

Mortgage Debt

At June 30, 2022 and December 31, 2021, the Company had $348 million and $350 million, respectively, in aggregate principal of mortgage debt outstanding, which was secured by 18 healthcare facilities, with an aggregate carrying value of $799 million and $811 million, respectively.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires insurance on the assets, and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

During each of the three months ended June 30, 2022 and 2021, the Company made aggregate principal repayments of mortgage debt of $1 million (excluding mortgage debt on assets held for sale and discontinued operations). During each of the six months ended June 30, 2022 and 2021, the Company made aggregate principal repayments of mortgage debt of $3 million (excluding mortgage debt on assets held for sale and discontinued operations).

In April 2021, in conjunction with the acquisition of the MOB Portfolio, the Company originated $142 million of secured mortgage debt (see Note 3) that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026 (see Note 17). The variable rate debt associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument.

Debt Maturities

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at June 30, 2022 (dollars in thousands):

					Senior Unsecured Notes(2)				Mortgage Debt(3)
Year	Bank Line of Credit		Commercial Paper(1)		Amount		Interest Rate		Amount		Interest Rate		Total
2022	$	—	$	—	$	—	—	%	$	2,541	3.80	%	$	2,541
2023	—		—		—		—	%	90,089		3.80	%	90,089
2024	—		—		—		—	%	7,024		4.28	%	7,024
2025	—		—		800,000		3.93	%	3,209		3.80	%	803,209
2026	—		1,448,569		650,000		3.39	%	244,523		4.48	%	2,343,092
Thereafter	—		—		3,250,000		3.24	%	366		5.91	%	3,250,366
	—		1,448,569		4,700,000				347,752				6,496,321
(Discounts), premium and debt costs, net	—		—		(44,148)				1,577				(42,571)
	$	—	$	1,448,569	$	4,655,852			$	349,329			$	6,453,750

_______________________________________

(1)Commercial Paper Program borrowings are backstopped by the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.

(2)Effective interest rates on the senior unsecured notes range from 1.54% to 6.91% with a weighted average effective interest rate of 3.39% and a weighted average maturity of 7 years.

(3)Effective interest rates on the mortgage debt range from 3.42% to 5.91% with a weighted average effective interest rate of 4.28% and a weighted average maturity of 3 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.

22

NOTE 10.  Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company’s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations, or cash flows. The Company’s policy is to expense legal costs as they are incurred.

DownREITs and Other Partnerships

In connection with the formation of certain limited liability companies (“DownREITs”), members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code (“make-whole payments”). These make-whole payments include a tax gross-up provision. These indemnification agreements have expirations terms that range through 2039 on a total of 29 properties.

Additionally, the Company owns a 49% interest in the Life Science JV (see Note 7). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the contribution to the joint venture.

NOTE 11.  Equity and Redeemable Noncontrolling Interests

Dividends

On July 28, 2022, the Company announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share. The common stock cash dividend will be paid on August 19, 2022 to stockholders of record as of the close of business on August 8, 2022.

During each of the three months ended June 30, 2022 and 2021, the Company declared and paid common stock cash dividends of $0.30 per share. During each of the six months ended June 30, 2022 and 2021, the Company declared and paid common stock cash dividends of $0.60 per share.

At-The-Market Equity Offering Program

In February 2020, the Company established an at-the-market equity offering program (as amended from time to time, the “ATM Program”), which was most recently amended in May 2021 to increase the size of the program from $1.25 billion to $1.5 billion, pursuant to which shares of common stock having an aggregate gross sales price of up to $1.5 billion may be sold (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an “ATM forward contract”). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract is effective, but defer receiving the proceeds from the sale of shares until a later date.

ATM forward contracts generally have a one to two year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company’s election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract.

At June 30, 2022, $1.18 billion of the Company’s common stock remained available for sale under the ATM Program.

23

ATM Forward Contracts

During the year ended December 31, 2021, the Company utilized the forward provisions under the ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $35.25 per share, after commissions. During the three and six months ended June 30, 2022, no shares were settled under ATM forward contracts. Therefore, at June 30, 2022, 9.1 million shares remained outstanding under ATM forward contracts. These ATM forward contracts mature in the first quarter of 2023.

During the three and six months ended June 30, 2021, the Company did not utilize the forward provisions under the ATM Program.

ATM Direct Issuances

During the three and six months ended June 30, 2022 and June 30, 2021, no shares of common stock were issued under the ATM Program.

Share Repurchase Program

On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company may acquire shares of its common stock in the open market up to an aggregate purchase price of $500 million (the “Share Repurchase Program”). Purchases of common stock under the Share Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The Share Repurchase Program expires in August 2024 and may be suspended or terminated at any time without prior notice. There have been no stock repurchases under the Share Repurchase Program through the date on which this Quarterly Report on Form 10-Q was filed.

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):

	June 30, 2022		December 31, 2021
Unrealized gains (losses) on derivatives, net	$	1,629	$	—
Supplemental Executive Retirement Plan minimum liability	(2,947)		(3,147)
Total accumulated other comprehensive income (loss)	$	(1,318)	$	(3,147)

Redeemable Noncontrolling Interests

Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company’s noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time. Each put option is payable in cash and subject to increases in redemption value in the event that the underlying property generates specified returns for the Company and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period.

During the year ended December 31, 2021, one of the redeemable noncontrolling interests met the conditions for redemption and the related put option was exercised during the year then ended. Accordingly, the Company made a cash payment for the redemption value of $60 million to the related noncontrolling interest holder during the year ended December 31, 2021 and acquired the redeemable noncontrolling interest associated with this entity. The remaining redeemable noncontrolling interests had not yet met the conditions for redemption as of June 30, 2022 or December 31, 2021. Three of the interests will become redeemable following the passage of a predetermined amount of time, one of which will occur in late 2022, and the remaining two in 2023 and 2024. The fourth interest will become redeemable at the earlier of a predetermined passage of time or stabilization of the underlying development property, which is expected to occur in 2023. The redemption values are subject to change based on the assessment of value at each redemption date.

24

NOTE 12.  Earnings Per Common Share

Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.

Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

Refer to Note 11 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented. The Company considered the potential dilution resulting from the forward agreements to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. The aggregate effect on the Company’s diluted weighted-average common shares for each of the three and six months ended June 30, 2022 and 2021 was zero weighted-average incremental shares from the forward equity sales agreements. 

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Numerator
Income (loss) from continuing operations	$	69,301	$	168,065	$	144,327	$	47,480
Noncontrolling interests' share in continuing operations	(3,955)		(3,535)		(7,685)		(6,841)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	65,346		164,530		136,642		40,639
Less: Participating securities' share in continuing operations	(281)		(287)		(2,258)		(2,732)
Income (loss) from continuing operations applicable to common shares	65,065		164,243		134,384		37,907
Income (loss) from discontinued operations	2,992		113,960		3,309		383,968
Noncontrolling interests' share in discontinued operations	—		(2,210)		—		(2,539)
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Numerator - Dilutive
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Add: distributions on dilutive convertible units and other	—		1,540		—		—
Dilutive net income (loss) available to common shares	$	68,057	$	277,533	$	137,693	$	419,336
Denominator
Basic weighted average shares outstanding	539,558		538,929		539,456		538,805
Dilutive potential common shares - equity awards(1)	257		264		245		276
Dilutive potential common shares - DownREIT conversions	—		5,501		—		—
Diluted weighted average common shares	539,815		544,694		539,701		539,081
Basic earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78
Diluted earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78

_______________________________________

(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).

For the three and six months ended June 30, 2022, the 9.1 million shares under forward sales agreements that have not been settled as of June 30, 2022 were anti-dilutive. For the three and six months ended June 30, 2021, forward sales agreements had no dilutive impact as no shares remained outstanding under ATM forward contracts during the period.

25

For the three months ended June 30, 2021, 6 million out of 7 million shares issuable upon conversion of DownREIT units were dilutive. For all other periods presented in the table above, all 7 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.

NOTE 13.  Segment Disclosures

The Company’s reportable segments, based on how its chief operating decision makers (“CODMs”) evaluate the business and allocate resources, are as follows: (i) life science, (ii) medical office, and (iii) CCRC. The Company has non-reportable segments that are comprised primarily of the Company’s interests in an unconsolidated JV that owns 19 senior housing assets (the “SWF SH JV”) and debt investments. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC, as updated by Note 2 herein.

The Company evaluates performance based on property Adjusted NOI. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.

NOI and Adjusted NOI include the Company’s share of income (loss) from unconsolidated joint ventures and exclude noncontrolling interests’ share of income (loss) from consolidated joint ventures. Management believes that Adjusted NOI is an important supplemental measure because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. Additionally, management believes that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items.

Non-segment assets consist of assets in the Company’s other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, loans receivable, marketable equity securities, other assets, real estate assets held for sale and discontinued operations, and liabilities related to assets held for sale.

26

The following tables summarize information for the reportable segments (in thousands):

For the three months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	207,771	$	179,308	$	125,360	$	5,493	$	—	$	517,932
Government grant income(1)	—		—		209		—		—		209
Less: Interest income	—		—		—		(5,493)		—		(5,493)
Healthpeak’s share of unconsolidated joint venture total revenues	1,267		761		—		18,215		—		20,243
Noncontrolling interests’ share of consolidated joint venture total revenues	(62)		(8,943)		—		—		—		(9,005)
Operating expenses	(49,446)		(63,321)		(102,277)		—		—		(215,044)
Healthpeak’s share of unconsolidated joint venture operating expenses	(483)		(301)		—		(14,150)		—		(14,934)
Noncontrolling interests’ share of consolidated joint venture operating expenses	19		2,726		—		—		—		2,745
Adjustments to NOI(2)	(21,644)		(2,949)		—		54		—		(24,539)
Adjusted NOI	137,422		107,281		23,292		4,119		—		272,114
Plus: Adjustments to NOI(2)	21,644		2,949		—		(54)		—		24,539
Interest income	—		—		—		5,493		—		5,493
Interest expense	—		(1,930)		(1,876)		—		(38,061)		(41,867)
Depreciation and amortization	(79,673)		(68,873)		(31,943)		—		—		(180,489)
General and administrative	—		—		—		—		(24,781)		(24,781)
Transaction costs	(35)		(70)		(64)		—		(443)		(612)
Impairments and loan loss reserves	—		—		—		(139)		—		(139)
Gain (loss) on sales of real estate, net	—		10,340		—		—		—		10,340
Other income (expense), net	29		1,264		630		18		920		2,861
Less: Government grant income	—		—		(209)		—		—		(209)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(784)		(460)		—		(4,065)		—		(5,309)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	43		6,217		—		—		—		6,260
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	78,646		56,718		(10,170)		5,372		(62,365)		68,201
Income tax benefit (expense)	—		—		—		—		718		718
Equity income (loss) from unconsolidated joint ventures	148		211		—		23		—		382
Income (loss) from continuing operations	78,794		56,929		(10,170)		5,395		(61,647)		69,301
Income (loss) from discontinued operations	—		—		—		—		2,992		2,992
Net income (loss)	$	78,794	$	56,929	$	(10,170)	$	5,395	$	(58,655)	$	72,293

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

27

For the three months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	177,527	$	165,295	$	117,308	$	16,108	$	—	$	476,238
Government grant income(1)	—		—		87		—		—		87
Less: Interest income	—		—		—		(16,108)		—		(16,108)
Healthpeak’s share of unconsolidated joint venture total revenues	1,412		710		2,415		16,740		—		21,277
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		—		583		—		583
Noncontrolling interests’ share of consolidated joint venture total revenues	(75)		(8,825)		—		—		—		(8,900)
Operating expenses	(40,724)		(54,648)		(94,760)		—		—		(190,132)
Healthpeak’s share of unconsolidated joint venture operating expenses	(428)		(317)		(2,208)		(12,451)		—		(15,404)
Noncontrolling interests’ share of consolidated joint venture operating expenses	21		2,552		—		—		—		2,573
Adjustments to NOI(2)	(12,366)		(2,003)		1,226		(27)		—		(13,170)
Adjusted NOI	125,367		102,764		24,068		4,845		—		257,044
Plus: Adjustments to NOI(2)	12,366		2,003		(1,226)		27		—		13,170
Interest income	—		—		—		16,108		—		16,108
Interest expense	(48)		(786)		(1,924)		—		(35,923)		(38,681)
Depreciation and amortization	(76,955)		(63,371)		(31,133)		—		—		(171,459)
General and administrative	—		—		—		—		(24,088)		(24,088)
Transaction costs	21		35		(657)		(18)		—		(619)
Impairments and loan loss reserves	—		—		—		(931)		—		(931)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(60,865)		(60,865)
Other income (expense), net	28		(175)		165		—		1,716		1,734
Less: Government grant income	—		—		(87)		—		—		(87)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(984)		(393)		(207)		(4,872)		—		(6,456)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	54		6,273		—		—		—		6,327
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	59,849		221,588		(11,001)		15,159		(119,160)		166,435
Income tax benefit (expense)	—		—		—		—		763		763
Equity income (loss) from unconsolidated joint ventures	111		137		639		(20)		—		867
Income (loss) from continuing operations	59,960		221,725		(10,362)		15,139		(118,397)		168,065
Income (loss) from discontinued operations	—		—		—		—		113,960		113,960
Net income (loss)	$	59,960	$	221,725	$	(10,362)	$	15,139	$	(4,437)	$	282,025

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

28

For the six months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	401,826	$	356,571	$	246,920	$	10,987	$	—	$	1,016,304
Government grant income(1)	—		—		6,762		—		—		6,762
Less: Interest income	—		—		—		(10,987)		—		(10,987)
Healthpeak’s share of unconsolidated joint venture total revenues	2,698		1,493		—		36,260		—		40,451
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		333		315		—		648
Noncontrolling interests’ share of consolidated joint venture total revenues	(119)		(17,763)		—		—		—		(17,882)
Operating expenses	(97,635)		(124,491)		(200,165)		—		—		(422,291)
Healthpeak’s share of unconsolidated joint venture operating expenses	(966)		(600)		—		(28,205)		—		(29,771)
Noncontrolling interests’ share of consolidated joint venture operating expenses	38		5,328		—		—		—		5,366
Adjustments to NOI(2)	(35,756)		(6,495)		—		45		—		(42,206)
Adjusted NOI	270,086		214,043		53,850		8,415		—		546,394
Plus: Adjustments to NOI(2)	35,756		6,495		—		(45)		—		42,206
Interest income	—		—		—		10,987		—		10,987
Interest expense	—		(2,966)		(3,741)		—		(72,746)		(79,453)
Depreciation and amortization	(157,811)		(136,646)		(63,765)		—		—		(358,222)
General and administrative	—		—		—		—		(48,612)		(48,612)
Transaction costs	(327)		(74)		(64)		—		(443)		(908)
Impairments and loan loss reserves	—		—		—		(271)		—		(271)
Gain (loss) on sales of real estate, net	3,856		10,340		—		—		—		14,196
Other income (expense), net	20		12,201		7,141		(13)		1,828		21,177
Less: Government grant income	—		—		(6,762)		—		—		(6,762)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,732)		(893)		(333)		(8,370)		—		(11,328)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	81		12,435		—		—		—		12,516
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	149,929		114,935		(13,674)		10,703		(119,973)		141,920
Income tax benefit (expense)	—		—		—		—		(59)		(59)
Equity income (loss) from unconsolidated joint ventures	1,114		411		539		402		—		2,466
Income (loss) from continuing operations	151,043		115,346		(13,135)		11,105		(120,032)		144,327
Income (loss) from discontinued operations	—		—		—		—		3,309		3,309
Net income (loss)	$	151,043	$	115,346	$	(13,135)	$	11,105	$	(116,723)	$	147,636

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

29

For the six months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	347,461	$	325,496	$	233,436	$	25,121	$	—	$	931,514
Government grant income(1)	—		—		1,397		—		—		1,397
Less: Interest income	—		—		—		(25,121)		—		(25,121)
Healthpeak’s share of unconsolidated joint venture total revenues	2,749		1,425		6,903		33,493		—		44,570
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		199		810		—		1,009
Noncontrolling interests’ share of consolidated joint venture total revenues	(140)		(17,751)		—		—		—		(17,891)
Operating expenses	(80,185)		(105,769)		(185,939)		—		—		(371,893)
Healthpeak’s share of unconsolidated joint venture operating expenses	(853)		(611)		(6,953)		(25,046)		—		(33,463)
Noncontrolling interests’ share of consolidated joint venture operating expenses	41		5,056		—		—		—		5,097
Adjustments to NOI(2)	(24,176)		(3,926)		1,246		85		—		(26,771)
Adjusted NOI	244,897		203,920		50,289		9,342		—		508,448
Plus: Adjustments to NOI(2)	24,176		3,926		(1,246)		(85)		—		26,771
Interest income	—		—		—		25,121		—		25,121
Interest expense	(150)		(881)		(3,842)		—		(80,651)		(85,524)
Depreciation and amortization	(145,388)		(121,326)		(62,283)		—		—		(328,997)
General and administrative	—		—		—		—		(48,990)		(48,990)
Transaction costs	(11)		(295)		(1,090)		(21)		—		(1,417)
Impairments and loan loss reserves	—		—		—		(4,173)		—		(4,173)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(225,157)		(225,157)
Other income (expense), net	33		(2,454)		2,341		482		3,532		3,934
Less: Government grant income	—		—		(1,397)		—		—		(1,397)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,896)		(814)		(149)		(9,257)		—		(12,116)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	99		12,695		—		—		—		12,794
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	121,760		270,009		(17,377)		21,409		(351,266)		44,535
Income tax benefit (expense)	—		—		—		—		755		755
Equity income (loss) from unconsolidated joint ventures	18		328		639		1,205		—		2,190
Income (loss) from continuing operations	121,778		270,337		(16,738)		22,614		(350,511)		47,480
Income (loss) from discontinued operations	—		—		—		—		383,968		383,968
Net income (loss)	$	121,778	$	270,337	$	(16,738)	$	22,614	$	33,457	$	431,448

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

See Notes 3, 4, and 5 for significant transactions impacting the Company’s segment assets during the periods presented.

30

NOTE 14.  Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Six Months Ended June 30,
	2022		2021
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	74,327	$	109,277
Income taxes paid (refunded)	(612)		4,026
Capitalized interest	16,320		10,867
Supplemental schedule of non-cash investing and financing activities:
Increase in ROU asset in exchange for new lease liability related to operating leases	508		13,157
Seller financing provided on disposition of real estate asset	—		559,745
Accrued construction costs	163,391		113,221
Vesting of restricted stock units and conversion of non-managing member units into common stock	803		900
Carrying value of mortgages assumed by buyer in real estate dispositions	—		106,632

The following table summarizes certain cash flow information related to assets classified as discontinued operations (in thousands):

	Six Months Ended June 30,
	2022		2021
Leasing costs, tenant improvements, and recurring capital expenditures	$	21	$	2,349
Development, redevelopment, and other major improvements of real estate	18		4,569
Depreciation and amortization of real estate, in-place lease, and other intangibles	—		—

The following table summarizes cash, cash equivalents and restricted cash (in thousands):

	Six Months Ended June 30,
	2022		2021		2022		2021		2022		2021
	Continuing operations				Discontinued operations				Total
Beginning of period:
Cash and cash equivalents	$	158,287	$	44,226	$	7,707	$	53,085	$	165,994	$	97,311
Restricted cash	53,454		67,206		—		17,168		53,454		84,374
Cash, cash equivalents and restricted cash	$	211,741	$	111,432	$	7,707	$	70,253	$	219,448	$	181,685
End of period:
Cash and cash equivalents	$	73,013	$	96,923	$	8,070	$	17,354	$	81,083	$	114,277
Restricted cash	54,815		129,052		—		974		54,815		130,026
Cash, cash equivalents and restricted cash	$	127,828	$	225,975	$	8,070	$	18,328	$	135,898	$	244,303

31

NOTE 15.  Variable Interest Entities

Unconsolidated Variable Interest Entities

At June 30, 2022 and December 31, 2021, the Company had investments in: (i) two unconsolidated VIE joint ventures and (ii) marketable debt securities of one VIE. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated joint ventures (the LLC investment and Needham Land Parcel JV discussed below), it has no formal involvement in these VIEs beyond its investments.

Debt Securities Investment. The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets. These securities are classified as held-to-maturity because the Company has the intent and ability to hold the securities until maturity.

LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).

Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a life science development joint venture in Needham, Massachusetts for $13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at June 30, 2022 was as follows (in thousands):

VIE Type	Asset Type	Maximum Loss Exposure and Carrying Amount(1)
Continuing operations:
CMBS and LLC investment	Other assets, net	$	36,599
Needham Land Parcel JV	Investments in and advances to unconsolidated joint ventures	14,831

_______________________________________

(1)The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

As of June 30, 2022, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including under circumstances in which it could be exposed to further losses (e.g., cash shortfalls).

See Notes 3, 4, and 7 for additional descriptions of the nature, purpose, and operating activities of the Company’s unconsolidated VIEs and interests therein.

32

Consolidated Variable Interest Entities

The Company’s consolidated total assets and total liabilities at June 30, 2022 and December 31, 2021 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to the Company.

Ventures V, LLC.  The Company holds a 51% ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases MOBs (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of Ventures V or kick-out rights over the managing member. The Company consolidates Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures).

Life Science JVs.  The Company holds a 99% ownership interest in multiple joint venture entities that own and lease life science assets (the “Life Science JVs”). The Life Science JVs are VIEs as the members share in certain decisions of the entities, but substantially all of the activities are performed on behalf of the Company. The Company consolidates the Life Science JVs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Life Science JVs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Life Science JVs may only be used to settle their contractual obligations (primarily from capital expenditures). Refer to Note 11 for a discussion of certain put options associated with the Life Science JVs.

MSREI MOB JV. The Company holds a 51% ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases MOBs (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint venture or kick-out rights over the managing member. The Company consolidates the MSREI JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of the MSREI JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the MSREI JV may only be used to settle its contractual obligations (primarily from capital expenditures).

DownREITs.  The Company holds a controlling ownership interest in and is the managing member of seven DownREITs. The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

33

Exchange Accommodation Titleholder. During the three months ended June 30, 2022, the Company acquired one MOB using a reverse like-kind exchange structure pursuant to Section 1031 of the Internal Revenue Code (a “reverse 1031 exchange”). Additionally, during the three months ended March 31, 2022, the Company acquired two MOBs using a reverse 1031 exchange. As of June 30, 2022, the Company had not completed these reverse 1031 exchanges and as such, the acquired properties remained in the possession of the Exchange Accommodation Titleholder (“EAT”). The EAT was classified as a VIE as it was a “thinly capitalized” entity. The Company consolidated the EAT because it had the ability to control the activities that most significantly impacted the economic performance of the EAT and was, therefore, the primary beneficiary of the EAT. The properties held by the EAT had a carrying value of $66 million as of June 30, 2022. The assets of the EAT primarily consisted of leased properties (net real estate, including intangibles) and rents receivable; their obligations primarily consisted of capital expenditures for the properties. Assets generated by the EAT may only be used to settle its contractual obligations (primarily from capital expenditures).

During the year ended December 31, 2021, the Company acquired two MOBs using reverse 1031 exchanges. As of December 31, 2021, the Company had not completed the reverse 1031 exchanges and as such, the acquired properties remained in the possession of the EAT. These properties held by the EAT had a carrying value of $77 million as of December 31, 2021. These reverse 1031 exchanges were completed in February 2022.

Total assets and total liabilities include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Buildings and improvements	$	2,331,975	$	2,303,920
Development costs and construction in progress	138,655		82,303
Land	510,096		548,168
Accumulated depreciation and amortization	(592,488)		(551,097)
Net real estate	2,388,238		2,383,294
Accounts receivable, net	3,933		5,455
Cash and cash equivalents	37,274		22,295
Restricted cash	211		114
Intangible assets, net	106,855		117,180
Assets held for sale and discontinued operations, net	216		754
Right-of-use asset, net	108,390		107,993
Other assets, net	66,610		62,886
Total assets	$	2,711,727	$	2,699,971
Liabilities
Mortgage debt	$	144,451	$	144,350
Intangible liabilities, net	27,410		23,909
Liabilities related to assets held for sale and discontinued operations, net	1,668		1,677
Lease liability	98,666		99,213
Accounts payable, accrued liabilities, and other liabilities	69,143		58,440
Deferred revenue	25,431		21,546
Total liabilities	$	366,769	$	349,135

34

Total assets and liabilities related to assets held for sale and discontinued operations include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Accounts receivable, net	$	—	$	62
Cash and cash equivalents	153		59
Other assets, net	63		633
Total assets	$	216	$	754
Liabilities
Accounts payable, accrued liabilities, and other liabilities	$	1,668	$	1,677
Total liabilities	$	1,668	$	1,677

NOTE 16.  Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets were immaterial at June 30, 2022 and December 31, 2021.

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	June 30, 2022(3)				December 31, 2021(3)
	Carrying Value		Fair Value		Carrying Value		Fair Value
Loans receivable, net(2)	$	413,962	$	432,914	$	415,811	$	437,607
Marketable debt securities(2)	21,345		21,345		21,003		21,003
Interest rate swap instruments(2)	1,629		1,629		—		—
Interest rate cap instruments(2)	—		—		397		397
Bank line of credit and commercial paper(2)	1,448,569		1,448,569		1,165,975		1,165,975
Senior unsecured notes(1)	4,655,852		4,360,241		4,651,933		5,054,747
Mortgage debt(2)	349,329		339,356		352,081		352,800

_______________________________________

(1)Level 1: Fair value calculated based on quoted prices in active markets.

(2)Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, interest rate swap instruments, and interest rate cap instruments, standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit and commercial paper, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3)During the six months ended June 30, 2022 and year ended December 31, 2021, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

NOTE 17.  Derivative Financial Instruments

The Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. At June 30, 2022, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by approximately $5 million.

35

In March 2021, the Company repaid $39 million of variable rate secured debt on two SHOP assets and terminated the two associated interest rate swap instruments. Therefore, at December 31, 2021, the Company had no interest rate swap instruments.

In April 2021, the Company executed two interest rate cap instruments on its $142 million of variable rate mortgage debt issued in conjunction with the acquisition of the MOB Portfolio (see Note 3).

In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026.

The following table summarizes the Company’s interest rate swap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Pay Rate	Receive Rate	June 30, 2022		December 31, 2021
April 2022(2)	May 2026	Cash flow	$	51,100	5.08 %	1 mo. USD-LIBOR-BBA + 2.50%	$	586	$	—
April 2022(2)	May 2026	Cash flow	91,000		4.63 %	1 mo. USD-LIBOR-BBA + 2.05%	1,043		—

_____________________________

(1)At June 30, 2022, the interest rate swap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate secured debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.

The following table summarizes the Company’s interest rate cap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Strike Rate	Index	June 30, 2022		December 31, 2021
April 2021(2)	May 2024	Non-designated	$	142,100	2.00 %	1 mo. USD-LIBOR-BBA	$	—	$	397

_____________________________

(1)At December 31, 2021, the interest rate cap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents two interest rate cap instruments that manage the Company’s exposure to variable cash flows on certain mortgage debt borrowings by limiting interest rates. These interest rate cap instruments were terminated in April 2022.

During the three and six months ended June 30, 2022, the Company recognized a $0.1 million and $2 million increase, respectively, in the fair value of the interest rate cap instruments within other income (expense), net.

NOTE 18.    Accounts Payable, Accrued Liabilities, and Other Liabilities

The following table summarizes the Company’s accounts payable, accrued liabilities, and other liabilities, excluding accounts payable, accrued liabilities, and other liabilities related to assets classified as discontinued operations (in thousands):

	June 30, 2022		December 31, 2021
Refundable entrance fees(1)	$	275,152	$	288,409
Accrued construction costs	163,391		179,995
Accrued interest	59,092		59,342
Other accounts payable and accrued liabilities	209,184		227,638
Accounts payable, accrued liabilities, and other liabilities	$	706,819	$	755,384

_______________________________________

(1)At June 30, 2022 and December 31, 2021, unamortized nonrefundable entrance fee liabilities were $508 million and $496 million, respectively, which are recorded within deferred revenue on the Consolidated Balance Sheets. During the three and six months ended June 30, 2022, the Company collected nonrefundable entrance fees of $29 million and $50 million, respectively, and recognized amortization of $19 million and $38 million, respectively. During the three and six months ended June 30, 2021, the Company collected nonrefundable entrance fees of $24 million and $38 million, respectively, and recognized amortization of $18 million and $38 million, respectively. The amortization of nonrefundable entrance fees is included within resident fees and services on the Consolidated Statements of Operations.

36

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this report to “Healthpeak,” the “Company,” “we,” “us” or “our” mean Healthpeak Properties, Inc., together with its consolidated subsidiaries. Unless the context suggests otherwise, references to “Healthpeak Properties, Inc.” mean the parent company without its subsidiaries.

Cautionary Language Regarding Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could cause actual results, including our future financial condition and results of operations, to differ materially from those expressed or implied by any forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and uncertainties that may affect our business and future financial performance.

Forward-looking statements are based on certain assumptions and analysis made in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors that we believe are appropriate under the circumstances. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Quarterly Report on Form 10-Q.

As more fully set forth under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:

•the coronavirus (“Covid”) pandemic and health and safety measures intended to reduce its spread, the availability, effectiveness and public usage and acceptance of vaccines, and how quickly and to what extent normal economic and operating conditions can resume within the markets in which we operate;

•the ability of our existing and future tenants, operators, and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and manage their expenses in order to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;

•increased competition, operating costs, and market changes affecting our tenants, operators, and borrowers;

•the financial condition of our tenants, operators, and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings;

•our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested in multiple industries and exposes us to the risks inherent in illiquid investments;

•our ability to identify and secure replacement tenants and operators and the potential renovation costs and regulatory approvals associated therewith;

•our property development, redevelopment, and tenant improvement activity risks, including project abandonments, project delays, and lower profits than expected;

•changes within the life science industry;

•high levels of regulation, funding requirements, expense and uncertainty faced by our life science tenants;

•the ability of the hospitals on whose campuses our medical office buildings (“MOBs”) are located and their affiliated healthcare systems to remain competitive or financially viable;

•our ability to maintain or expand our hospital and health system client relationships;

•operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEA”);

37

•economic and other conditions that negatively affect geographic areas from which we recognize a greater percentage of our revenue;

•uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators;

•our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation;

•our use of fixed rent escalators, contingent rent provisions and/or rent escalators based on the Consumer Price Index;

•competition for suitable healthcare properties to grow our investment portfolio;

•our ability to foreclose on collateral securing our real estate-related loans;

•our ability to make material acquisitions and successfully integrate them;

•the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs;

•an increase in our borrowing costs, including due to higher interest rates;

•the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, volatility or uncertainty in the capital markets, and other factors;

•cash available for distribution to stockholders and our ability to make dividend distributions at expected levels;

•our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness;

•changes in global, national and local economic and other conditions;

•laws or regulations prohibiting eviction of our tenants;

•the failure of our tenants, operators, and borrowers to comply with federal, state and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements;

•required regulatory approvals to transfer our senior housing properties;

•compliance with the Americans with Disabilities Act and fire, safety and other regulations;

•the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid;

•legislation to address federal government operations and administration decisions affecting the Centers for Medicare and Medicaid Services;

•our participation in the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) Provider Relief Fund and other Covid-related stimulus and relief programs;

•provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders;

•environmental compliance costs and liabilities associated with our real estate investments;

•our ability to maintain our qualification as a real estate investment trust (“REIT”);

•changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions;

•calculating non-REIT tax earnings and profits distributions;

•ownership limits in our charter that restrict ownership in our stock;

•the loss or limited availability of our key personnel; and

•our reliance on information technology systems and the potential impact of system failures, disruptions or breaches.

Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

38

Overview

The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations. We will discuss and provide our analysis in the following order:

•Executive Summary

•Market Trends and Uncertainties

•Overview of Transactions

•Dividends

•Results of Operations

•Liquidity and Capital Resources

•Non-GAAP Financial Measures Reconciliations

•Critical Accounting Estimates and Recent Accounting Pronouncements

Executive Summary

Healthpeak Properties, Inc. is a Standard & Poor’s (“S&P”) 500 company that acquires, develops, owns, leases and manages healthcare real estate across the United States (“U.S.”). Our company was originally founded in 1985. We are a Maryland corporation and qualify as a self-administered REIT. Our corporate headquarters are located in Denver, Colorado and we have additional offices in California, Tennessee, and Massachusetts.

During 2020, we began the process of disposing of our senior housing triple-net and senior housing operating property (“SHOP”) portfolios. As of December 31, 2020, we concluded that the planned dispositions represented a strategic shift that had and will have a major effect on our operations and financial results and, therefore, the assets are classified as discontinued operations in all periods presented herein. In September 2021, we successfully completed the disposition of both portfolios. See Note 4 to the Consolidated Financial Statements for further information regarding discontinued operations.

In conjunction with the disposal of our senior housing triple-net and SHOP portfolios, we focused our strategy on investing in a diversified portfolio of high-quality healthcare properties across our three core asset classes of life science, medical office, and continuing care retirement community (“CCRC”) real estate. Under the life science and medical office segments, we invest through the acquisition, development and management of life science facilities, MOBs, and hospitals. Under the CCRC segment, our properties are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of debt investments and an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH JV”).

At June 30, 2022, our portfolio of investments, including properties in our unconsolidated joint ventures, consisted of interests in 481 properties. The following table summarizes information for our reportable and other non-reportable segments, excluding discontinued operations, for the three months ended June 30, 2022 (dollars in thousands):

Segment	Total Portfolio Adjusted NOI(1)		Percentage of Total Portfolio Adjusted NOI		Number of Properties
Life science	$	137,422	50	%	149
Medical office	107,281		39	%	298
CCRC	23,292		9	%	15
Other non-reportable	4,119		2	%	19
Totals	$	272,114	100	%	481

_______________________________________

(1)Total Portfolio metrics include results of operations from disposed properties through the disposition date. See “Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for additional information regarding Adjusted NOI and see Note 13 to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by segment to net income (loss).

For a description of our significant activities during 2022, see “Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Overview of Transactions” in this report.

39

We invest in and manage our real estate portfolio for the long-term to maximize benefit to our stockholders and support the growth of our dividends. Our strategy consists of four core elements:

(i)Our real estate: Our portfolio is grounded in high-quality properties in desirable locations. We focus on three purposely selected private pay asset classes—life science, medical office, and continuing care retirement community—to provide stability through inevitable market cycles.

(ii)Our financials: We maintain a strong investment-grade balance sheet with ample liquidity as well as long-term fixed-rate debt financing with staggered maturities to reduce our exposure to interest rate volatility and refinancing risk.

(iii)Our partnerships: We work with leading healthcare companies, operators, and service providers and are responsive to their space and capital needs. We provide high-quality property management services to encourage tenants to renew, expand, and relocate into our properties, which drives increased occupancy, rental rates, and property values.

(iv)Our platform: We have a people-first culture that we believe attracts, develops and retains top talent. We continually strive to create and maintain an industry-leading platform, with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.

Market Trends and Uncertainties

Our operating results, including our sources and uses of capital, have been and will continue to be impacted by the Covid pandemic, as well as by global and national economic and market conditions generally and by the local economic conditions where our properties are located.

We do not yet know the full, long-term economic impact of the Covid pandemic and whether or when occupancy and revenue in our CCRC communities and the senior housing facilities owned by our SWF SH JV will return to pre-pandemic levels. In addition, our tenants, operators, and borrowers have experienced significant cost increases as a result of increased health and safety measures, staffing shortages, increased governmental regulation and compliance, vaccine mandates, and other operational changes necessitated either directly or indirectly by the Covid pandemic, as well as due to current inflationary pressures. Labor costs in particular have increased as a result of higher staffing hours, increased hourly wages and bonuses, greater overtime, and increased usage of contract labor. We anticipate that many of these expenses will remain at these higher levels even after the pandemic passes, and are likely to reduce margins in the business.

Further, the Covid pandemic and its ongoing impacts continue to cause disruptions in the U.S. and global economies and capital markets, resulting in volatility, widening credit spreads, and limited liquidity availability. Other factors, such as rising interest rates, high inflation, supply chain disruptions, growing geopolitical tensions, and increased volatility in public equity and fixed income markets have also led to increased costs and limited the availability of capital. To the extent our tenants or operators experience increased costs or financing difficulties due to the foregoing macroeconomic conditions, they may be unable or unwilling to make payments or perform their obligations when due.

We have also seen significant inflation in construction costs over the past 12-18 months, which may, together with rising costs of capital, negatively affect the expected yields on our development and redevelopment projects. In addition, labor shortages and global supply chain disruptions, including procurement delays and long lead times on certain materials, have adversely impacted and could continue to adversely impact the scheduled completion and/or costs of these projects.

We continuously monitor the effects of domestic and global events, including but not limited to the current and expected impact of the Covid pandemic, inflation, labor shortages, supply chain matters, and rising interest rates, on our operations and financial position, as well as on the operations and financial position of our tenants, operators, and borrowers, to ensure that we remain responsive and adaptable to the dynamic changes in our operating environment.

A discussion of potential long-term changes in the industry are more fully set forth under Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Covid Update” in our Annual Report on Form 10-K for the year ended December 31, 2021.

See Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 for additional discussion of the risks posed by the Covid pandemic and macroeconomic conditions, as well as the uncertainties we and our tenants, operators, and borrowers may face as a result.

40

Overview of Transactions

67 Smith Place

In January 2022, we closed a life science acquisition in Cambridge, Massachusetts for $72 million.

Vista Sorrento Phase II

In January 2022, we closed a life science acquisition in San Diego, California for $24 million.

Webster MOB Portfolio

In March 2022, we acquired a portfolio of two MOBs in Houston, Texas for $43 million.

Northwest Medical Plaza

In May 2022, we acquired one MOB in Bentonville, Arkansas for $26 million.

Other Real Estate Transactions

•During the six months ended June 30, 2022, we sold one life science facility in Utah for $14 million.

•Also during the six months ended June 30, 2022, we sold our remaining hospital classified as a direct financing lease (“DFL”) for $68 million.

•During the three months ended June 30, 2022, we sold three MOBs and one MOB land parcel for $27 million.

•In July 2022, we completed two MOB sales for aggregate proceeds of $9 million.

•On August 1, 2022, we entered into a master equity transaction agreement with a sovereign wealth fund (“SWF Partner”) that provides us the opportunity to sell up to 30% interests in certain redevelopment and future development projects owned by us.

Concurrently, we executed definitive agreements with the SWF Partner to sell a 30% interest in seven life science assets in South San Francisco, California for gross proceeds of $126 million. We and the SWF Partner will share in key decisions related to the planned redevelopment and operation of the assets, resulting in us deconsolidating the previously wholly-owned assets and recognizing our 70% share as an equity method investment.

Financing Activities

•In April 2022, we terminated our existing interest rate cap instruments associated with $142 million of variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026.

Development Activities

•At June 30, 2022, we had six life science development projects in process with an aggregate total estimated cost of approximately $1.0 billion.

•During the six months ended June 30, 2022, the following projects were placed in service: (i) three MOB development projects with total costs incurred of $58 million, (ii) one MOB redevelopment project with total costs incurred of $10 million, (iii) three life science development projects with total costs incurred of $269 million, (iv) one life science redevelopment project with total costs incurred of $60 million, and (v) a portion of one life science development project with total costs incurred of $40 million.

Dividends

The following table summarizes our common stock cash dividends declared in 2022:

Declaration Date	Record Date	Amount Per Share		Dividend Payment Date
January 27	February 11	$	0.30	February 22
April 28	May 9	0.30		May 20
July 28	August 8	0.30		August 19

41

Results of Operations

We evaluate our business and allocate resources among our reportable business segments: (i) life science, (ii) medical office, and (iii) CCRC. Under the life science and medical office segments, we invest through the acquisition, development, and management of life science facilities, MOBs, and hospitals, which generally requires a greater level of property management. Our CCRCs are operated through RIDEA structures. We have other non-reportable segments that are comprised primarily of: (i) an interest in our unconsolidated SWF SH JV and (ii) debt investments. We evaluate performance based upon property adjusted net operating income (“Adjusted NOI” or “Cash NOI”) in each segment. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in Note 2 to the Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (“SEC”), as updated by Note 2 to the Consolidated Financial Statements herein.

Non-GAAP Financial Measures

Net Operating Income

NOI and Adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 13 to the Consolidated Financial Statements. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. NOI and Adjusted NOI include our share of income (loss) generated by unconsolidated joint ventures and exclude noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. Adjusted NOI is oftentimes referred to as “Cash NOI.” Management believes NOI and Adjusted NOI are important supplemental measures because they provide relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and present them on an unlevered basis. We use NOI and Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our Same-Store (“SS”) performance, as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items. Further, our definitions of NOI and Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating NOI and Adjusted NOI. For a reconciliation of NOI and Adjusted NOI to net income (loss) by segment, refer to Note 13 to the Consolidated Financial Statements.

Operating expenses generally relate to leased medical office and life science properties, as well as CCRC facilities. We generally recover all or a portion of our leased medical office and life science property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense.

Same-Store

Same-Store NOI and Adjusted (Cash) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our consolidated portfolio of properties. Same-Store Adjusted NOI excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.

Properties are included in Same-Store once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, a change in reporting structure or operator transition has been agreed to, or a significant tenant relocates from a Same-Store property to a non Same-Store property and that change results in a corresponding increase in revenue. We do not report Same-Store metrics for our other non-reportable segments. For a reconciliation of Same-Store to total portfolio Adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.

42

Funds From Operations (“FFO”)

FFO encompasses Nareit FFO and FFO as Adjusted, each of which is described in detail below. We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

Nareit FFO. FFO, as defined by the National Association of Real Estate Investment Trusts (“Nareit”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other real estate-related depreciation and amortization, and adjustments to compute our share of Nareit FFO and FFO as Adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of Nareit FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our Nareit FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in Nareit FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

The presentation of pro-rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement.

Nareit FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute Nareit FFO in accordance with the current Nareit definition; however, other REITs may report Nareit FFO differently or have a different interpretation of the current Nareit definition from ours.

43

FFO as Adjusted. In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction-related items, other impairments (recoveries) and other losses (gains), restructuring and severance related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), foreign currency remeasurement losses (gains), deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”). Transaction-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Other impairments (recoveries) and other losses (gains) include interest income associated with early and partial repayments of loans receivable and other losses or gains associated with non-depreciable assets including goodwill, DFLs, undeveloped land parcels, and loans receivable. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that Nareit created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the Nareit defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to Nareit FFO and FFO as Adjusted and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

Adjusted FFO (“AFFO”). AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) amortization of stock-based compensation, (ii) amortization of deferred financing costs, net, (iii) straight-line rents, (iv) deferred income taxes, and (v) other AFFO adjustments, which include: (a) amortization of acquired market lease intangibles, net, (b) non-cash interest related to DFLs and lease incentive amortization (reduction of straight-line rents), (c) actuarial reserves for insurance claims that have been incurred but not reported, and (d) amortization of deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, AFFO is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements, and includes adjustments to compute our share of AFFO from our unconsolidated joint ventures. More specifically, recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements ("AFFO capital expenditures") excludes our share from unconsolidated joint ventures (reported in “other AFFO adjustments”). Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of AFFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our AFFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (reported in “other AFFO adjustments”). See FFO for further disclosure regarding our use of pro-rata share information and its limitations. Other REITs or real estate companies may use different methodologies for calculating AFFO, and accordingly, our AFFO may not be comparable to those reported by other REITs. Although our AFFO computation may not be comparable to that of other REITs, management believes AFFO provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. We believe AFFO is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. AFFO does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, and (iv) restructuring and severance-related charges. Furthermore, AFFO is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP. For a reconciliation of net income (loss) to AFFO and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

44

Comparison of the Three and Six Months Ended June 30, 2022 to the Three and Six Months Ended June 30, 2021

Overview

Three Months Ended June 30, 2022 and 2021

The following table summarizes results for the three months ended June 30, 2022 and 2021 (in thousands):

	Three Months Ended June 30,
	2022		2021		Change
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	(207,936)
Nareit FFO	236,154		149,671		86,483
FFO as Adjusted	236,478		217,242		19,236
AFFO	195,595		189,038		6,557

Net income (loss) applicable to common shares decreased primarily as a result of the following:

•a decrease in income from discontinued operations, primarily as a result of: (i) a decrease in gain on sales of real estate from dispositions of our senior housing portfolios and (ii) decreased NOI from dispositions of our senior housing portfolios, partially offset by lower impairments of depreciable real estate and goodwill;

•a decrease in gains on sale of depreciable real estate related to the Hoag Hospital sale in May 2021;

•a decrease in interest income primarily as a result of principal repayments on and sales of loans receivable in 2021 and 2022;

•an increase in depreciation, primarily as a result of: (i) 2021 and 2022 acquisitions of real estate and (ii) development and redevelopment projects placed in service during 2021 and 2022; and

•an increase in interest expense, primarily as a result of higher interest rates under the commercial paper program.

The decrease in net income (loss) applicable to common shares was partially offset by:

•a decrease in loss on debt extinguishments related to our repurchase and redemption of certain outstanding senior notes in the second quarter of 2021;

•an increase in NOI generated from our life science and medical office segments related to: (i) 2021 and 2022 acquisitions of real estate, (ii) development and redevelopment projects placed in service during 2021 and 2022, and (iii) new leasing activity during 2021 and 2022 (including the impact to straight-line rents); and

•a reduction in loan loss reserves in 2022 primarily due to a lower loans receivable balance.

Nareit FFO increased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO:

•gain on sales of depreciable real estate;

•depreciation and amortization expense; and

•impairment charges related to depreciable real estate.

FFO as Adjusted increased primarily as a result of the aforementioned events impacting Nareit FFO, except for the following, which are excluded from FFO as Adjusted:

•loss on debt extinguishment;

•the goodwill impairment charge related to senior housing triple-net asset sales; and

•loan loss reserves.

AFFO increased primarily as a result of the aforementioned events impacting FFO as Adjusted, except for the impact of straight-line rents, which is excluded from AFFO. The increase was partially offset by higher AFFO capital expenditures during the period.

45

Six Months Ended June 30, 2022 and 2021

The following table summarizes results for the six months ended June 30, 2022 and 2021 (in thousands):

	Six Months Ended June 30,
	2022		2021		Change
Net income (loss) applicable to common shares	$	137,693	$	419,336	$	(281,643)
Nareit FFO	479,583		189,905		289,678
FFO as Adjusted	471,295		432,635		38,660
AFFO	397,625		373,839		23,786

Net income (loss) applicable to common shares decreased primarily as a result of the following:

•a decrease in income from discontinued operations, primarily as a result of: (i) a decrease in gain on sales of real estate from dispositions of our senior housing portfolios and (ii) decreased NOI from dispositions of our senior housing portfolios, partially offset by lower impairments of depreciable real estate and goodwill;

•a decrease in gains on sale of depreciable real estate related to the Hoag Hospital sale in May 2021;

•an increase in depreciation, primarily as a result of: (i) 2021 and 2022 acquisitions of real estate and (ii) development and redevelopment projects placed in service during 2021 and 2022;

•a decrease in interest income primarily as a result of principal repayments on and sales of loans receivable in 2021 and 2022; and

•expenses incurred for tenant relocation and other costs associated with a planned MOB demolition.

The decrease in net income (loss) applicable to common shares was partially offset by:

•a decrease in loss on debt extinguishments related to our repurchase and redemption of certain outstanding senior notes in the first and second quarters of 2021;

•an increase in NOI generated from our life science and medical office segments related to: (i) 2021 and 2022 acquisitions of real estate, (ii) development and redevelopment projects placed in service during 2021 and 2022, and (iii) new leasing activity during 2021 and 2022 (including the impact to straight-line rents);

•a gain on sale of a hospital that was classified as a DFL that was sold in the first quarter of 2022;

•a reduction in interest expense, primarily as a result of senior unsecured notes repurchases and redemptions in the first and second quarters of 2021, partially offset by higher interest rates under the commercial paper program;

•an increase in government grant income received under the CARES Act in 2022; and

•a reduction in loan loss reserves in 2022 primarily due to a lower loans receivable balance.

Nareit FFO increased primarily as a result of the aforementioned events impacting net income (loss) applicable to common shares, except for the following, which are excluded from Nareit FFO:

•net gain on sales of depreciable real estate;

•depreciation and amortization expense;

•impairment charges related to depreciable real estate.

FFO as Adjusted increased primarily as a result of the aforementioned events impacting Nareit FFO, except for the following, which are excluded from FFO as Adjusted:

•loss on debt extinguishment;

•the gain on sale of a hospital that was classified as a DFL;

•the expenses for tenant relocation and other costs associated with a planned MOB demolition;

•the goodwill impairment charge related to senior housing triple-net asset sales; and

•loan loss reserves.

AFFO increased primarily as a result of the aforementioned events impacting FFO as Adjusted, except for the impact of straight-line rents, which is excluded from AFFO. The increase was partially offset by higher AFFO capital expenditures during the period.

46

Segment Analysis 

The following tables provide selected operating information for our Same-Store and total property portfolio for each of our reportable segments. For the three months ended June 30, 2022, our Same-Store consists of 381 properties representing properties acquired or placed in service and stabilized on or prior to April 1, 2021 and that remained in operations under a consistent reporting structure through June 30, 2022. For the six months ended June 30, 2022, our Same-Store consists of 379 properties representing properties acquired or placed in service and stabilized on or prior to January 1, 2021 and that remained in operations under a consistent reporting structure through June 30, 2022. Our total property portfolio consisted of 481 and 473 properties at June 30, 2022 and 2021, respectively.

47

Life Science

The following table summarizes results at and for the three months ended June 30, 2022 and 2021 (dollars and square feet in thousands, except per square foot data):

	SS									Total Portfolio
	Three Months Ended June 30,									Three Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Rental and related revenues	$	158,881		$	147,204		$	11,677		$	207,771		$	177,527		$	30,244
Healthpeak’s share of unconsolidated joint venture total revenues	1,253			1,412			(159)			1,267			1,412			(145)
Noncontrolling interests’ share of consolidated joint venture total revenues	(25)			(24)			(1)			(62)			(75)			13
Operating expenses	(37,007)			(32,837)			(4,170)			(49,446)			(40,724)			(8,722)
Healthpeak’s share of unconsolidated joint venture operating expenses	(483)			(427)			(56)			(483)			(428)			(55)
Noncontrolling interests’ share of consolidated joint venture operating expenses	8			7			1			19			21			(2)
Adjustments to NOI(1)	(12,022)			(9,288)			(2,734)			(21,644)			(12,366)			(9,278)
Adjusted NOI	$	110,605		$	106,047		$	4,558		137,422			125,367			12,055
Less: non-SS Adjusted NOI										(26,817)			(19,320)			(7,497)
SS Adjusted NOI										$	110,605		$	106,047		$	4,558
Adjusted NOI % change							4.3		%
Property count(2)	119			119						149			142
End of period occupancy	98.8		%	97.5		%				98.6		%	96.6		%
Average occupancy	98.9		%	97.8		%				98.8		%	96.8		%
Average occupied square feet	8,742			8,658						10,607			9,971
Average annual total revenues per occupied square foot(3)	$	68		$	65					$	71		$	67
Average annual base rent per occupied square foot(4)	$	53		$	51					$	55		$	53

_______________________________________

(1)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(2)From our second quarter 2021 presentation of Same-Store, we added: (i) five stabilized developments placed in service, (ii) five stabilized acquisitions, (iii) three stabilized redevelopments placed in service, and (iv) one stabilized property that previously experienced a significant tenant relocation, and we removed: (i) three life science facilities that were placed into redevelopment, (ii) one life science facility that was placed into development, (iii) one life science facility that was sold, and (iv) one life science facility that was classified as held for sale.

(3)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

(4)Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result of the following:

•annual rent escalations;

•higher occupancy;

•new leasing activity; and

•mark-to-market lease renewals.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Same-Store and the following Non-Same-Store impacts:

•an increase in NOI from (i) increased occupancy in developments and redevelopments placed in service in 2021 and 2022 and (ii) acquisitions in 2021 and 2022.

48

The following table summarizes results at and for the six months ended June 30, 2022 and 2021 (dollars and square feet in thousands, except per square foot data):

	SS									Total Portfolio(1)
	Six Months Ended June 30,									Six Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Rental and related revenues	$	309,327		$	288,403		$	20,924		$	401,826		$	347,461		$	54,365
Healthpeak’s share of unconsolidated joint venture total revenues	2,685			2,749			(64)			2,698			2,749			(51)
Noncontrolling interests’ share of consolidated joint venture total revenues	(51)			(49)			(2)			(119)			(140)			21
Operating expenses	(72,540)			(64,114)			(8,426)			(97,635)			(80,185)			(17,450)
Healthpeak’s share of unconsolidated joint venture operating expenses	(966)			(853)			(113)			(966)			(853)			(113)
Noncontrolling interests’ share of consolidated joint venture operating expenses	16			14			2			38			41			(3)
Adjustments to NOI(2)	(20,992)			(18,594)			(2,398)			(35,756)			(24,176)			(11,580)
Adjusted NOI	$	217,479		$	207,556		$	9,923		270,086			244,897			25,189
Less: non-SS Adjusted NOI										(52,607)			(37,341)			(15,266)
SS Adjusted NOI										$	217,479		$	207,556		$	9,923
Adjusted NOI % change							4.8		%
Property count(3)	118			118						149			142
End of period occupancy	98.8		%	97.6		%				98.6		%	96.6		%
Average occupancy	98.7		%	97.9		%				98.5		%	96.7		%
Average occupied square feet	8,674			8,615						10,589			9,890
Average annual total revenues per occupied square foot(4)	$	68		$	64					$	70		$	66
Average annual base rent per occupied square foot(5)	$	53		$	50					$	54		$	52

_______________________________________

(1)Total Portfolio includes results of operations from disposed properties through the disposition date.

(2)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(3)From our second quarter 2021 presentation of Same-Store, we added: (i) six stabilized developments placed in service, (ii) five stabilized acquisitions, and (iii) four stabilized redevelopments placed in service, and we removed: (i) three life science facilities that were placed into redevelopment, (ii) one life science facility that was placed into development, (iii) one life science facility that was sold, and (iv) one life science facility that was classified as held for sale.

(4)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

(5)Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result of the following:

•annual rent escalations;

•higher occupancy;

•new leasing activity; and

•mark-to-market lease renewals.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned impacts to Same-Store and the following Non-Same-Store impacts:

•an increase in NOI from (i) increased occupancy in developments and redevelopments placed in service in 2021 and 2022 and (ii) acquisitions in 2021 and 2022.

49

Medical Office

The following table summarizes results at and for the three months ended June 30, 2022 and 2021 (dollars and square feet in thousands, except per square foot data):

	SS									Total Portfolio(1)
	Three Months Ended June 30,									Three Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Rental and related revenues	$	145,498		$	138,542		$	6,956		$	179,308		$	163,115		$	16,193
Income from direct financing leases	—			—			—			—			2,180			(2,180)
Healthpeak’s share of unconsolidated joint venture total revenues	739			687			52			761			710			51
Noncontrolling interests’ share of consolidated joint venture total revenues	(8,786)			(8,483)			(303)			(8,943)			(8,825)			(118)
Operating expenses	(48,781)			(45,234)			(3,547)			(63,321)			(54,648)			(8,673)
Healthpeak’s share of unconsolidated joint venture operating expenses	(300)			(317)			17			(301)			(317)			16
Noncontrolling interests’ share of consolidated joint venture operating expenses	2,726			2,473			253			2,726			2,552			174
Adjustments to NOI(2)	(1,546)			(1,952)			406			(2,949)			(2,003)			(946)
Adjusted NOI	$	89,550		$	85,716		$	3,834		107,281			102,764			4,517
Less: non-SS Adjusted NOI										(17,731)			(17,048)			(683)
SS Adjusted NOI										$	89,550		$	85,716		$	3,834
Adjusted NOI % change							4.5		%
Property count(3)	247			247						298			297
End of period occupancy	91.5		%	91.4		%				89.9		%	89.9		%
Average occupancy	91.6		%	91.3		%				89.9		%	90.0		%
Average occupied square feet	18,435			18,372						21,627			20,862
Average annual total revenues per occupied square foot(4)	$	32		$	31					$	34		$	31
Average annual base rent per occupied square foot(5)	$	27		$	26					$	27		$	27

___________________________________

(1)Total Portfolio includes results of operations from disposed properties through the disposition date.

(2)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(3)From our second quarter 2021 presentation of Same-Store, we added: (i) 11 stabilized acquisitions and (ii) 3 stabilized redevelopments placed in service, and we removed: (i) 8 MOBs that were placed into redevelopment, (ii) 6 MOBs that were sold, and (iii) 2 MOBs that were classified as held for sale.

(4)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

(5)Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result of the following:

•mark-to-market lease renewals;

•higher occupancy;

•annual rent escalations; and

•higher parking income and percentage-based rents.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned increases to Same-Store and the following Non-Same-Store impacts:

•increased NOI from our 2021 and 2022 acquisitions;

•increased occupancy in former redevelopment and development properties that have been placed in service; partially offset by

•decreased NOI from our 2021 and 2022 dispositions.

50

The following table summarizes results at and for the six months ended June 30, 2022 and 2021 (dollars and square feet in thousands, except per square foot data):

	SS									Total Portfolio(1)
	Six Months Ended June 30,									Six Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Rental and related revenues	$	288,720		$	275,648		$	13,072		$	355,403		$	321,153		$	34,250
Income from direct financing leases	—			—			—			1,168			4,343			(3,175)
Healthpeak’s share of unconsolidated joint venture total revenues	1,447			1,380			67			1,493			1,425			68
Noncontrolling interests’ share of consolidated joint venture total revenues	(17,452)			(17,069)			(383)			(17,763)			(17,751)			(12)
Operating expenses	(95,728)			(88,610)			(7,118)			(124,491)			(105,769)			(18,722)
Healthpeak’s share of unconsolidated joint venture operating expenses	(599)			(610)			11			(600)			(611)			11
Noncontrolling interests’ share of consolidated joint venture operating expenses	5,327			4,908			419			5,328			5,056			272
Adjustments to NOI(2)	(3,418)			(4,417)			999			(6,495)			(3,926)			(2,569)
Adjusted NOI	$	178,297		$	171,230		$	7,067		214,043			203,920			10,123
Less: non-SS Adjusted NOI										(35,746)			(32,690)			(3,056)
SS Adjusted NOI										$	178,297		$	171,230		$	7,067
Adjusted NOI % change							4.1		%
Property count(3)	246			246						298			297
End of period occupancy	91.5		%	91.5		%				89.9		%	89.9		%
Average occupancy	91.6		%	91.4		%				90.1		%	90.2		%
Average occupied square feet	18,387			18,343						21,661			20,783
Average annual total revenues per occupied square foot(4)	$	32		$	31					$	33		$	31
Average annual base rent per occupied square foot(5)	$	27		$	26					$	27		$	26

_______________________________________

(1)Total Portfolio includes results of operations from disposed properties through the disposition date.

(2)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(3)From our second quarter 2021 presentation of Same-Store, we added: (i) 10 stabilized acquisitions and (ii) 3 stabilized redevelopments placed in service, and we removed: (i) 8 MOBs that were placed into redevelopment, (ii) 6 MOBs that were sold, and (iii) 2 MOBs that were classified as held for sale.

(4)Average annual total revenues does not include non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

(5)Base rent does not include tenant recoveries, additional rents in excess of floors and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest, and deferred revenues).

Same-Store Adjusted NOI increased primarily as a result of the following:

•mark-to-market lease renewals;

•higher occupancy;

•annual rent escalations; and

•higher parking income and percentage-based rents.

Total Portfolio Adjusted NOI increased primarily as a result of the aforementioned increases to Same-Store and the following Non-Same-Store impacts:

•increased NOI from our 2021 and 2022 acquisitions;

•increased occupancy in former redevelopment and development properties that have been placed in service; partially offset by

•decreased NOI from our 2021 and 2022 dispositions.

51

Continuing Care Retirement Community

The following table summarizes results at and for the three months ended June 30, 2022 and 2021 (dollars in thousands, except per unit data):

	SS									Total Portfolio
	Three Months Ended June 30,									Three Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Resident fees and services	$	125,360		$	117,308		$	8,052		$	125,360		$	117,308		$	8,052
Government grant income(1)	209			87			122			209			87			122
Healthpeak’s share of unconsolidated joint venture total revenues	—			—			—			—			2,415			(2,415)
Operating expenses	(101,834)			(94,366)			(7,468)			(102,277)			(94,760)			(7,517)
Healthpeak’s share of unconsolidated joint venture operating expenses	—			—			—			—			(2,208)			2,208
Adjustments to NOI(2)	—			1,209			(1,209)			—			1,226			(1,226)
Adjusted NOI	$	23,735		$	24,238		$	(503)		23,292			24,068			(776)
Plus: non-SS adjustments										443			170			273
SS Adjusted NOI										$	23,735		$	24,238		$	(503)
Adjusted NOI % change							(2.1)		%
Property count(3)	15			15						15			15
Average occupancy	81.1		%	79.4		%				81.1		%	79.4		%
Average occupied units(4)	5,952			5,906						5,952			6,071
Average annual rent per occupied unit	$	84,388		$	79,509					$	84,388		$	78,955

_______________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations.

(2)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(3)From our second quarter 2021 presentation of Same-Store, no properties were added or removed.

(4)Represents average occupied units as reported by the operators for the three-month period.

Same-Store Adjusted NOI and Total Portfolio Adjusted NOI decreased primarily as a result of the following:

•higher labor costs; partially offset by

•increased occupancy and rates for resident fees; and

•lower Covid-related expenses

52

The following table summarizes results at and for the six months ended June 30, 2022 and 2021 (dollars in thousands, except per unit data):

	SS									Total Portfolio
	Six Months Ended June 30,									Six Months Ended June 30,
	2022			2021			Change			2022			2021			Change
Resident fees and services	$	246,920		$	233,436		$	13,484		$	246,920		$	233,436		$	13,484
Government grant income(1)	6,762			1,397			5,365			6,762			1,397			5,365
Healthpeak’s share of unconsolidated joint venture total revenues	—			—			—			—			6,903			(6,903)
Healthpeak’s share of unconsolidated joint venture government grant income	—			—			—			333			199			134
Operating expenses	(199,233)			(184,795)			(14,438)			(200,165)			(185,939)			(14,226)
Healthpeak’s share of unconsolidated joint venture operating expenses	—			—			—			—			(6,953)			6,953
Adjustments to NOI(2)	—			1,209			(1,209)			—			1,246			(1,246)
Adjusted NOI	$	54,449		$	51,247		$	3,202		53,850			50,289			3,561
Plus: non-SS adjustments										599			958			(359)
SS Adjusted NOI										$	54,449		$	51,247		$	3,202
Adjusted NOI % change							6.2		%
Property count(3)	15			15						15			15
Average occupancy	81.0		%	79.1		%				81.0		%	79.0		%
Average occupied units(4)	5,946			5,880						5,946			6,124
Average annual rent per occupied unit	$	85,328		$	79,875					$	85,440		$	79,013

_______________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations.

(2)Represents adjustments to NOI in accordance with our definition of Adjusted NOI. Refer to “Non-GAAP Financial Measures” above for definitions of NOI and Adjusted NOI.

(3)From our second quarter 2021 presentation of Same-Store, we added 13 properties that previously experienced an operator transition.

(4)Represents average occupied units as reported by the respective tenants or operators for the six-month period.

Same‐Store Adjusted NOI and Total Portfolio Adjusted NOI increased primarily as a result of the following:

•increased occupancy and rates for resident fees;

•increased government grant income received under the CARES Act; and

•lower Covid-related expenses; partially offset by

•higher labor costs.

53

Other Income and Expense Items

The following table summarizes the results of our other income and expense items for the three and six months ended June 30, 2022 and 2021 (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022		2021		Change		2022		2021		Change
Interest income	$	5,493	$	16,108	$	(10,615)	$	10,987	$	25,121	$	(14,134)
Interest expense	41,867		38,681		3,186		79,453		85,524		(6,071)
Depreciation and amortization	180,489		171,459		9,030		358,222		328,997		29,225
General and administrative	24,781		24,088		693		48,612		48,990		(378)
Transaction costs	612		619		(7)		908		1,417		(509)
Impairments and loan loss reserves (recoveries), net	139		931		(792)		271		4,173		(3,902)
Gain (loss) on sales of real estate, net	10,340		175,238		(164,898)		14,196		175,238		(161,042)
Gain (loss) on debt extinguishments	—		(60,865)		60,865		—		(225,157)		225,157
Other income (expense), net	2,861		1,734		1,127		21,177		3,934		17,243
Income tax benefit (expense)	718		763		(45)		(59)		755		(814)
Equity income (loss) from unconsolidated joint ventures	382		867		(485)		2,466		2,190		276
Income (loss) from discontinued operations	2,992		113,960		(110,968)		3,309		383,968		(380,659)
Noncontrolling interests’ share in continuing operations	(3,955)		(3,535)		(420)		(7,685)		(6,841)		(844)
Noncontrolling interests’ share in discontinued operations	—		(2,210)		2,210		—		(2,539)		2,539

Interest income

Interest income decreased for the three and six months ended June 30, 2022 primarily as a result of principal repayments on and sales of loans receivable in 2021 and 2022.

Interest expense

Interest expense increased for the three months ended June 30, 2022 primarily as a result of higher interest rates under the commercial paper program. Interest expense decreased for the six months ended June 30, 2022 primarily as a result of senior unsecured notes repurchases and redemptions in the first and second quarters of 2021, partially offset by higher interest rates under the commercial paper program.

Depreciation and amortization expense

Depreciation and amortization expense increased for the three and six months ended June 30, 2022 primarily as a result of: (i) assets acquired during 2021 and 2022 and (ii) development and redevelopment projects placed in service during 2021 and 2022, partially offset by dispositions of real estate in 2021 and 2022.

Impairments and loan loss reserves (recoveries), net

Impairments and loan loss reserves (recoveries), net decreased for the three and six months ended June 30, 2022 as a result of a decrease in loan loss reserves under the current expected credit losses model. The reduction in loan loss reserves for the three and six months ended June 30, 2022 is primarily due to a lower loans receivable balance.

Gain (loss) on sales of real estate, net

Gain (loss) on sales of real estate, net decreased during the three and six months ended June 30, 2022 primarily due to the $172 million gain on sale of Hoag Hospital in May 2021. Refer to Note 4 to the Consolidated Financial Statements for additional information regarding dispositions of real estate and the associated gain (loss) on sales recognized.

Gain (loss) on debt extinguishments

Loss on debt extinguishments decreased for the three and six months ended June 30, 2022 as a result of the repurchase and redemption of certain outstanding senior notes in the first and second quarters of 2021 with no repurchases or redemptions during the comparable periods of 2022.

54

Other income (expense), net

Other income increased for the six months ended June 30, 2022 primarily as a result of: (i) a gain on sale of a hospital that was classified as a DFL and (ii) an increase in government grant income received under the CARES Act in 2022, partially offset by expenses incurred for tenant relocation and other costs associated with a planned MOB demolition.

Income tax benefit (expense)

Income tax expense increased for the six months ended June 30, 2022 primarily as a result of the tax impact of an increase in government grant income received under the CARES Act.

Equity income (loss) from unconsolidated joint ventures

Equity income from unconsolidated joint ventures decreased for the three months ended June 30, 2022 as a result of the sale of the two remaining CCRCs in the CCRC JV in May 2021.

Income (loss) from discontinued operations

Income from discontinued operations decreased for the three and six months ended June 30, 2022 primarily as a result of: (i) decreased gain on sales of real estate from the completion of dispositions of our senior housing portfolios, (ii) decreased NOI following the dispositions of our senior housing portfolios, and (iii) a decline in government grant income received under the CARES Act for the senior housing portfolio. The decrease in income from discontinued operations during the three and six months ended June 30, 2022 was partially offset by decreased impairment charges on depreciable real estate and goodwill.

Noncontrolling interests’ share in continuing operations

Noncontrolling interests’ share in continuing operations increased for the three and six months ended June 30, 2022 primarily as a result of an increase in net income related to our consolidated partnerships.

Noncontrolling interests’ share in discontinued operations

Noncontrolling interests’ share in discontinued operations decreased for the three and six months ended June 30, 2022 as a result of the completion of our dispositions of our senior housing portfolios.

Liquidity and Capital Resources

We anticipate that our cash flow from operations, available cash balances, and cash from our various financing activities will be adequate for the next 12 months and for the foreseeable future for purposes of: (i) funding recurring operating expenses; (ii) meeting debt service requirements; and (iii) satisfying funding of distributions to our stockholders and non-controlling interest members. Distributions are made using a combination of cash flows from operations, funds available under our bank line of credit (the “Revolving Facility”) and commercial paper program, proceeds from the sale of properties, and other sources of cash available to us. 

In addition to funding the activities above, our principal liquidity needs for the next 12 months are to:

•fund capital expenditures, including tenant improvements and leasing costs; and

•fund future acquisition, transactional, and development and redevelopment activities.

Our longer term liquidity needs include the items listed above as well as meeting debt service requirements.

We anticipate satisfying these future needs using one or more of the following:

•cash flow from operations;

•sale of, or exchange of ownership interests in, properties or other investments;

•borrowings under our Revolving Facility and commercial paper program;

•issuance of additional debt, including unsecured notes, term loans, and mortgage debt; and/or

•issuance of common or preferred stock or its equivalent, including the settlement of forward contracts or other sales of common stock under the ATM Program (as defined below).

55

Our ability to access the capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, our Revolving Facility accrues interest at a rate per annum equal to LIBOR plus a margin that depends upon our credit ratings for our senior unsecured long-term debt. Our Revolving Facility includes customary LIBOR replacement language, including, but not limited to, the use of rates based on the secured overnight financing rate administered by the Federal Reserve Bank of New York. We also pay a facility fee on the entire revolving commitment that depends upon our credit ratings. As of August 1, 2022, we had long-term credit ratings of Baa1 from Moody’s and BBB+ from S&P Global and Fitch, and short-term credit ratings of P-2, A-2, and F2 from Moody’s, S&P Global, and Fitch, respectively.

A downgrade in credit ratings by Moody’s, S&P Global, and Fitch may have a negative impact on the interest rates and facility fees for our Revolving Facility and may negatively impact the pricing of notes issued under our commercial paper program and senior unsecured notes. While a downgrade in our credit ratings would adversely impact our cost of borrowing, we believe we would continue to have access to the unsecured debt markets, and we could also seek to enter into one or more secured debt financings, issue additional securities, including under our ATM Program, or dispose of certain assets to fund future operating costs, capital expenditures, or acquisitions, although no assurances can be made in this regard. Refer to “Market Trends and Uncertainties” above for a more comprehensive discussion of the potential impact of Covid as well as economic and market conditions on our business.

Changes in Material Cash Requirements and Off-Balance Sheet Arrangements

Our material cash requirements related to debt increased by $284 million to $6.5 billion at June 30, 2022, when compared to December 31, 2021, primarily as a result of issuances of notes under our commercial paper program. As of June 30, 2022, we had $1.45 billion outstanding under our commercial paper program. See Note 9 to the Consolidated Financial Statements for additional information about our debt commitments.

Our material cash requirements related to development and redevelopment projects and tenant improvements decreased by $16 million, to $454 million at June 30, 2022, when compared to December 31, 2021, primarily as a result of construction spend on existing projects in the first half of 2022 thereby decreasing the remaining commitment.

Our material cash requirements to provide additional funding for senior housing redevelopment and capital expenditure projects decreased by $10 million, to $48 million at June 30, 2022, when compared to December 31, 2021, primarily as a result of reduced commitments from current year principal repayments on our seller financing. See Note 6 to the Consolidated Financial Statements for additional information.

Certain of our noncontrolling interest holders have the ability to put their equity interests to us upon specified events or after the passage of a predetermined period of time. Each put option is subject to changes in redemption value in the event that the underlying property generates specified returns for us and meets certain promote thresholds pursuant to the respective agreements. As of June 30, 2022, we had $116 million of redeemable noncontrolling interests, none of which met the conditions for redemption as of the balance sheet date. See Note 11 to the Consolidated Financial Statements for additional information.

There have been no changes to our distribution and dividend requirements during the six months ended June 30, 2022.

We own interests in certain unconsolidated joint ventures as described in Note 7 to the Consolidated Financial Statements. Two of these joint ventures have mortgage debt of $87 million, of which our share is $40 million. Except in limited circumstances, our risk of loss is limited to our investment in the joint ventures.

There have been no other material changes, outside of the ordinary course of business, during the six months ended June 30, 2022 to the material cash requirements or material off-balance sheet arrangements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021 under “Material Cash Requirements” and “Off-Balance Sheet Arrangements” in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Cash Flow Summary

The following summary discussion of our cash flows is based on the Consolidated Statements of Cash Flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.

56

The following table sets forth changes in cash flows (in thousands):

	Six Months Ended June 30,
	2022		2021		Change
Net cash provided by (used in) operating activities	$	449,668	$	359,594	$	90,074
Net cash provided by (used in) investing activities	(461,136)		1,712,296		(2,173,432)
Net cash provided by (used in) financing activities	(72,082)		(2,009,272)		1,937,190

Operating Cash Flows

The increase in operating cash flow is primarily the result of an increase in income related to: (i) 2021 and 2022 acquisitions, (ii) annual rent increases, (iii) new leasing and renewal activity, and (iv) developments and redevelopments placed in service during 2021 and 2022. The increase in operating cash flow is partially offset by a decrease in income related to assets sold during 2021 and 2022. Our cash flow from operations is dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants’ performance on their lease obligations, the level of operating expenses, and other factors.

Investing Cash Flows

The following are significant investing activities for the six months ended June 30, 2022:

•made investments of $582 million primarily related to the acquisition, development, and redevelopment of real estate; and

•received net proceeds of $121 million primarily from sales of real estate assets and repayments on loans receivable and direct financing leases.

The following are significant investing activities for the six months ended June 30, 2021:

•made investments of $842 million primarily related to the acquisition, development, and redevelopment of real estate and funding of new and existing loans; and

•received net proceeds of $2.6 billion primarily from sales of real estate assets and repayments on loans receivable.

Financing Cash Flows

The following are significant financing activities for the six months ended June 30, 2022:

•made net borrowings of $283 million under our commercial paper program; and

•paid cash dividends on common stock of $325 million.

The following are significant financing activities for the six months ended June 30, 2021:

•made net borrowings of $590 million under our Revolving Facility and commercial paper program;

•made net repayments of $2.2 billion under our senior unsecured notes (including debt extinguishment costs) and mortgage debt; and

•paid cash dividends on common stock of $326 million.

Discontinued Operations

Operating, investing, and financing cash flows in our Consolidated Statements of Cash Flows are reported inclusive of both cash flows from continuing operations and cash flows from discontinued operations. Certain significant cash flows from discontinued operations are disclosed in Note 14 to the Consolidated Financial Statements. The absence of future cash flows from discontinued operations is not expected to significantly impact our liquidity, as the proceeds from senior housing triple-net and SHOP dispositions were used to pay down debt and invest in additional real estate in our other business lines. Additionally, we have multiple other sources of liquidity that can be utilized in the future, as needed. Refer to the beginning of the Liquidity and Capital Resources section above for additional information regarding our liquidity.

Debt

In July 2022, we increased the maximum aggregate face or principal amount that can be outstanding at any one time under the commercial paper program from $1.5 billion to $2.0 billion.

57

See Note 9 to the Consolidated Financial Statements for additional information about our outstanding debt.

Approximately 77% and 78% of our consolidated debt, excluding debt classified as liabilities related to assets held for sale and discontinued operations, net, was fixed rate debt as of June 30, 2022 and 2021, respectively. At June 30, 2022, our fixed rate debt and variable rate debt had weighted average interest rates of 3.45% and 1.96%, respectively. At June 30, 2021, our fixed rate debt and variable rate debt had weighted average interest rates of 3.75% and 0.73%, respectively. As of June 30, 2022, we had $142 million of variable rate debt swapped to fixed through interest rate swap instruments, designated as cash flow hedges, and as of June 30, 2021, we had $142 million of variable rate debt subject to interest rate cap instruments. For purposes of classification of the amounts above, variable rate debt with a derivative financial instrument designated as a cash flow hedge is reported as fixed rate debt due to us having effectively established a fixed interest rate for the underlying debt instrument. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.

Equity

At June 30, 2022, we had 540 million shares of common stock outstanding, equity totaled $6.8 billion, and our equity securities had a market value of $14.2 billion.

At June 30, 2022, non-managing members held an aggregate of five million units in seven limited liability companies (“DownREITs”) for which we are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications). At June 30, 2022, the outstanding DownREIT units were convertible into approximately seven million shares of our common stock.

At-The-Market Program

Our at-the-market equity offering program (as amended from time to time, the “ATM Program”) has a capacity of $1.5 billion. In addition to the issuance and sale of shares of our common stock, we may also enter into one or more forward sales agreements (each, an “ATM forward contract”) with sales agents for the sale of our shares of common stock under our ATM Program.

During the year ended December 31, 2021, we utilized the forward provisions under the ATM Program to allow for the sale of an aggregate of 9.1 million shares of our common stock at an initial weighted average net price of $35.25 per share, after commissions. During the three and six months ended June 30, 2022, no shares were settled under ATM forward contracts. Therefore, at June 30, 2022, 9.1 million shares remained outstanding under ATM forward contracts. These ATM forward contracts mature in the first quarter of 2023.

During the three and six months ended June 30, 2022, we did not issue any shares of our common stock under the ATM Program.

At June 30, 2022, $1.18 billion of our common stock remained available for sale under the ATM Program. Actual future sales of our common stock will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock, and our capital needs. We have no obligation to sell any of the remaining shares under our ATM Program.

See Note 11 to the Consolidated Financial Statements for additional information about our ATM Program.

Share Repurchase Program

On August 1, 2022, our Board of Directors approved a share repurchase program under which we may acquire shares of our common stock in the open market up to an aggregate purchase price of $500 million (the “Share Repurchase Program”). Purchases of common stock under the Share Repurchase Program may be exercised at our discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The Share Repurchase Program expires in August 2024 and may be suspended or terminated at any time without prior notice. There have been no stock repurchases under the Share Repurchase Program through the date on which this Quarterly Report on Form 10-Q was filed.

Shelf Registration

In May 2021, we filed a prospectus with the SEC as part of a registration statement on Form S-3, using an automatic shelf registration process. This shelf registration statement expires on May 13, 2024 and at or prior to such time, we expect to file a new shelf registration statement. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include common stock, preferred stock, depositary shares, debt securities, and warrants.

58

Non-GAAP Financial Measures Reconciliations

The following is a reconciliation from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Nareit FFO, FFO as Adjusted, and AFFO (in thousands, except per share data):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Real estate related depreciation and amortization	180,489		171,459		358,222		328,997
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures	5,210		2,869		10,345		7,322
Noncontrolling interests’ share of real estate related depreciation and amortization	(4,844)		(4,923)		(9,685)		(9,809)
Loss (gain) on sales of depreciable real estate, net(1)	(12,903)		(297,476)		(16,688)		(557,138)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures	129		(5,866)		(150)		(5,866)
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net	—		2,179		12		2,179
Loss (gain) upon change of control, net	—		—		—		(1,042)
Taxes associated with real estate dispositions	16		1,693		(166)		2,183
Impairments (recoveries) of depreciable real estate, net	—		3,743		—		3,743
Nareit FFO applicable to common shares	236,154		149,671		479,583		189,905
Distributions on dilutive convertible units and other	2,352		—		4,704		—
Diluted Nareit FFO applicable to common shares	$	238,506	$	149,671	$	484,287	$	189,905
Weighted average shares outstanding - diluted Nareit FFO	547,132		539,193		547,018		539,081
Impact of adjustments to Nareit FFO:
Transaction-related items	$	596	$	1,265	$	893	$	5,379
Other impairments (recoveries) and other losses (gains), net(2)	139		1,845		(8,770)		5,087
Restructuring and severance related charges	—		—		—		2,463
Loss (gain) on debt extinguishments	—		60,865		—		225,157
Casualty-related charges (recoveries), net	(411)		3,596		(411)		4,644
Total adjustments	$	324	$	67,571	$	(8,288)	$	242,730
FFO as Adjusted applicable to common shares	$	236,478	$	217,242	$	471,295	$	432,635
Distributions on dilutive convertible units and other	2,351		2,144		4,719		4,067
Diluted FFO as Adjusted applicable to common shares	$	238,829	$	219,386	$	476,014	$	436,702
Weighted average shares outstanding - diluted FFO as Adjusted	547,132		546,519		547,018		546,407

59

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
FFO as Adjusted applicable to common shares	$	236,478	$	217,242	$	471,295	$	432,635
Amortization of stock-based compensation	5,300		5,095		10,021		9,459
Amortization of deferred financing costs	2,689		2,121		5,377		4,334
Straight-line rents	(12,713)		(6,201)		(23,872)		(15,336)
AFFO capital expenditures	(27,906)		(22,422)		(50,745)		(43,132)
Deferred income taxes	(1,188)		(2,771)		(927)		(4,493)
Other AFFO adjustments	(7,065)		(4,026)		(13,524)		(9,628)
AFFO applicable to common shares	195,595		189,038		397,625		373,839
Distributions on dilutive convertible units and other	1,649		1,541		3,296		2,862
Diluted AFFO applicable to common shares	$	197,244	$	190,579	$	400,921	$	376,701
Weighted average shares outstanding - diluted AFFO	545,307		544,694		545,193		544,582

    

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Diluted earnings per common share	$	0.13	$	0.51	$	0.26	$	0.78
Depreciation and amortization	0.33		0.32		0.66		0.60
Loss (gain) on sales of depreciable real estate, net	(0.02)		(0.56)		(0.03)		(1.04)
Loss (gain) upon change of control, net	—		—		—		0.00
Taxes associated with real estate dispositions	0.00		0.00		0.00		0.00
Impairments (recoveries) of depreciable real estate, net	—		0.01		—		0.01
Diluted Nareit FFO per common share	$	0.44	$	0.28	$	0.89	$	0.35
Transaction-related items	0.00		0.00		0.00		0.01
Other impairments (recoveries) and other losses (gains), net(2)	0.00		0.00		(0.02)		0.01
Restructuring and severance related charges	—		—		—		0.00
Loss (gain) on debt extinguishments	—		0.11		—		0.42
Casualty-related charges (recoveries), net	0.00		0.01		0.00		0.01
Diluted FFO as Adjusted per common share	$	0.44	$	0.40	$	0.87	$	0.80

_______________________________________

(1)This amount can be reconciled by combining the balances from the corresponding line of the Consolidated Statements of Operations and the detailed financial information for discontinued operations in Note 4 to the Consolidated Financial Statements.

(2)The six months ended June 30, 2022 includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) a $23 million gain on sale of a hospital that was in a direct financing lease and (ii) $14 million of expenses incurred for tenant relocation and other costs associated with a planned MOB demolition. The three and six months ended June 30, 2021 includes the following: (i) a $7 million goodwill impairment charge in connection with our senior housing triple-net asset sales which is reported in income (loss) from discontinued operations in the Consolidated Statements of Operations and (ii) a $6 million of accelerated recognition of a mark-to-market discount, less loan fees, resulting from prepayments on loans receivable which is included in interest income in the Consolidated Statements of Operations. The remaining activity for the three and six months ended June 30, 2022 and 2021 includes reserves for loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

60

Critical Accounting Estimates and Recent Accounting Pronouncements

The preparation of financial statements in conformity with U.S. GAAP requires our management to use judgment in the application of critical accounting estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A discussion of accounting estimates that we consider critical in that they may require complex judgment in their application or require estimates about matters that are inherently uncertain is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2 to the Consolidated Financial Statements. There have been no significant changes to our critical accounting estimates during the three and six months ended June 30, 2022.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates. We use derivative and other financial instruments in the normal course of business to mitigate interest rate risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note 17 to the Consolidated Financial Statements).

To illustrate the effect of movements in the interest rate markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves of our derivative portfolio in order to determine the change in fair value. At June 30, 2022, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by approximately $5 million.

Interest Rate Risk. At June 30, 2022, our exposure to interest rate risk was primarily on our variable rate debt. At June 30, 2022, $142 million of our variable rate debt was swapped to fixed by interest rate swap instruments. The interest rate swap instruments are designated as cash flow hedges, with the objective of managing the exposure to interest rate risk by converting the interest rates on our variable rate debt to fixed interest rates. At June 30, 2022, both the fair value and carrying value of the interest rate swap instruments were $2 million.

Our remaining variable rate debt at June 30, 2022 was comprised of our commercial paper program and certain of our mortgage debt. Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could be adversely affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. However, interest rate changes will affect the fair value of our fixed rate instruments. At June 30, 2022, a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately $242 million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately $261 million. These changes would not materially impact earnings or cash flows. Conversely, changes in interest rates on variable rate debt and investments would change our future earnings and cash flows, but not materially impact the fair value of those instruments. Assuming a one percentage point increase in the interest rate related to our variable rate debt and investments, and assuming no other changes in the outstanding balance at June 30, 2022, our annual interest expense would increase by approximately $15 million.

Market Risk.  We have investments in marketable debt securities classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity. We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer’s financial condition, capital strength, and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any. At June 30, 2022, both the fair value and carrying value of marketable debt securities was $21 million. These marketable debt securities mature in December 2022.

61

Item 4.  Controls and Procedures

Disclosure Controls and Procedures.  We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2022. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2022.

Changes in Internal Control Over Financial Reporting.  There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

62

PART II. OTHER INFORMATION

Item 1A.  Risk Factors

There are no material changes to the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)

None.

(b)

None.

(c)

The following table sets forth information with respect to purchases of our common stock made by us or on our behalf during the three months ended June 30, 2022.

Period Covered	Total Number Of Shares Purchased(1)	Average Price Paid Per Share		Total Number Of Shares (Or Units) Purchased As Part Of Publicly Announced Plans Or Programs	Maximum Number (Or Approximate Dollar Value) Of Shares (Or Units) That May Yet Be Purchased Under The Plans Or Programs
April 1-30, 2022	—	$	—	—	—
May 1-31, 2022	8,746	30.08		—	—
June 1-30, 2022	—	—		—	—
Total	8,746	$	30.08	—	—

_______________________________________

(1)Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted shares. The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurred.

Item 5. Other Information

Adoption of Updates to the Executive Severance Plan

On July 28, 2022, our Board of Directors adopted updates to the Healthpeak Properties, Inc. Executive Severance Plan (the “Executive Severance Plan”), effective as of the same date. The Compensation and Human Capital Committee of the Board of Directors (the “Compensation Committee”) will codify such updates, as summarized below, in an amended and restated Executive Severance Plan to be filed as an exhibit to a future Quarterly Report on Form 10-Q.

The Executive Severance Plan was updated to conform the definition of a qualifying termination to the definition in the Healthpeak Properties, Inc. Executive Change in Control Severance Plan (the “CIC Plan”) to include a termination of employment by a named executive officer (a “Named Executive”) of the Company (as identified pursuant to Item 402(a)(3) of Regulation S-K) for “good reason” (as defined in the Executive Severance Plan). The Executive Severance Plan was also updated to revise the method for calculating severance payments that are determined with reference to a participant’s annual bonus to clarify that the bonus portion of the cash severance formula for Named Executives will be based on the greater of a Named Executive’s (1) target level bonus, or (2) prior year’s bonus payment. The Named Executive’s prorated cash bonus in the year of termination will continue to be based on actual performance for the quantitative portion, while the qualitative portion will continue to be based on the Named Executive’s individual performance for that year as determined by the Compensation Committee; however, the Executive Severance Plan has been updated to ensure that the qualitative portion of the prorated cash bonus will be no less than the target level. In addition, the Executive Severance Plan was updated to provide that outstanding stock options will remain exercisable for two years or upon earlier expiration following a Named Executive’s termination of employment.

The Executive Severance Plan was not otherwise updated to change the amounts payable to Named Executives under the Executive Severance Plan, and the changes made are not expected to materially increase the aggregate amounts payable under the Executive Severance Plan.

63

Adoption of Updates to the Executive Change in Control Severance Plan

On July 28, 2022, our Board of Directors adopted updates to the CIC Plan, effective as of the same date. The Compensation Committee will codify such updates, as summarized below, in an amended and restated CIC Plan to be filed as an exhibit to a future Quarterly Report on Form 10-Q.

The CIC Plan was updated to make clarifying changes to the definition of a qualifying termination of employment by a participant for “good reason” (as defined in the CIC Plan). The CIC Plan was also updated to revise the method for calculating severance payments that are determined with reference to a participant’s annual bonus to conform the method to the method used in the Executive Severance Plan and clarify that the bonus portion of the cash severance formula for Named Executives of the Company will be based on the greater of a Named Executive’s (1) target level bonus or (2) prior year’s bonus payment. In addition, the CIC Plan was updated to provide that outstanding stock options will remain exercisable for two years or upon earlier expiration following a Named Executive’s termination of employment. In addition, the severance multiple for the President and Chief Investment Officer was updated to 2.75x, while the severance multiple for each of the Chief Financial Officer, Chief Operating Officer and Chief Legal Officer was updated to 2.5x. No changes were made to the Chief Executive Officer’s severance multiple, which remains 3.0x.

The CIC Plan was also updated to require a mutual release of claims by a Named Executive and the Company. In addition, the CIC Plan was updated to provide that if payments under the CIC Plan would be subject to the requirements of Internal Revenue Code Section 409A, which would impose a six-month delay on certain severance payments made to Named Executives, the CIC Plan would require that the Company and acquiror enter into and fund a rabbi trust sufficient to pay all potential cash severance obligations under the CIC Plan.

The CIC Plan was not otherwise updated to change the amounts payable to Named Executives under the CIC Plan, and the changes made are not expected to materially increase the aggregate amounts payable under the CIC Plan.

64

Item 6. Exhibits

3.1	Articles of Restatement of Healthpeak Properties, Inc. (formerly HCP, Inc.) dated June 1, 2012, as supplemented by the Articles Supplementary, dated July 31, 2017, and as amended by the Articles of Amendment, dated October 30, 2019 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Annual Report on Form 10-K filed February 13, 2020).
3.2	Articles of Amendment to Articles of Restatement of Healthpeak Properties, Inc. (formerly HCP, Inc.), dated October 30, 2019 (incorporated herein by reference to Exhibit 3.1 to Healthpeak’s Current Report on Form 8-K filed October 30, 2019).
3.3	Sixth Amended and Restated Bylaws of Healthpeak Properties, Inc., dated October 30, 2019 (incorporated herein by reference to Exhibit 3.2 to Healthpeak’s Current Report on Form 8-K filed October 30, 2019).
31.1*	Certification by Thomas M. Herzog, Healthpeak’s Principal Executive Officer, pursuant to Securities Exchange Act Rule 13a-14(a).
31.2*	Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, pursuant to Securities Exchange Act Rule 13a-14(a).
32.1**	Certification by Thomas M. Herzog, Healthpeak’s Principal Executive Officer, pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.
32.2**	Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.
101.INS*	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

_______________________________________

*       Filed herewith.

**     Furnished herewith.

65

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 3, 2022	Healthpeak Properties, Inc.
	(Registrant)
	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)
	/s/ PETER A. SCOTT
	Peter A. Scott
	Chief Financial Officer
	(Principal Financial Officer)
	/s/ SHAWN G. JOHNSTON
	Shawn G. Johnston
	Executive Vice President and
	Chief Accounting Officer
	(Principal Accounting Officer)

66

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Thomas M. Herzog, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Healthpeak Properties, Inc. for the period ended June 30, 2022;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

4
Date: August 3, 2022	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Peter A. Scott, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Healthpeak Properties, Inc. for the period ended June 30, 2022;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

4
Date: August 3, 2022	/s/ PETER A. SCOTT
	Peter A. Scott
	Chief Financial Officer
	(Principal Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:

(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2022	/s/ THOMAS M. HERZOG
	Thomas M. Herzog
	Chief Executive Officer
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.

EX-32.2

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Healthpeak Properties, Inc., a Maryland corporation (the “Company”), hereby certifies, to his knowledge, that:

(i) the accompanying quarterly report on Form 10-Q of the Company for the period ended June 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 3, 2022	/s/ PETER A. SCOTT
	Peter A. Scott
	Chief Financial Officer
	(Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates it by reference.

XML

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-08895
Entity Registrant Name	Healthpeak Properties, Inc.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	33-0091377
Entity Address, Address Line One	5050 South Syracuse Street
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	428-5050
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	PEAK
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		539,581,438
Entity Central Index Key	0000765880
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Real estate:
Buildings and improvements	$ 12,590,403	$ 12,025,271
Development costs and construction in progress	675,713	877,423
Land	2,705,260	2,603,964
Accumulated depreciation and amortization	(3,097,748)	(2,839,229)
Net real estate	12,873,628	12,667,429
Net investment in direct financing leases	0	44,706
Loans receivable, net of reserves of $2,015 and $1,813	413,962	415,811
Investments in and advances to unconsolidated joint ventures	402,154	403,634
Accounts receivable, net of allowance of $2,122 and $1,870	47,340	48,691
Cash and cash equivalents	73,013	158,287
Restricted cash	54,815	53,454
Intangible assets, net	470,865	519,760
Assets held for sale and discontinued operations, net	66,647	37,190
Right-of-use asset, net	233,391	233,942
Other assets, net	682,388	674,615
Total assets	15,318,203	15,257,519
LIABILITIES AND EQUITY
Bank line of credit and commercial paper	1,448,569	1,165,975
Senior unsecured notes	4,655,852	4,651,933
Mortgage debt	349,329	352,081
Intangible liabilities, net	169,622	177,232
Liabilities related to assets held for sale and discontinued operations, net	15,869	15,056
Lease liability	201,124	204,547
Accounts payable, accrued liabilities, and other liabilities	706,819	755,384
Deferred revenue	814,754	789,207
Total liabilities	8,361,938	8,111,415
Commitments and contingencies (Note 10)
Redeemable noncontrolling interests	115,877	87,344
Common stock, $1.00 par value: 750,000,000 shares authorized; 539,580,161 and 539,096,879 shares issued and outstanding	539,580	539,097
Additional paid-in capital	10,073,712	10,100,294
Cumulative dividends in excess of earnings	(4,306,762)	(4,120,774)
Accumulated other comprehensive income (loss)	(1,318)	(3,147)
Total stockholders’ equity	6,305,212	6,515,470
Joint venture partners	334,120	342,234
Non-managing member unitholders	201,056	201,056
Total noncontrolling interests	535,176	543,290
Total equity	6,840,388	7,058,760
Total liabilities and equity	$ 15,318,203	$ 15,257,519

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balance Sheet Parenthetical Disclosures
Reserves for loans receivable	$ 2,015	$ 1,813
Allowance for accounts receivable	$ 2,122	$ 1,870
Common stock, par value (in dollars per share)	$ 1.00	$ 1.00
Common stock, shares authorized (in shares)	750,000,000	750,000,000
Common stock, shares issued (in shares)	539,580,161	539,096,879
Common stock, shares outstanding (in shares)	539,580,161	539,096,879

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Rental and related revenues	$ 387,079	$ 340,642	$ 757,229	$ 668,614
Resident fees and services	125,360	117,308	246,920	233,436
Income from direct financing leases	0	2,180	1,168	4,343
Interest income	5,493	16,108	10,987	25,121
Total revenues	517,932	476,238	1,016,304	931,514
Costs and expenses:
Interest expense	41,867	38,681	79,453	85,524
Depreciation and amortization	180,489	171,459	358,222	328,997
Operating	215,044	190,132	422,291	371,893
General and administrative	24,781	24,088	48,612	48,990
Transaction costs	612	619	908	1,417
Impairments and loan loss reserves (recoveries), net	139	931	271	4,173
Total costs and expenses	462,932	425,910	909,757	840,994
Other income (expense):
Gain (loss) on sales of real estate, net	10,340	175,238	14,196	175,238
Gain (loss) on debt extinguishments	0	(60,865)	0	(225,157)
Other income (expense), net	2,861	1,734	21,177	3,934
Total other income (expense), net	13,201	116,107	35,373	(45,985)
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	68,201	166,435	141,920	44,535
Income tax benefit (expense)	718	763	(59)	755
Equity income (loss) from unconsolidated joint ventures	382	867	2,466	2,190
Income (loss) from continuing operations	69,301	168,065	144,327	47,480
Income (loss) from discontinued operations	2,992	113,960	3,309	383,968
Net income (loss)	72,293	282,025	147,636	431,448
Noncontrolling interests’ share in continuing operations	(3,955)	(3,535)	(7,685)	(6,841)
Noncontrolling interests’ share in discontinued operations	0	(2,210)	0	(2,539)
Net income (loss) attributable to Healthpeak Properties, Inc.	68,338	276,280	139,951	422,068
Participating securities’ share in earnings	(281)	(287)	(2,258)	(2,732)
Net income (loss) applicable to common shares	$ 68,057	$ 275,993	$ 137,693	$ 419,336
Basic earnings (loss) per common share:
Continuing operations (in dollars per share)	$ 0.12	$ 0.30	$ 0.25	$ 0.07
Discontinued operations (in dollars per share)	0.01	0.21	0.01	0.71
Net income (loss) applicable to common shares (in dollars per share)	0.13	0.51	0.26	0.78
Diluted earnings (loss) per common share:
Continuing operations (in dollars per share)	0.12	0.30	0.25	0.07
Discontinued operations (in dollars per share)	0.01	0.21	0.01	0.71
Net income (loss) applicable to common shares (in dollars per share)	$ 0.13	$ 0.51	$ 0.26	$ 0.78
Weighted average shares outstanding:
Basic (in shares)	539,558	538,929	539,456	538,805
Diluted (in shares)	539,815	544,694	539,701	539,081

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 72,293	$ 282,025	$ 147,636	$ 431,448
Other comprehensive income (loss):
Net unrealized gains (losses) on derivatives	1,629	0	1,629	332
Change in Supplemental Executive Retirement Plan obligation and other	100	108	200	215
Reclassification adjustment realized in net income (loss)	0	0	0	(251)
Total other comprehensive income (loss)	1,729	108	1,829	296
Total comprehensive income (loss)	74,022	282,133	149,465	431,744
Total comprehensive income (loss) attributable to Healthpeak Properties, Inc.	70,067	276,388	141,780	422,364
Continuing Operations
Total comprehensive (income) loss attributable to noncontrolling interests	(3,955)	(3,535)	(7,685)	(6,841)
Discontinued Operations
Total comprehensive (income) loss attributable to noncontrolling interests	$ 0	$ (2,210)	$ 0	$ (2,539)

XML

CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS - USD ($) shares in Thousands, $ in Thousands	Total	Total Stockholders’ Equity	Common Stock	Additional Paid-In Capital	Cumulative Dividends In Excess Of Earnings	Accumulated Other Comprehensive Income (Loss)	Total Noncontrolling Interests
Balance (in shares) at Dec. 31, 2020			538,405
Balance at Dec. 31, 2020	$ 7,289,950	$ 6,733,723	$ 538,405	$ 10,175,235	$ (3,976,232)	$ (3,685)	$ 556,227
Increase (Decrease) in Stockholders' Equity
Net income (loss)	431,448	422,068			422,068		9,380
Other comprehensive income (loss)	296	296				296
Issuance of common stock, net (in shares)			954
Issuance of common stock, net	1,044	1,044	$ 954	90
Repurchase of common stock (in shares)			(408)
Repurchase of common stock	(12,480)	(12,480)	$ (408)	(12,072)
Exercise of stock options (in shares)			4
Exercise of stock options	126	126	$ 4	122
Amortization of stock-based compensation	11,557	11,557		11,557
Common dividends	(326,089)	(326,089)			(326,089)
Distributions to noncontrolling interests	(16,675)						(16,675)
Purchase of noncontrolling interests	(70)	(5)		(5)			(65)
Adjustments to redemption value of redeemable noncontrolling interests	(27,697)	(27,697)		(27,697)
Balance (in shares) at Jun. 30, 2021			538,955
Balance at Jun. 30, 2021	7,351,410	6,802,543	$ 538,955	10,147,230	(3,880,253)	(3,389)	548,867
Beginning balance at Dec. 31, 2020	57,396
Increase (Decrease) in Redeemable Noncontrolling Interests
Distributions to noncontrolling interests	(52)
Contributions from noncontrolling interests	326
Adjustments to redemption value of redeemable noncontrolling interests	27,697
Ending balance at Jun. 30, 2021	85,367
Balance (in shares) at Mar. 31, 2021			538,886
Balance at Mar. 31, 2021	7,241,139	6,688,995	$ 538,886	10,148,168	(3,994,562)	(3,497)	552,144
Increase (Decrease) in Stockholders' Equity
Net income (loss)	282,025	276,280			276,280		5,745
Other comprehensive income (loss)	108	108				108
Issuance of common stock, net (in shares)			75
Issuance of common stock, net	(43)	(43)	$ 75	(118)
Repurchase of common stock (in shares)			(10)
Repurchase of common stock	(315)	(315)	$ (10)	(305)
Exercise of stock options (in shares)			4
Exercise of stock options	126	126	$ 4	122
Amortization of stock-based compensation	6,144	6,144		6,144
Common dividends	(161,971)	(161,971)			(161,971)
Distributions to noncontrolling interests	(8,957)						(8,957)
Purchase of noncontrolling interests	(70)	(5)		(5)			(65)
Adjustments to redemption value of redeemable noncontrolling interests	(6,776)	(6,776)		(6,776)
Balance (in shares) at Jun. 30, 2021			538,955
Balance at Jun. 30, 2021	7,351,410	6,802,543	$ 538,955	10,147,230	(3,880,253)	(3,389)	548,867
Beginning balance at Mar. 31, 2021	78,413
Increase (Decrease) in Redeemable Noncontrolling Interests
Contributions from noncontrolling interests	178
Adjustments to redemption value of redeemable noncontrolling interests	6,776
Ending balance at Jun. 30, 2021	85,367
Balance (in shares) at Dec. 31, 2021			539,097
Balance at Dec. 31, 2021	7,058,760	6,515,470	$ 539,097	10,100,294	(4,120,774)	(3,147)	543,290
Increase (Decrease) in Stockholders' Equity
Net income (loss)	147,611	139,951			139,951		7,660
Other comprehensive income (loss)	1,829	1,829				1,829
Issuance of common stock, net (in shares)			831
Issuance of common stock, net	656	656	$ 831	(175)
Repurchase of common stock (in shares)			(348)
Repurchase of common stock	(11,615)	(11,615)	$ (348)	(11,267)
Amortization of stock-based compensation	12,865	12,865		12,865
Common dividends	(325,939)	(325,939)			(325,939)
Distributions to noncontrolling interests	(15,774)						(15,774)
Adjustments to redemption value of redeemable noncontrolling interests	(28,005)	(28,005)		(28,005)
Balance (in shares) at Jun. 30, 2022			539,580
Balance at Jun. 30, 2022	6,840,388	6,305,212	$ 539,580	10,073,712	(4,306,762)	(1,318)	535,176
Beginning balance at Dec. 31, 2021	87,344
Increase (Decrease) in Redeemable Noncontrolling Interests
Net income (loss)	25
Distributions to noncontrolling interests	(85)
Contributions from noncontrolling interests	588
Adjustments to redemption value of redeemable noncontrolling interests	28,005
Ending balance at Jun. 30, 2022	115,877
Balance (in shares) at Mar. 31, 2022			539,524
Balance at Mar. 31, 2022	6,947,722	6,408,223	$ 539,524	10,084,687	(4,212,941)	(3,047)	539,499
Increase (Decrease) in Stockholders' Equity
Net income (loss)	72,280	68,338			68,338		3,942
Other comprehensive income (loss)	1,729	1,729				1,729
Issuance of common stock, net (in shares)			65
Issuance of common stock, net	327	327	$ 65	262
Repurchase of common stock (in shares)			(9)
Repurchase of common stock	(263)	(263)	$ (9)	(254)
Amortization of stock-based compensation	6,721	6,721		6,721
Common dividends	(162,159)	(162,159)			(162,159)
Distributions to noncontrolling interests	(8,265)						(8,265)
Adjustments to redemption value of redeemable noncontrolling interests	(17,704)	(17,704)		(17,704)
Balance (in shares) at Jun. 30, 2022			539,580
Balance at Jun. 30, 2022	6,840,388	$ 6,305,212	$ 539,580	$ 10,073,712	$ (4,306,762)	$ (1,318)	$ 535,176
Beginning balance at Mar. 31, 2022	97,890
Increase (Decrease) in Redeemable Noncontrolling Interests
Net income (loss)	13
Distributions to noncontrolling interests	(85)
Contributions from noncontrolling interests	355
Adjustments to redemption value of redeemable noncontrolling interests	17,704
Ending balance at Jun. 30, 2022	$ 115,877

XML

CONSOLIDATED STATEMENTS OF EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Stockholders' Equity [Abstract]
Common dividends, per share (in dollars per share)	$ 0.30	$ 0.30	$ 0.60	$ 0.60

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income (loss)	$ 147,636	$ 431,448
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of real estate, in-place lease, and other intangibles	358,222	328,997
Amortization of stock-based compensation	10,021	9,459
Amortization of deferred financing costs	5,377	4,334
Straight-line rents	(23,872)	(15,336)
Amortization of nonrefundable entrance fees and above/below market lease intangibles	(50,054)	(45,842)
Equity loss (income) from unconsolidated joint ventures	(2,530)	(7,100)
Distributions of earnings from unconsolidated joint ventures	476	4,015
Loss (gain) on sale of real estate under direct financing leases	(22,693)	0
Deferred income tax expense (benefit)	(1,038)	(2,538)
Impairments and loan loss reserves (recoveries), net	271	15,168
Loss (gain) on debt extinguishments	0	225,157
Loss (gain) on sales of real estate, net	(16,688)	(557,138)
Loss (gain) upon change of control, net	0	(1,042)
Casualty-related loss (recoveries), net	78	1,061
Other non-cash items	(1,187)	(8,057)
Changes in:
Decrease (increase) in accounts receivable and other assets, net	10,714	32,928
Increase (decrease) in accounts payable, accrued liabilities, and deferred revenue	34,935	(55,920)
Net cash provided by (used in) operating activities	449,668	359,594
Cash flows from investing activities:
Acquisitions of real estate	(159,206)	(498,142)
Development, redevelopment, and other major improvements of real estate	(366,404)	(281,829)
Leasing costs, tenant improvements, and recurring capital expenditures	(50,745)	(43,132)
Proceeds from sales of real estate, net	37,719	2,253,889
Contributions to unconsolidated joint ventures	(1,971)	(10,168)
Distributions in excess of earnings from unconsolidated joint ventures	5,496	34,586
Proceeds from sales/principal repayments on loans receivable and direct financing leases	77,685	265,934
Investments in loans receivable and other	(3,710)	(8,842)
Net cash provided by (used in) investing activities	(461,136)	1,712,296
Cash flows from financing activities:
Borrowings under bank line of credit and commercial paper	8,242,327	8,177,450
Repayments under bank line of credit and commercial paper	(7,959,733)	(7,587,040)
Issuance and borrowings of debt, excluding bank line of credit and commercial paper	0	142,100
Repayments and repurchase of debt, excluding bank line of credit and commercial paper	(2,507)	(2,170,170)
Payments for debt extinguishment and deferred financing costs	0	(217,468)
Issuance of common stock and exercise of options, net of offering costs	(7)	1,170
Repurchase of common stock	(11,615)	(12,480)
Dividends paid on common stock	(325,276)	(326,089)
Distributions to and purchase of noncontrolling interests	(15,859)	(16,745)
Contributions from and issuance of noncontrolling interests	588	0
Net cash provided by (used in) financing activities	(72,082)	(2,009,272)
Net increase (decrease) in cash, cash equivalents and restricted cash	(83,550)	62,618
Cash, cash equivalents and restricted cash, beginning of period	219,448	181,685
Cash, cash equivalents and restricted cash, end of period	$ 135,898	$ 244,303

XML

Business

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business

Business

Overview

Healthpeak Properties, Inc., a Standard & Poor’s 500 company, is a Maryland corporation that is organized to qualify as a real estate investment trust (“REIT”) that, together with its consolidated entities (collectively, “Healthpeak” or the “Company”), invests primarily in real estate serving the healthcare industry in the United States (“U.S.”). Healthpeak® acquires, develops, owns, leases, and manages healthcare real estate. The Company’s diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) life science; (ii) medical office; and (iii) continuing care retirement community (“CCRC”).

The Company’s corporate headquarters are in Denver, Colorado and it has additional offices in California, Tennessee, and Massachusetts.

XML

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”), and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (“SEC”).

Revision to Additional Paid-In Capital and Redeemable Noncontrolling Interests

During the third quarter of 2021, the Company identified and corrected immaterial errors in the classification and redemption value of redeemable noncontrolling interests of consolidated joint ventures in its life science segment. The Company corrected the classification of its redeemable noncontrolling interests and increased the balance to its estimated redemption value, with a corresponding decrease to additional paid-in capital (“APIC”) in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity.

The increase in the unrealized value of the redeemable noncontrolling interests was largely attributable to rapidly rising rents and compressing capitalization rates in the market in which the entities operate, and was identified and corrected by management. The Company determined the impact of the adjustments to be immaterial, individually and in the aggregate, based on consideration of quantitative and qualitative factors. As such, these adjustments are reflected in this Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021.

These adjustments had no impact on the Consolidated Statements of Cash Flows, Consolidated Statements of Operations, or any per share amounts. The Company made changes (all amounts in thousands) to the Consolidated Statements of Equity and Redeemable Noncontrolling Interests to decrease APIC, total stockholders’ equity, and total equity as of June 30, 2021 by $82,319 with a corresponding increase to redeemable noncontrolling interests of $85,367 and a decrease to accounts payable, accrued liabilities, and other liabilities as of June 30, 2021 of $3,048 on the Consolidated Balance Sheet.

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide financial aid to individuals, businesses, and state and local governments. During the three and six months ended June 30, 2022 and 2021, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenue during the coronavirus (“Covid”) pandemic. Grant income is recognized when there is reasonable assurance that the grant will be received and the Company will comply with all conditions attached to the grant. Additionally, grants are recognized over the periods in which the Company recognizes the increased expenses and lost revenue the grants are intended to defray. As of June 30, 2022, the amount of qualifying expenditures and lost revenue exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture.

The following table summarizes information related to government grant income received and recognized by the Company (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Government grant income recorded in other income (expense), net	$	209	$	87	$	6,762	$	1,397
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	—		584		648		1,010
Government grant income recorded in income (loss) from discontinued operations	—		428		206		3,660
Total government grants received	$	209	$	1,099	$	7,616	$	6,067

Discontinued Operations

Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

During 2020, the Company established and began executing a plan to dispose of its senior housing triple-net and Senior Housing Operating Property (“SHOP”) properties and concluded that the planned dispositions represented a strategic shift that had and will have a major effect on the Company’s operations and financial results. Therefore, senior housing triple-net and SHOP assets meeting the held for sale criteria are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 4 for further information.

Recent Accounting Pronouncements

Adopted

Government Assistance. In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which increases the transparency of government assistance including the disclosure of the types of assistance, an entity’s accounting for assistance, and the effect of the assistance on an entity’s financial statements. The adoption of ASU 2021-10 on January 1, 2022 did not have a material impact on the Company’s consolidated financial position, results of operations, cash flows, or disclosures.

Not Yet Adopted

Reference Rate Reform. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional guidance for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on financial reporting. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”), which amends the scope of ASU 2020-04 to include derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. The amendments in ASU 2020-04 and ASU 2021-01 were effective immediately and may be applied through December 31, 2022. The Company is evaluating whether the optional relief provided by ASU 2020-04 or ASU 2021-01 will be adopted but does not expect the adoption of these standards to have a material impact on its consolidated financial position, results of operations, cash flows, or disclosures.

XML

Real Estate Transactions

6 Months Ended

Jun. 30, 2022

Real Estate [Abstract]

Real Estate Transactions

Real Estate Transactions

2022 Real Estate Investment Acquisitions

67 Smith Place

In January 2022, the Company closed a life science acquisition in Cambridge, Massachusetts for $72 million.

Vista Sorrento Phase II

In January 2022, the Company closed a life science acquisition in San Diego, California for $24 million.

Webster MOB Portfolio

In March 2022, the Company acquired a portfolio of two medical office buildings (“MOBs”) in Houston, Texas for $43 million.

Northwest Medical Plaza

In May 2022, the Company acquired one MOB in Bentonville, Arkansas for $26 million.

2021 Real Estate Investment Acquisitions

In 2021, the Company closed the following life science acquisitions: (i) eight acquisitions in Cambridge, Massachusetts for $498 million, (ii) one life science acquisition in San Diego, California for $20 million, and (iii) 12 acres of land for $128 million in South San Francisco, California.

Also during 2021, the Company closed the following MOB acquisitions: (i) one MOB in Nashville, Tennessee for $13 million, (ii) one MOB in Denver, Colorado for $38 million, (iii) a portfolio of 14 MOBs for $371 million (the “MOB Portfolio”), (iv) one MOB in Fort Lauderdale, Florida for $16 million; (v) one MOB in Wichita, Kansas for $50 million, (vi) three MOBs in Morristown, New Jersey for $155 million, (vii) two MOBs in Dallas, Texas for $60 million, (viii) one MOB in Seattle, Washington for $43 million, (ix) one MOB in New Orleans, Louisiana for $34 million, and (x) one MOB in Cambridge, Massachusetts for $55 million. In conjunction with the acquisition of the MOB Portfolio, the Company originated $142 million of secured mortgage debt.

Development Activities

The Company’s commitments, which are primarily related to development and redevelopment projects and tenant improvements, decreased by $16 million, to $454 million at June 30, 2022, when compared to December 31, 2021, primarily as a result of construction spend on existing projects in the first half of 2022 thereby decreasing the remaining commitment.

XML

Dispositions of Real Estate and Discontinued Operations

6 Months Ended

Jun. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Dispositions of Real Estate and Discontinued Operations

Dispositions of Real Estate and Discontinued Operations

2022 Dispositions of Real Estate

In January 2022, the Company sold one life science facility in Salt Lake City, Utah for $14 million, resulting in a gain on sale of $4 million.

During the three months ended June 30, 2022, the Company sold three MOBs and one MOB land parcel for $27 million, resulting in total gain on sales of $10 million.

In July 2022, the Company completed two MOB sales for aggregate proceeds of $9 million.

2021 Dispositions of Real Estate

Sunrise Senior Housing Portfolio

In January 2021, the Company sold a portfolio of 32 SHOP assets (the “Sunrise Senior Housing Portfolio”) for $664 million, resulting in an immaterial loss on sale, which is recognized in income (loss) from discontinued operations, and provided the buyer with: (i) financing of $410 million (see Note 6) and (ii) a commitment to finance up to $92 million of additional debt for capital expenditures. The commitment to finance additional debt for capital expenditures was subsequently reduced to $56 million in June 2021, $47 million in February 2022, and $40 million in July 2022 (see Note 6). As of June 30, 2022, $0.4 million of the additional financing has been funded. Upon completion of the license transfer process in June 2021, the Company sold the two remaining Sunrise senior housing triple-net assets for $80 million, resulting in a gain on sale of $22 million, which is recognized in income (loss) from discontinued operations.

Brookdale Triple-Net Portfolio

In January 2021, the Company sold 24 senior housing assets in a triple-net lease with Brookdale Senior Living Inc. for $510 million, resulting in total gain on sale of $169 million, which is recognized in income (loss) from discontinued operations.

Additional SHOP Portfolio

In January 2021, the Company sold a portfolio of 16 SHOP assets for $230 million, resulting in total gain on sale of $59 million, which is recognized in income (loss) from discontinued operations. The Company provided the buyer with financing of $150 million (see Note 6).

HRA Triple-Net Portfolio

In February 2021, the Company sold eight senior housing assets in a triple-net lease with Harbor Retirement Associates for $132 million, resulting in total gain on sale of $33 million, which is recognized in income (loss) from discontinued operations.

Oakmont SHOP Portfolio

In April 2021, the Company sold a portfolio of 12 SHOP assets for $564 million. In conjunction with the sale, mortgage debt held on two properties with a carrying value of $64 million was repaid and the remaining mortgage debt held on four properties with a carrying value of $107 million was assumed by the buyer. The transaction resulted in total gain on sale of $80 million, which is recognized in income (loss) from discontinued operations.

Discovery SHOP Portfolio

In April 2021, the Company sold a portfolio of 10 SHOP assets for $334 million, resulting in total gain on sale of $9 million, which is recognized in income (loss) from discontinued operations. Also included in this transaction was the sale of two mezzanine loans and two preferred equity investments for $21 million, resulting in no gain or loss on sale of the investments (collectively, the “Discovery SHOP Portfolio”).

Sonata SHOP Portfolio

In April 2021, the Company sold a portfolio of five SHOP assets for $64 million, resulting in total gain on sale of $3 million, which is recognized in income (loss) from discontinued operations.

SLC SHOP Portfolio

In May 2021, the Company sold seven SHOP assets for $113 million and repaid $70 million of mortgage debt that was held on six of the assets, resulting in total gain on sale of $1 million, which is recognized in income (loss) from discontinued operations.

Hoag Hospital

In May 2021, the Company sold one hospital for $226 million through the exercise of a purchase option by a tenant, resulting in gain on sale of $172 million.

2021 Other Dispositions

In addition to the portfolio and individual sales discussed above, the Company sold the following during the three months ended June 30, 2021: (i) six SHOP assets for $44 million, (ii) three senior housing triple-net assets for $12 million, and (iii) four MOBs for $21 million, resulting in total gain on sales of $10 million ($7 million of which is recognized in income (loss) from discontinued operations). Additionally, during the three months ended March 31, 2021, the Company sold one SHOP asset for $5 million resulting in an immaterial gain on sale, which is recognized in income (loss) from discontinued operations.

During the second half of 2021, the Company sold the following: (i) eight SHOP assets for $120 million, (ii) four senior housing triple-net assets for $12 million, and (iii) six MOBs and a portion of one MOB land parcel for $47 million, resulting in total gain on sales of $48 million ($32 million of which is recognized in income (loss) from discontinued operations). In conjunction with one of the SHOP asset sales, mortgage debt held on the property with a carrying value of $36 million was assumed by the buyer.

Held for Sale and Discontinued Operations

During 2020, the Company established and began executing a plan to dispose of its senior housing triple-net and SHOP properties. As of December 31, 2020, the Company concluded that the planned dispositions represented a strategic shift that had and will have a major effect on the Company’s operations and financial results. Therefore, senior housing triple-net and SHOP assets meeting the held for sale criteria are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties.

The following summarizes the assets and liabilities classified as held for sale or as discontinued operations at June 30, 2022 and December 31, 2021, which are included in assets held for sale and discontinued operations, net and liabilities related to assets held for sale and discontinued operations, net, respectively, on the Consolidated Balance Sheets (in thousands):

	June 30, 2022		December 31, 2021
ASSETS
Accounts receivable, net of allowance of $990 and $4,138	$	761	$	2,446
Cash and cash equivalents	8,070		7,707
Right-of-use asset, net	19		26
Other assets, net	1,400		3,237
Total assets of discontinued operations, net	10,250		13,416
Assets held for sale, net(1)	56,397		23,774
Assets held for sale and discontinued operations, net	$	66,647	$	37,190
LIABILITIES
Lease liability	$	19	$	26
Accounts payable, accrued liabilities, and other liabilities	11,479		14,843
Deferred revenue	102		92
Total liabilities of discontinued operations, net	11,600		14,961
Liabilities related to assets held for sale, net(1)	4,269		95
Liabilities related to assets held for sale and discontinued operations, net	$	15,869	$	15,056

_______________________________________

(1)As of June 30, 2022, includes two life science assets and two MOBs primarily comprised of net real estate assets of $51 million. As of December 31, 2021, includes four MOBs and one life science facility primarily comprised of net real estate assets of $23 million.

The results of discontinued operations during the three and six months ended June 30, 2022 and 2021, or through the disposal date of each asset or portfolio of assets held within discontinued operations if sold during such periods, as applicable, are included in the consolidated results of operations for the three and six months ended June 30, 2022 and 2021. Summarized financial information for discontinued operations for the three and six months ended June 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues:
Rental and related revenues	$	—	$	1,613	$	—	$	6,841
Resident fees and services	2,825		30,273		5,480		103,270
Total revenues	2,825		31,886		5,480		110,111
Costs and expenses:
Interest expense	—		1,177		—		3,853
Operating	2,442		33,647		5,116		105,165
Transaction costs	—		—		—		76
Impairments and loan loss reserves (recoveries), net	—		10,995		—		10,995
Total costs and expenses	2,442		45,819		5,116		120,089
Other income (expense):
Gain (loss) on sales of real estate, net	2,563		122,238		2,492		381,900
Other income (expense), net	16		128		19		6,012
Total other income (expense), net	2,579		122,366		2,511		387,912
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	2,962		108,433		2,875		377,934
Income tax benefit (expense)	30		302		370		1,124
Equity income (loss) from unconsolidated joint ventures	—		5,225		64		4,910
Income (loss) from discontinued operations	$	2,992	$	113,960	$	3,309	$	383,968

Impairments of Real Estate

2022

During the three and six months ended June 30, 2022, the Company did not recognize any impairment charges.

2021

During the three and six months ended June 30, 2021, the Company recognized an impairment charge of $4 million related to one SHOP asset classified as held for sale, which is reported in income (loss) from discontinued operations. Following a reduction in the expected sales price of the asset occurring in the second quarter of 2021, the Company wrote down its carrying value of $20 million to its fair value, less estimated costs to sell, of $16 million.

The fair value of the impaired asset was based on a forecasted sales price, which is considered to be a Level 3 measurement within the fair value hierarchy. The Company’s forecasted sales prices are typically determined using an income approach and/or a market approach (comparable sales model), which rely on certain assumptions by management, including: (i) market capitalization rates, (ii) comparable market transactions, (iii) estimated prices per unit, (iv) negotiations with prospective buyers, and (v) forecasted cash flow streams (lease revenue rates, expense rates, growth rates, etc.). There are inherent uncertainties in making these assumptions. For the Company’s impairment calculation as of June 30, 2021, the Company’s fair value estimate primarily relied on a market approach and utilized comparable market transactions and negotiations with prospective buyers.

Goodwill Impairment

When testing goodwill for impairment, if the Company concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company recognizes an impairment charge for the amount by which the carrying value, including goodwill, exceeds the reporting unit’s fair value. Following the senior housing triple-net and SHOP dispositions, the Company performed an impairment assessment to evaluate the fair value of its reporting units as of June 30, 2021. These fair value estimates primarily relied on a market approach, utilizing comparable market transactions, forecasted sales prices, and negotiations with prospective buyers. These estimates are considered to be a Level 3 measurement within the fair value hierarchy, and are subject to inherent uncertainties.

As a result of this assessment, during the three and six months ended June 30, 2021, the Company recognized a $7 million goodwill impairment charge reported in income (loss) from discontinued operations as the fair value of the remaining assets based on forecasted sales prices was less than the carrying value of the assets, including the related goodwill. The fair value was greater than the carrying value of the assets and related goodwill of all other reporting units, and as a result, no impairment charge was recognized.

Other Losses

During the first quarter of 2022, the Company recognized $14 million of expenses for tenant relocation and other costs associated with a planned MOB demolition. These expenses are included in other income (expense), net on the Consolidated Statements of Operations for the six months ended June 30, 2022.

XML

Leases

6 Months Ended

Jun. 30, 2022

Leases [Abstract]

Leases

Leases

Lease Income

The following table summarizes the Company’s lease income, excluding discontinued operations (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Fixed income from operating leases	$	296,729	$	268,290	$	584,020	$	531,246
Variable income from operating leases	90,350		72,352		173,209		137,368
Interest income from direct financing leases	—		2,180		1,168		4,343

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital classified as a direct financing lease (“DFL”) for $68 million and recognized a gain on sale of $23 million, which is included in other income (expense), net.

Net investment in DFLs consists of the following (in thousands):

	June 30, 2022		December 31, 2021
Present value of minimum lease payments receivable	$	—	$	1,220
Present value of estimated residual value	—		44,706
Less deferred selling profits	—		(1,220)
Net investment in direct financing leases	$	—	$	44,706

Direct Financing Lease Internal Ratings

At June 30, 2022, the Company had no properties classified as a DFL. At December 31, 2021, the Company had one hospital classified as a DFL with a carrying amount of $45 million and an internal rating of “performing”.

Leases

Leases

Lease Income

The following table summarizes the Company’s lease income, excluding discontinued operations (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Fixed income from operating leases	$	296,729	$	268,290	$	584,020	$	531,246
Variable income from operating leases	90,350		72,352		173,209		137,368
Interest income from direct financing leases	—		2,180		1,168		4,343

Direct Financing Leases

2022 Direct Financing Lease Sale

During the first quarter of 2022, the Company sold its remaining hospital classified as a direct financing lease (“DFL”) for $68 million and recognized a gain on sale of $23 million, which is included in other income (expense), net.

Net investment in DFLs consists of the following (in thousands):

	June 30, 2022		December 31, 2021
Present value of minimum lease payments receivable	$	—	$	1,220
Present value of estimated residual value	—		44,706
Less deferred selling profits	—		(1,220)
Net investment in direct financing leases	$	—	$	44,706

Direct Financing Lease Internal Ratings

At June 30, 2022, the Company had no properties classified as a DFL. At December 31, 2021, the Company had one hospital classified as a DFL with a carrying amount of $45 million and an internal rating of “performing”.

XML

Loans Receivable

6 Months Ended

Jun. 30, 2022

Receivables [Abstract]

Loans Receivable

Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

	June 30, 2022		December 31, 2021
Secured loans(1)	$	387,447	$	396,281
Mezzanine and other	31,098		25,529
Unamortized discounts, fees, and costs	(2,568)		(4,186)
Reserve for loan losses	(2,015)		(1,813)
Loans receivable, net	$	413,962	$	415,811

_______________________________________

(1)At June 30, 2022, the Company had $48 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects. At December 31, 2021, the Company had $58 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects.

SHOP Seller Financing

In conjunction with the sale of 32 SHOP facilities in the Sunrise Senior Housing Portfolio for $664 million in January 2021 (see Note 4), the Company provided the buyer with initial financing of $410 million. The remainder of the sales price was received in cash at the time of sale. Additionally, the Company agreed to provide up to $92 million of additional financing for capital expenditures (up to 65% of the estimated cost of capital expenditures). The additional financing was subsequently reduced to $56 million in June 2021, $47 million in February 2022, and $40 million in July 2022 in conjunction with the principal repayments discussed below. Through June 30, 2022, $0.4 million of the additional financing had been funded. The initial and additional financing is secured by the buyer's equity ownership in each property.

In June 2021, the Company received principal repayments of $246 million on the initial financing provided in conjunction with the sale of the Sunrise Senior Housing Portfolio. In connection with the June 2021 principal repayment, the Company accelerated recognition of $7 million of the related mark-to-market discount, which is included in interest income in the Consolidated Statements of Operations. Additionally, in February 2022, the Company received principal repayments of $8 million in conjunction with the disposition of the underlying collateral. As of June 30, 2022 and December 31, 2021, this secured loan had an outstanding balance of $157 million and $165 million, respectively. In July 2022, the Company received principal repayments of $27 million in conjunction with the disposition of the underlying collateral, resulting in a $7 million reduction in the Company’s remaining commitment to provide additional financing for capital expenditures.

In conjunction with the sale of 16 additional SHOP facilities for $230 million in January 2021 (see Note 4), the Company provided the buyer with financing of $150 million. The remainder of the sales price was received in cash at the time of sale. The financing is secured by the buyer's equity ownership in each property.

During the first quarter of 2021, the Company reduced the consideration and reported gain on sales of real estate and recognized a mark-to-market discount of $16 million for certain transactions with seller financing. The Company’s discount is based on the difference between the stated interest rates (ranging from 3.50% to 4.50%) and corresponding prevailing market rates of approximately 5.25% as of the transaction dates. The discount is recognized as interest income over the term of the discounted loans (ranging from one to three years) using the effective interest rate method. During the three and six months ended June 30, 2022, the Company recognized $1 million and $2 million, respectively, of non-cash interest income related to the amortization of its mark-to-market discounts. During the three and six months ended June 30, 2021, the Company recognized $9 million and $10 million, respectively, of non-cash interest income related to the amortization of its mark-to-market discounts, of which $7 million was recognized as a result of the accelerated recognition discussed above related to the Sunrise Senior Housing Portfolio.

2022 Other Loans Receivable Transactions

In May 2022, the Company received full repayment of the outstanding balance of a $2 million secured loan.

2021 Other Loans Receivable Transactions

The Company classifies a loan receivable as held for sale when management no longer has the intent or ability to hold the loan receivable for the foreseeable future or until maturity. If a loan receivable is classified as held for sale, previously recorded reserves for loan losses are reversed and the loan is reported at the lower of amortized cost or fair value. During the second quarter of 2021, two loans receivable with a total amortized cost of $64 million were classified as held for sale. Upon the transfer of these two loans to held for sale, the carrying value was decreased by $11 million to an estimated fair value of $53 million, $8 million of which was previously recognized as a reserve for loan losses. As a result, a $3 million net loss was recognized in impairments and loan loss reserves (recoveries), net during the three and six months ended June 30, 2021. In the second half of 2021, the Company sold these two loans receivable previously classified as held for sale for their aggregate carrying value of $53 million.

These fair value estimates were made for each individual loan classified as held for sale and primarily relied on a market approach, utilizing comparable market transactions, forecasted sales prices, and negotiations with prospective buyers. These estimates are considered to be a Level 3 measurement within the fair value hierarchy, and are subject to inherent uncertainties.

Additionally, in April 2021, the Company sold two mezzanine loans as part of the Discovery SHOP Portfolio disposition (see Note 4), resulting in no gain or loss on sale of the mezzanine loans.

In May 2021, the Company received a $10 million principal repayment related to one of its secured loans. In September 2021, the Company received repayment of the remaining $15 million balance.

In July 2021, the Company received full repayment of the outstanding balance of an $8 million secured loan.

CCRC Resident Loans

For certain residents that qualify, CCRCs may offer to lend residents the necessary funds to satisfy the entrance fee requirements so that they are able to move into a community while still continuing the process of selling their previous home. The loans are due upon sale of the previous residence. At June 30, 2022 and December 31, 2021, the Company held $30 million and $24 million, respectively, of such notes receivable, which are included in mezzanine and other in the table above.

Loans Receivable Internal Ratings

In connection with the Company’s quarterly review process or upon the occurrence of a significant event, loans receivable are reviewed and assigned an internal rating of Performing, Watch List, or Workout. Loans that are deemed Performing meet all present contractual obligations, and collection and timing of all amounts owed is reasonably assured. Watch List Loans are defined as loans that do not meet the definition of Performing or Workout. Workout Loans are defined as loans in which the Company has determined, based on current information and events, that: (i) it is probable it will be unable to collect all amounts due according to the contractual terms of the agreement, (ii) the borrower is delinquent on making payments under the contractual terms of the agreement, and (iii) the Company has commenced action or anticipates pursuing action in the near term to seek recovery of its investment.

The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of June 30, 2022 (in thousands):

Investment Type	Year of Origination												Total
	2022		2021		2020		2019		2018		Prior
Secured loans
Risk rating:
Performing loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total secured loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Mezzanine and other
Risk rating:
Performing loans	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total mezzanine and other	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092

Reserve for Loan Losses

The Company evaluates the liquidity and creditworthiness of its borrowers on a quarterly basis to determine whether any updates to the future expected losses recognized upon inception are necessary. The Company’s evaluation considers industry and economic conditions, individual and portfolio property performance, credit enhancements, liquidity, and other factors. The determination of loan losses also considers concentration of credit risk associated with the senior housing industry to which its loans receivable relate. The Company’s borrowers furnish property, portfolio, and guarantor/operator-level financial statements, among other information, on a monthly or quarterly basis, which the Company utilizes to calculate the debt service coverages used in its assessment of internal ratings, which is a primary credit quality indicator. Debt service coverage information is evaluated together with other property, portfolio, and operator performance information, including revenue, expense, NOI, occupancy, rental rates, capital expenditures, and EBITDA (defined as earnings before interest, tax, and depreciation and amortization), along with other liquidity measures.

In its assessment of current expected credit losses for loans receivable and unfunded loan commitments, the Company utilizes past payment history of its borrowers, current economic conditions, and forecasted economic conditions through the maturity date of each loan to estimate a probability of default and a resulting loss for each loan receivable. Future economic conditions are based primarily on near-term economic forecasts from the Federal Reserve and reasonable assumptions for long-term economic trends.

The following table summarizes the Company’s reserve for loan losses (in thousands):

	June 30, 2022						December 31, 2021
	Secured Loans		Mezzanine and Other		Total		Secured Loans		Mezzanine and Other		Total
Reserve for loan losses, beginning of period	$	1,804	$	9	$	1,813	$	3,152	$	7,128	$	10,280
Provision for expected loan losses	256		(3)		253		793		896		1,689
Expected loan losses related to loans sold or repaid(1)	(51)		—		(51)		(2,141)		(8,015)		(10,156)
Reserve for loan losses, end of period	$	2,009	$	6	$	2,015	$	1,804	$	9	$	1,813

_______________________________________

(1)Includes one loan repaid during the six months ended June 30, 2022 and six loans sold or repaid during the year ended December 31, 2021.

Additionally, at June 30, 2022 and December 31, 2021, a liability of $0.4 million and $0.3 million, respectively, related to expected credit losses for unfunded loan commitments was included in accounts payable, accrued liabilities, and other liabilities.

XML

Investments in and Advances to Unconsolidated Joint Ventures

6 Months Ended

Jun. 30, 2022

Equity Method Investments and Joint Ventures [Abstract]

Investments in and Advances to Unconsolidated Joint Ventures

Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method, excluding investments classified as discontinued operations (dollars in thousands): 

				Carrying Amount
				June 30,		December 31,
Entity(1)	Segment	Property Count(2)	Ownership %(2)	2022		2021
SWF SH JV	Other	19	54	$	351,686	$	355,394
Life Science JV	Life science	1	49	26,719		25,605
Needham Land Parcel JV(3)	Life science	—	38	14,831		13,566
Medical Office JVs(4)	Medical office	3	20 - 67	8,918		9,069
				$	402,154	$	403,634

_______________________________________

(1)These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

(2)Property counts and ownership percentages are as of June 30, 2022.

(3)In December 2021, the Company acquired a 38% interest in a life science development joint venture in Needham, Massachusetts for $13 million. Land held for development is excluded from the property count as of June 30, 2022.

(4)Includes two unconsolidated medical office joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). During 2021, the Company also held a 30% interest in Ventures III, which issued its final distribution and was dissolved.

In April 2021, the Company sold its two preferred equity investments for their carrying value as part of the Discovery SHOP Portfolio disposition (see Note 4). Prior to the sale, the Company’s ownership percentage in these two unconsolidated joint ventures was as follows: (i) Discovery Naples JV (41%) and (ii) Discovery Sarasota JV (47%).

In May 2021, the two remaining CCRCs in the CCRC JV were sold for $38 million, $19 million of which represents the Company’s 49% interest, resulting in an immaterial gain on sale recorded within equity income (loss) from unconsolidated joint ventures during the year ended December 31, 2021.

South San Francisco Joint Ventures

On August 1, 2022, the Company entered into a master equity transaction agreement with a sovereign wealth fund (“SWF Partner”) that provides the Company the opportunity to sell up to 30% interests in certain redevelopment and future development projects owned by the Company.

Concurrently, the Company executed definitive agreements with the SWF Partner to sell a 30% interest in seven life science assets in South San Francisco, California for gross proceeds of $126 million. The Company and the SWF Partner will share in key decisions related to the planned redevelopment and operation of the assets, resulting in the Company deconsolidating the previously wholly-owned assets and recognizing its 70% share as an equity method investment.

XML

Intangibles

6 Months Ended

Jun. 30, 2022

Intangibles [Abstract]

Intangibles

Intangibles

Intangible assets primarily consist of lease-up intangibles and above market tenant lease intangibles. The following table summarizes the Company’s intangible lease assets (dollars in thousands):

Intangible lease assets	June 30, 2022		December 31, 2021
Gross intangible lease assets	$	802,180	$	797,675
Accumulated depreciation and amortization	(331,315)		(277,915)
Intangible assets, net(1)	$	470,865	$	519,760
Weighted average remaining amortization period in years	6		6

_______________________________________

(1)Excludes intangible assets reported in assets held for sale and discontinued operations, net of $2 million and zero as of June 30, 2022 and December 31, 2021, respectively.

Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (dollars in thousands):

Intangible lease liabilities	June 30, 2022		December 31, 2021
Gross intangible lease liabilities	$	240,733	$	234,917
Accumulated depreciation and amortization	(71,111)		(57,685)
Intangible liabilities, net	$	169,622	$	177,232
Weighted average remaining amortization period in years	8		8

During the six months ended June 30, 2022, in conjunction with the Company’s acquisitions of real estate, the Company acquired intangible assets of $7 million and intangible liabilities of $6 million. The intangible assets and liabilities acquired had a weighted average amortization period at acquisition of 7 years and 11 years, respectively.

During the year ended December 31, 2021, in conjunction with the Company’s acquisitions of real estate, the Company acquired intangible assets of $109 million and intangible liabilities of $57 million. The intangible assets and intangible liabilities acquired each had a weighted average amortization period at acquisition of 9 years.

XML

Debt

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Debt

Debt

Bank Line of Credit and Term Loan

On May 23, 2019, the Company executed a $2.5 billion unsecured revolving line of credit facility, with a maturity date of May 23, 2023 and two six-month extension options, subject to certain customary conditions. Also in May 2019, the Company entered into a $250 million unsecured term loan facility, with a maturity date of May 23, 2024 (the “2019 Term Loan”). In July 2021, the Company repaid the $250 million 2019 Term Loan.

In September 2021, the Company executed an amended and restated unsecured revolving line of credit (the “Revolving Facility”) to increase total revolving commitments from $2.5 billion to $3.0 billion and extend the maturity date to January 20, 2026. This maturity date may be further extended pursuant to two six-month extension options, subject to certain customary conditions. Borrowings under the Revolving Facility accrue interest at LIBOR plus a margin that depends on the credit ratings of the Company’s senior unsecured long-term debt. The Company also pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company’s credit ratings at June 30, 2022, the margin on the Revolving Facility was 0.78% and the facility fee was 0.15%. At June 30, 2022 and December 31, 2021, the Company had no balance outstanding under the Revolving Facility.

The Revolving Facility includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to $750 million, subject to securing additional commitments. Further, the Revolving Facility includes customary LIBOR replacement language, including, but not limited to, the use of rates based on the secured overnight financing rate administered by the Federal Reserve Bank of New York. The Revolving Facility also includes a sustainability-linked pricing component whereby the applicable margin may be reduced by up to 0.025% based on the Company’s achievement of specified sustainability-linked metrics, subject to certain conditions.

The Revolving Facility also contains certain financial restrictions and other customary requirements, including financial covenants and cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreement: (i) limit the ratio of Enterprise Total Indebtedness to Enterprise Gross Asset Value to 60%; (ii) limit the ratio of Enterprise Secured Debt to Enterprise Gross Asset Value to 40%; (iii) limit the ratio of Enterprise Unsecured Debt to Enterprise Unencumbered Asset Value to 60%; (iv) require a minimum Fixed Charge Coverage ratio of 1.5 times; and (v) require a minimum Consolidated Tangible Net Worth of $7.7 billion. The Company believes it was in compliance with each of these covenants at June 30, 2022.

Commercial Paper Program

In September 2019, the Company established an unsecured commercial paper program (the “Commercial Paper Program”). Under the terms of the Commercial Paper Program, the Company may issue, from time to time, unsecured short-term debt securities with varying maturities. Amounts available under the Commercial Paper Program may be borrowed, repaid, and re-borrowed from time to time. At June 30, 2022 and December 31, 2021, the maximum aggregate face or principal amount that can be outstanding at any one time was $1.5 billion. Amounts borrowed under the Commercial Paper Program will be sold on terms that are customary for the U.S. commercial paper market and will be at least equal in right of payment with all of the Company’s other unsecured and unsubordinated indebtedness. The Company uses its Revolving Facility as a liquidity backstop for the repayment of unsecured short-term debt securities issued under the Commercial Paper Program. At June 30, 2022, the Company had $1.45 billion of securities outstanding under the Commercial Paper Program, with original maturities of approximately 45 days and a weighted average interest rate of 1.95%. At December 31, 2021, the Company had $1.17 billion of securities outstanding under the Commercial Paper Program, with original maturities of approximately two months and a weighted average interest rate of 0.32%.

In July 2022, the Company increased the maximum aggregate face or principal amount that can be outstanding at any one time from $1.5 billion to $2.0 billion.

Senior Unsecured Notes

At each of June 30, 2022 and December 31, 2021, the Company had senior unsecured notes outstanding with an aggregate principal balance of $4.7 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at June 30, 2022.

During the three and six months ended June 30, 2022, the Company did not issue, repurchase, or redeem any senior unsecured notes.

The following table summarizes the Company’s senior unsecured notes repurchases and redemptions during the year ended December 31, 2021 (dollars in thousands):

Payoff Date	Amount		Coupon Rate		Maturity Year
May 19, 2021(1)	$	251,806	3.40	%	2025
May 19, 2021(1)	298,194		4.00	%	2025
February 26, 2021(2)	188,000		4.25	%	2023
February 26, 2021(2)	149,000		4.20	%	2024
February 26, 2021(2)	331,000		3.88	%	2024
January 28, 2021(2)	112,000		4.25	%	2023
January 28, 2021(2)	201,000		4.20	%	2024
January 28, 2021(2)	469,000		3.88	%	2024

_______________________________________

(1)Upon repurchasing a portion of the 3.40% and 4.00% senior unsecured notes due 2025, the Company recognized a $61 million loss on debt extinguishment during the three and six months ended June 30, 2021.

(2)Upon completing the repurchases and redemptions of all outstanding 4.25%, 4.20%, and 3.88% senior unsecured notes due 2023 and 2024, the Company recognized a $164 million loss on debt extinguishment during the six months ended June 30, 2021.

In 2021, the Company completed two green bond offerings. The net proceeds from both green bonds have been allocated to eligible green projects, and the Company may choose to re-allocate net proceeds from such offerings to one or more other eligible green projects. The following table summarizes these senior unsecured note issuances for the year ended December 31, 2021 (dollars in thousands):

Issue Date	Amount		Coupon Rate		Maturity Year
November 24, 2021	$	500,000	2.13	%	2028
July 12, 2021	450,000		1.35	%	2027

Mortgage Debt

At June 30, 2022 and December 31, 2021, the Company had $348 million and $350 million, respectively, in aggregate principal of mortgage debt outstanding, which was secured by 18 healthcare facilities, with an aggregate carrying value of $799 million and $811 million, respectively.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets, and is non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires insurance on the assets, and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

During each of the three months ended June 30, 2022 and 2021, the Company made aggregate principal repayments of mortgage debt of $1 million (excluding mortgage debt on assets held for sale and discontinued operations). During each of the six months ended June 30, 2022 and 2021, the Company made aggregate principal repayments of mortgage debt of $3 million (excluding mortgage debt on assets held for sale and discontinued operations).

In April 2021, in conjunction with the acquisition of the MOB Portfolio, the Company originated $142 million of secured mortgage debt (see Note 3) that matures in May 2026. In April 2022, the Company terminated its existing interest rate cap instruments associated with this variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026 (see Note 17). The variable rate debt associated with these interest rate swap instruments is reported as fixed rate debt due to the Company having effectively established a fixed interest rate for the underlying debt instrument.

Debt Maturities

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at June 30, 2022 (dollars in thousands):

					Senior Unsecured Notes(2)				Mortgage Debt(3)
Year	Bank Line of Credit		Commercial Paper(1)		Amount		Interest Rate		Amount		Interest Rate		Total
2022	$	—	$	—	$	—	—	%	$	2,541	3.80	%	$	2,541
2023	—		—		—		—	%	90,089		3.80	%	90,089
2024	—		—		—		—	%	7,024		4.28	%	7,024
2025	—		—		800,000		3.93	%	3,209		3.80	%	803,209
2026	—		1,448,569		650,000		3.39	%	244,523		4.48	%	2,343,092
Thereafter	—		—		3,250,000		3.24	%	366		5.91	%	3,250,366
	—		1,448,569		4,700,000				347,752				6,496,321
(Discounts), premium and debt costs, net	—		—		(44,148)				1,577				(42,571)
	$	—	$	1,448,569	$	4,655,852			$	349,329			$	6,453,750

_______________________________________

(1)Commercial Paper Program borrowings are backstopped by the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.

(2)Effective interest rates on the senior unsecured notes range from 1.54% to 6.91% with a weighted average effective interest rate of 3.39% and a weighted average maturity of 7 years.

(3)Effective interest rates on the mortgage debt range from 3.42% to 5.91% with a weighted average effective interest rate of 4.28% and a weighted average maturity of 3 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company’s business. The Company is not aware of any legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company’s financial condition, results of operations, or cash flows. The Company’s policy is to expense legal costs as they are incurred.

DownREITs and Other Partnerships

In connection with the formation of certain limited liability companies (“DownREITs”), members may contribute appreciated real estate to a DownREIT in exchange for DownREIT units. These contributions are generally tax-deferred, so that the pre-contribution gain related to the property is not taxed to the member. However, if a contributed property is later sold by the DownREIT, the unamortized pre-contribution gain that exists at the date of sale is specifically allocated and taxed to the contributing members. In many of the DownREITs, the Company has entered into indemnification agreements with those members who contributed appreciated property into the DownREIT. Under these indemnification agreements, if any of the appreciated real estate contributed by the members is sold by the DownREIT in a taxable transaction within a specified number of years, the Company will reimburse the affected members for the federal and state income taxes associated with the pre-contribution gain that is specially allocated to the affected member under the Internal Revenue Code (“make-whole payments”). These make-whole payments include a tax gross-up provision. These indemnification agreements have expirations terms that range through 2039 on a total of 29 properties.

Additionally, the Company owns a 49% interest in the Life Science JV (see Note 7). If the property in the joint venture is sold in a taxable transaction, the Company is generally obligated to indemnify its joint venture partner for its federal and state income taxes associated with the gain that existed at the time of the contribution to the joint venture.

XML

Equity and Redeemable Noncontrolling Interests

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Equity and Redeemable Noncontrolling Interests

Equity and Redeemable Noncontrolling Interests

Dividends

On July 28, 2022, the Company announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share. The common stock cash dividend will be paid on August 19, 2022 to stockholders of record as of the close of business on August 8, 2022.

During each of the three months ended June 30, 2022 and 2021, the Company declared and paid common stock cash dividends of $0.30 per share. During each of the six months ended June 30, 2022 and 2021, the Company declared and paid common stock cash dividends of $0.60 per share.

At-The-Market Equity Offering Program

In February 2020, the Company established an at-the-market equity offering program (as amended from time to time, the “ATM Program”), which was most recently amended in May 2021 to increase the size of the program from $1.25 billion to $1.5 billion, pursuant to which shares of common stock having an aggregate gross sales price of up to $1.5 billion may be sold (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement (each, an “ATM forward contract”). The use of ATM forward contracts allows the Company to lock in a share price on the sale of shares at the time the ATM forward contract is effective, but defer receiving the proceeds from the sale of shares until a later date.

ATM forward contracts generally have a one to two year term. At any time during the term, the Company may settle a forward sale by delivery of physical shares of common stock to the forward seller or, at the Company’s election, in cash or net shares. The forward sale price the Company expects to receive upon settlement of outstanding ATM forward contracts will be the initial forward price established upon the effective date, subject to adjustments for: (i) accrued interest, (ii) the forward purchasers’ stock borrowing costs, and (iii) certain fixed price reductions during the term of the ATM forward contract.

At June 30, 2022, $1.18 billion of the Company’s common stock remained available for sale under the ATM Program.

ATM Forward Contracts

During the year ended December 31, 2021, the Company utilized the forward provisions under the ATM Program to allow for the sale of an aggregate of 9.1 million shares of its common stock at an initial weighted average net price of $35.25 per share, after commissions. During the three and six months ended June 30, 2022, no shares were settled under ATM forward contracts. Therefore, at June 30, 2022, 9.1 million shares remained outstanding under ATM forward contracts. These ATM forward contracts mature in the first quarter of 2023.

During the three and six months ended June 30, 2021, the Company did not utilize the forward provisions under the ATM Program.

ATM Direct Issuances

During the three and six months ended June 30, 2022 and June 30, 2021, no shares of common stock were issued under the ATM Program.

Share Repurchase Program

On August 1, 2022, the Company’s Board of Directors approved a share repurchase program under which the Company may acquire shares of its common stock in the open market up to an aggregate purchase price of $500 million (the “Share Repurchase Program”). Purchases of common stock under the Share Repurchase Program may be exercised at the Company’s discretion with the timing and number of shares repurchased depending on a variety of factors, including price, corporate and regulatory requirements, and other corporate liquidity requirements and priorities. The Share Repurchase Program expires in August 2024 and may be suspended or terminated at any time without prior notice. There have been no stock repurchases under the Share Repurchase Program through the date on which this Quarterly Report on Form 10-Q was filed.

Accumulated Other Comprehensive Income (Loss)

The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):

	June 30, 2022		December 31, 2021
Unrealized gains (losses) on derivatives, net	$	1,629	$	—
Supplemental Executive Retirement Plan minimum liability	(2,947)		(3,147)
Total accumulated other comprehensive income (loss)	$	(1,318)	$	(3,147)

Redeemable Noncontrolling Interests

Arrangements with noncontrolling interest holders are assessed for appropriate balance sheet classification based on the redemption and other rights held by the noncontrolling interest holder. Certain of the Company’s noncontrolling interest holders have the ability to put their equity interests to the Company upon specified events or after the passage of a predetermined period of time. Each put option is payable in cash and subject to increases in redemption value in the event that the underlying property generates specified returns for the Company and meets certain promote thresholds pursuant to the respective agreements. Accordingly, the Company records redeemable noncontrolling interests outside of permanent equity and presents the redeemable noncontrolling interests at the greater of their carrying amount or redemption value at the end of each reporting period.

During the year ended December 31, 2021, one of the redeemable noncontrolling interests met the conditions for redemption and the related put option was exercised during the year then ended. Accordingly, the Company made a cash payment for the redemption value of $60 million to the related noncontrolling interest holder during the year ended December 31, 2021 and acquired the redeemable noncontrolling interest associated with this entity. The remaining redeemable noncontrolling interests had not yet met the conditions for redemption as of June 30, 2022 or December 31, 2021. Three of the interests will become redeemable following the passage of a predetermined amount of time, one of which will occur in late 2022, and the remaining two in 2023 and 2024. The fourth interest will become redeemable at the earlier of a predetermined passage of time or stabilization of the underlying development property, which is expected to occur in 2023. The redemption values are subject to change based on the assessment of value at each redemption date.

XML

Earnings Per Common Share

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Earnings Per Common Share

Earnings Per Common Share

Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method and common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented.

Restricted stock and certain performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share.

Refer to Note 11 for a discussion of the sale of shares under and settlement of forward sales agreements during the periods presented. The Company considered the potential dilution resulting from the forward agreements to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. The aggregate effect on the Company’s diluted weighted-average common shares for each of the three and six months ended June 30, 2022 and 2021 was zero weighted-average incremental shares from the forward equity sales agreements. 

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Numerator
Income (loss) from continuing operations	$	69,301	$	168,065	$	144,327	$	47,480
Noncontrolling interests' share in continuing operations	(3,955)		(3,535)		(7,685)		(6,841)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	65,346		164,530		136,642		40,639
Less: Participating securities' share in continuing operations	(281)		(287)		(2,258)		(2,732)
Income (loss) from continuing operations applicable to common shares	65,065		164,243		134,384		37,907
Income (loss) from discontinued operations	2,992		113,960		3,309		383,968
Noncontrolling interests' share in discontinued operations	—		(2,210)		—		(2,539)
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Numerator - Dilutive
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Add: distributions on dilutive convertible units and other	—		1,540		—		—
Dilutive net income (loss) available to common shares	$	68,057	$	277,533	$	137,693	$	419,336
Denominator
Basic weighted average shares outstanding	539,558		538,929		539,456		538,805
Dilutive potential common shares - equity awards(1)	257		264		245		276
Dilutive potential common shares - DownREIT conversions	—		5,501		—		—
Diluted weighted average common shares	539,815		544,694		539,701		539,081
Basic earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78
Diluted earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78

_______________________________________

(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).

For the three and six months ended June 30, 2022, the 9.1 million shares under forward sales agreements that have not been settled as of June 30, 2022 were anti-dilutive. For the three and six months ended June 30, 2021, forward sales agreements had no dilutive impact as no shares remained outstanding under ATM forward contracts during the period.

For the three months ended June 30, 2021, 6 million out of 7 million shares issuable upon conversion of DownREIT units were dilutive. For all other periods presented in the table above, all 7 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.

XML

Segment Disclosures

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Disclosures

Segment Disclosures

The Company’s reportable segments, based on how its chief operating decision makers (“CODMs”) evaluate the business and allocate resources, are as follows: (i) life science, (ii) medical office, and (iii) CCRC. The Company has non-reportable segments that are comprised primarily of the Company’s interests in an unconsolidated JV that owns 19 senior housing assets (the “SWF SH JV”) and debt investments. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC, as updated by Note 2 herein.

The Company evaluates performance based on property Adjusted NOI. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense.

NOI and Adjusted NOI include the Company’s share of income (loss) from unconsolidated joint ventures and exclude noncontrolling interests’ share of income (loss) from consolidated joint ventures. Management believes that Adjusted NOI is an important supplemental measure because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. Additionally, management believes that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items.

Non-segment assets consist of assets in the Company’s other non-reportable segments and corporate non-segment assets. Corporate non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, loans receivable, marketable equity securities, other assets, real estate assets held for sale and discontinued operations, and liabilities related to assets held for sale.

The following tables summarize information for the reportable segments (in thousands):

For the three months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	207,771	$	179,308	$	125,360	$	5,493	$	—	$	517,932
Government grant income(1)	—		—		209		—		—		209
Less: Interest income	—		—		—		(5,493)		—		(5,493)
Healthpeak’s share of unconsolidated joint venture total revenues	1,267		761		—		18,215		—		20,243
Noncontrolling interests’ share of consolidated joint venture total revenues	(62)		(8,943)		—		—		—		(9,005)
Operating expenses	(49,446)		(63,321)		(102,277)		—		—		(215,044)
Healthpeak’s share of unconsolidated joint venture operating expenses	(483)		(301)		—		(14,150)		—		(14,934)
Noncontrolling interests’ share of consolidated joint venture operating expenses	19		2,726		—		—		—		2,745
Adjustments to NOI(2)	(21,644)		(2,949)		—		54		—		(24,539)
Adjusted NOI	137,422		107,281		23,292		4,119		—		272,114
Plus: Adjustments to NOI(2)	21,644		2,949		—		(54)		—		24,539
Interest income	—		—		—		5,493		—		5,493
Interest expense	—		(1,930)		(1,876)		—		(38,061)		(41,867)
Depreciation and amortization	(79,673)		(68,873)		(31,943)		—		—		(180,489)
General and administrative	—		—		—		—		(24,781)		(24,781)
Transaction costs	(35)		(70)		(64)		—		(443)		(612)
Impairments and loan loss reserves	—		—		—		(139)		—		(139)
Gain (loss) on sales of real estate, net	—		10,340		—		—		—		10,340
Other income (expense), net	29		1,264		630		18		920		2,861
Less: Government grant income	—		—		(209)		—		—		(209)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(784)		(460)		—		(4,065)		—		(5,309)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	43		6,217		—		—		—		6,260
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	78,646		56,718		(10,170)		5,372		(62,365)		68,201
Income tax benefit (expense)	—		—		—		—		718		718
Equity income (loss) from unconsolidated joint ventures	148		211		—		23		—		382
Income (loss) from continuing operations	78,794		56,929		(10,170)		5,395		(61,647)		69,301
Income (loss) from discontinued operations	—		—		—		—		2,992		2,992
Net income (loss)	$	78,794	$	56,929	$	(10,170)	$	5,395	$	(58,655)	$	72,293

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the three months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	177,527	$	165,295	$	117,308	$	16,108	$	—	$	476,238
Government grant income(1)	—		—		87		—		—		87
Less: Interest income	—		—		—		(16,108)		—		(16,108)
Healthpeak’s share of unconsolidated joint venture total revenues	1,412		710		2,415		16,740		—		21,277
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		—		583		—		583
Noncontrolling interests’ share of consolidated joint venture total revenues	(75)		(8,825)		—		—		—		(8,900)
Operating expenses	(40,724)		(54,648)		(94,760)		—		—		(190,132)
Healthpeak’s share of unconsolidated joint venture operating expenses	(428)		(317)		(2,208)		(12,451)		—		(15,404)
Noncontrolling interests’ share of consolidated joint venture operating expenses	21		2,552		—		—		—		2,573
Adjustments to NOI(2)	(12,366)		(2,003)		1,226		(27)		—		(13,170)
Adjusted NOI	125,367		102,764		24,068		4,845		—		257,044
Plus: Adjustments to NOI(2)	12,366		2,003		(1,226)		27		—		13,170
Interest income	—		—		—		16,108		—		16,108
Interest expense	(48)		(786)		(1,924)		—		(35,923)		(38,681)
Depreciation and amortization	(76,955)		(63,371)		(31,133)		—		—		(171,459)
General and administrative	—		—		—		—		(24,088)		(24,088)
Transaction costs	21		35		(657)		(18)		—		(619)
Impairments and loan loss reserves	—		—		—		(931)		—		(931)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(60,865)		(60,865)
Other income (expense), net	28		(175)		165		—		1,716		1,734
Less: Government grant income	—		—		(87)		—		—		(87)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(984)		(393)		(207)		(4,872)		—		(6,456)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	54		6,273		—		—		—		6,327
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	59,849		221,588		(11,001)		15,159		(119,160)		166,435
Income tax benefit (expense)	—		—		—		—		763		763
Equity income (loss) from unconsolidated joint ventures	111		137		639		(20)		—		867
Income (loss) from continuing operations	59,960		221,725		(10,362)		15,139		(118,397)		168,065
Income (loss) from discontinued operations	—		—		—		—		113,960		113,960
Net income (loss)	$	59,960	$	221,725	$	(10,362)	$	15,139	$	(4,437)	$	282,025

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the six months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	401,826	$	356,571	$	246,920	$	10,987	$	—	$	1,016,304
Government grant income(1)	—		—		6,762		—		—		6,762
Less: Interest income	—		—		—		(10,987)		—		(10,987)
Healthpeak’s share of unconsolidated joint venture total revenues	2,698		1,493		—		36,260		—		40,451
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		333		315		—		648
Noncontrolling interests’ share of consolidated joint venture total revenues	(119)		(17,763)		—		—		—		(17,882)
Operating expenses	(97,635)		(124,491)		(200,165)		—		—		(422,291)
Healthpeak’s share of unconsolidated joint venture operating expenses	(966)		(600)		—		(28,205)		—		(29,771)
Noncontrolling interests’ share of consolidated joint venture operating expenses	38		5,328		—		—		—		5,366
Adjustments to NOI(2)	(35,756)		(6,495)		—		45		—		(42,206)
Adjusted NOI	270,086		214,043		53,850		8,415		—		546,394
Plus: Adjustments to NOI(2)	35,756		6,495		—		(45)		—		42,206
Interest income	—		—		—		10,987		—		10,987
Interest expense	—		(2,966)		(3,741)		—		(72,746)		(79,453)
Depreciation and amortization	(157,811)		(136,646)		(63,765)		—		—		(358,222)
General and administrative	—		—		—		—		(48,612)		(48,612)
Transaction costs	(327)		(74)		(64)		—		(443)		(908)
Impairments and loan loss reserves	—		—		—		(271)		—		(271)
Gain (loss) on sales of real estate, net	3,856		10,340		—		—		—		14,196
Other income (expense), net	20		12,201		7,141		(13)		1,828		21,177
Less: Government grant income	—		—		(6,762)		—		—		(6,762)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,732)		(893)		(333)		(8,370)		—		(11,328)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	81		12,435		—		—		—		12,516
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	149,929		114,935		(13,674)		10,703		(119,973)		141,920
Income tax benefit (expense)	—		—		—		—		(59)		(59)
Equity income (loss) from unconsolidated joint ventures	1,114		411		539		402		—		2,466
Income (loss) from continuing operations	151,043		115,346		(13,135)		11,105		(120,032)		144,327
Income (loss) from discontinued operations	—		—		—		—		3,309		3,309
Net income (loss)	$	151,043	$	115,346	$	(13,135)	$	11,105	$	(116,723)	$	147,636

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the six months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	347,461	$	325,496	$	233,436	$	25,121	$	—	$	931,514
Government grant income(1)	—		—		1,397		—		—		1,397
Less: Interest income	—		—		—		(25,121)		—		(25,121)
Healthpeak’s share of unconsolidated joint venture total revenues	2,749		1,425		6,903		33,493		—		44,570
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		199		810		—		1,009
Noncontrolling interests’ share of consolidated joint venture total revenues	(140)		(17,751)		—		—		—		(17,891)
Operating expenses	(80,185)		(105,769)		(185,939)		—		—		(371,893)
Healthpeak’s share of unconsolidated joint venture operating expenses	(853)		(611)		(6,953)		(25,046)		—		(33,463)
Noncontrolling interests’ share of consolidated joint venture operating expenses	41		5,056		—		—		—		5,097
Adjustments to NOI(2)	(24,176)		(3,926)		1,246		85		—		(26,771)
Adjusted NOI	244,897		203,920		50,289		9,342		—		508,448
Plus: Adjustments to NOI(2)	24,176		3,926		(1,246)		(85)		—		26,771
Interest income	—		—		—		25,121		—		25,121
Interest expense	(150)		(881)		(3,842)		—		(80,651)		(85,524)
Depreciation and amortization	(145,388)		(121,326)		(62,283)		—		—		(328,997)
General and administrative	—		—		—		—		(48,990)		(48,990)
Transaction costs	(11)		(295)		(1,090)		(21)		—		(1,417)
Impairments and loan loss reserves	—		—		—		(4,173)		—		(4,173)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(225,157)		(225,157)
Other income (expense), net	33		(2,454)		2,341		482		3,532		3,934
Less: Government grant income	—		—		(1,397)		—		—		(1,397)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,896)		(814)		(149)		(9,257)		—		(12,116)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	99		12,695		—		—		—		12,794
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	121,760		270,009		(17,377)		21,409		(351,266)		44,535
Income tax benefit (expense)	—		—		—		—		755		755
Equity income (loss) from unconsolidated joint ventures	18		328		639		1,205		—		2,190
Income (loss) from continuing operations	121,778		270,337		(16,738)		22,614		(350,511)		47,480
Income (loss) from discontinued operations	—		—		—		—		383,968		383,968
Net income (loss)	$	121,778	$	270,337	$	(16,738)	$	22,614	$	33,457	$	431,448

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

See Notes 3, 4, and 5 for significant transactions impacting the Company’s segment assets during the periods presented.

XML

Supplemental Cash Flow Information

6 Months Ended

Jun. 30, 2022

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Six Months Ended June 30,
	2022		2021
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	74,327	$	109,277
Income taxes paid (refunded)	(612)		4,026
Capitalized interest	16,320		10,867
Supplemental schedule of non-cash investing and financing activities:
Increase in ROU asset in exchange for new lease liability related to operating leases	508		13,157
Seller financing provided on disposition of real estate asset	—		559,745
Accrued construction costs	163,391		113,221
Vesting of restricted stock units and conversion of non-managing member units into common stock	803		900
Carrying value of mortgages assumed by buyer in real estate dispositions	—		106,632

The following table summarizes certain cash flow information related to assets classified as discontinued operations (in thousands):

	Six Months Ended June 30,
	2022		2021
Leasing costs, tenant improvements, and recurring capital expenditures	$	21	$	2,349
Development, redevelopment, and other major improvements of real estate	18		4,569
Depreciation and amortization of real estate, in-place lease, and other intangibles	—		—

The following table summarizes cash, cash equivalents and restricted cash (in thousands):

	Six Months Ended June 30,
	2022		2021		2022		2021		2022		2021
	Continuing operations				Discontinued operations				Total
Beginning of period:
Cash and cash equivalents	$	158,287	$	44,226	$	7,707	$	53,085	$	165,994	$	97,311
Restricted cash	53,454		67,206		—		17,168		53,454		84,374
Cash, cash equivalents and restricted cash	$	211,741	$	111,432	$	7,707	$	70,253	$	219,448	$	181,685
End of period:
Cash and cash equivalents	$	73,013	$	96,923	$	8,070	$	17,354	$	81,083	$	114,277
Restricted cash	54,815		129,052		—		974		54,815		130,026
Cash, cash equivalents and restricted cash	$	127,828	$	225,975	$	8,070	$	18,328	$	135,898	$	244,303

XML

Variable Interest Entities

6 Months Ended

Jun. 30, 2022

Variable Interest Entities [Abstract]

Variable Interest Entities

Variable Interest Entities

Unconsolidated Variable Interest Entities

At June 30, 2022 and December 31, 2021, the Company had investments in: (i) two unconsolidated VIE joint ventures and (ii) marketable debt securities of one VIE. The Company determined it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company’s equity interest in the unconsolidated joint ventures (the LLC investment and Needham Land Parcel JV discussed below), it has no formal involvement in these VIEs beyond its investments.

Debt Securities Investment. The Company holds commercial mortgage-backed securities (“CMBS”) issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is “thinly capitalized.” The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets. These securities are classified as held-to-maturity because the Company has the intent and ability to hold the securities until maturity.

LLC Investment. The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company’s involvement in the entity is limited to its equity investment as a limited partner and it does not have any substantive participating rights or kick-out rights over the general partner. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate. Any assets generated by the entity may only be used to settle its contractual obligations (primarily capital expenditures and debt service payments).

Needham Land Parcel JV. In December 2021, the Company acquired a 38% interest in a life science development joint venture in Needham, Massachusetts for $13 million. Current equity at risk is not sufficient to finance the joint venture’s activities. The assets and liabilities of the entity primarily consist of real estate and debt service obligations. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at June 30, 2022 was as follows (in thousands):

VIE Type	Asset Type	Maximum Loss Exposure and Carrying Amount(1)
Continuing operations:
CMBS and LLC investment	Other assets, net	$	36,599
Needham Land Parcel JV	Investments in and advances to unconsolidated joint ventures	14,831

_______________________________________

(1)The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

As of June 30, 2022, the Company had not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including under circumstances in which it could be exposed to further losses (e.g., cash shortfalls).

See Notes 3, 4, and 7 for additional descriptions of the nature, purpose, and operating activities of the Company’s unconsolidated VIEs and interests therein.

Consolidated Variable Interest Entities

The Company’s consolidated total assets and total liabilities at June 30, 2022 and December 31, 2021 include certain assets of VIEs that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to the Company.

Ventures V, LLC.  The Company holds a 51% ownership interest in and is the managing member of a joint venture entity formed in October 2015 that owns and leases MOBs (“Ventures V”). The Company classifies Ventures V as a VIE due to the non-managing member lacking substantive participation rights in the management of Ventures V or kick-out rights over the managing member. The Company consolidates Ventures V as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Ventures V primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by Ventures V may only be used to settle its contractual obligations (primarily from capital expenditures).

Life Science JVs.  The Company holds a 99% ownership interest in multiple joint venture entities that own and lease life science assets (the “Life Science JVs”). The Life Science JVs are VIEs as the members share in certain decisions of the entities, but substantially all of the activities are performed on behalf of the Company. The Company consolidates the Life Science JVs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Life Science JVs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Life Science JVs may only be used to settle their contractual obligations (primarily from capital expenditures). Refer to Note 11 for a discussion of certain put options associated with the Life Science JVs.

MSREI MOB JV. The Company holds a 51% ownership interest in, and is the managing member of, a joint venture entity formed in August 2018 that owns and leases MOBs (the “MSREI JV”). The MSREI JV is a VIE due to the non-managing member lacking substantive participation rights in the management of the joint venture or kick-out rights over the managing member. The Company consolidates the MSREI JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of the MSREI JV primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by the MSREI JV may only be used to settle its contractual obligations (primarily from capital expenditures).

DownREITs.  The Company holds a controlling ownership interest in and is the managing member of seven DownREITs. The Company classifies the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). The Company classifies the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Exchange Accommodation Titleholder. During the three months ended June 30, 2022, the Company acquired one MOB using a reverse like-kind exchange structure pursuant to Section 1031 of the Internal Revenue Code (a “reverse 1031 exchange”). Additionally, during the three months ended March 31, 2022, the Company acquired two MOBs using a reverse 1031 exchange. As of June 30, 2022, the Company had not completed these reverse 1031 exchanges and as such, the acquired properties remained in the possession of the Exchange Accommodation Titleholder (“EAT”). The EAT was classified as a VIE as it was a “thinly capitalized” entity. The Company consolidated the EAT because it had the ability to control the activities that most significantly impacted the economic performance of the EAT and was, therefore, the primary beneficiary of the EAT. The properties held by the EAT had a carrying value of $66 million as of June 30, 2022. The assets of the EAT primarily consisted of leased properties (net real estate, including intangibles) and rents receivable; their obligations primarily consisted of capital expenditures for the properties. Assets generated by the EAT may only be used to settle its contractual obligations (primarily from capital expenditures).

During the year ended December 31, 2021, the Company acquired two MOBs using reverse 1031 exchanges. As of December 31, 2021, the Company had not completed the reverse 1031 exchanges and as such, the acquired properties remained in the possession of the EAT. These properties held by the EAT had a carrying value of $77 million as of December 31, 2021. These reverse 1031 exchanges were completed in February 2022.

Total assets and total liabilities include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Buildings and improvements	$	2,331,975	$	2,303,920
Development costs and construction in progress	138,655		82,303
Land	510,096		548,168
Accumulated depreciation and amortization	(592,488)		(551,097)
Net real estate	2,388,238		2,383,294
Accounts receivable, net	3,933		5,455
Cash and cash equivalents	37,274		22,295
Restricted cash	211		114
Intangible assets, net	106,855		117,180
Assets held for sale and discontinued operations, net	216		754
Right-of-use asset, net	108,390		107,993
Other assets, net	66,610		62,886
Total assets	$	2,711,727	$	2,699,971
Liabilities
Mortgage debt	$	144,451	$	144,350
Intangible liabilities, net	27,410		23,909
Liabilities related to assets held for sale and discontinued operations, net	1,668		1,677
Lease liability	98,666		99,213
Accounts payable, accrued liabilities, and other liabilities	69,143		58,440
Deferred revenue	25,431		21,546
Total liabilities	$	366,769	$	349,135

Total assets and liabilities related to assets held for sale and discontinued operations include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Accounts receivable, net	$	—	$	62
Cash and cash equivalents	153		59
Other assets, net	63		633
Total assets	$	216	$	754
Liabilities
Accounts payable, accrued liabilities, and other liabilities	$	1,668	$	1,677
Total liabilities	$	1,668	$	1,677

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the Consolidated Balance Sheets were immaterial at June 30, 2022 and December 31, 2021.

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	June 30, 2022(3)				December 31, 2021(3)
	Carrying Value		Fair Value		Carrying Value		Fair Value
Loans receivable, net(2)	$	413,962	$	432,914	$	415,811	$	437,607
Marketable debt securities(2)	21,345		21,345		21,003		21,003
Interest rate swap instruments(2)	1,629		1,629		—		—
Interest rate cap instruments(2)	—		—		397		397
Bank line of credit and commercial paper(2)	1,448,569		1,448,569		1,165,975		1,165,975
Senior unsecured notes(1)	4,655,852		4,360,241		4,651,933		5,054,747
Mortgage debt(2)	349,329		339,356		352,081		352,800

_______________________________________

(1)Level 1: Fair value calculated based on quoted prices in active markets.

(2)Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, interest rate swap instruments, and interest rate cap instruments, standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit and commercial paper, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3)During the six months ended June 30, 2022 and year ended December 31, 2021, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

XML

Derivative Financial Instruments

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

Derivative Financial InstrumentsThe Company uses derivative instruments to mitigate the effects of interest rate fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes. At June 30, 2022, a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by approximately $5 million.

In March 2021, the Company repaid $39 million of variable rate secured debt on two SHOP assets and terminated the two associated interest rate swap instruments. Therefore, at December 31, 2021, the Company had no interest rate swap instruments.

In April 2021, the Company executed two interest rate cap instruments on its $142 million of variable rate mortgage debt issued in conjunction with the acquisition of the MOB Portfolio (see Note 3).

In April 2022, the Company terminated these interest rate cap instruments and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026.

The following table summarizes the Company’s interest rate swap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Pay Rate	Receive Rate	June 30, 2022		December 31, 2021
April 2022(2)	May 2026	Cash flow	$	51,100	5.08 %	1 mo. USD-LIBOR-BBA + 2.50%	$	586	$	—
April 2022(2)	May 2026	Cash flow	91,000		4.63 %	1 mo. USD-LIBOR-BBA + 2.05%	1,043		—

_____________________________

(1)At June 30, 2022, the interest rate swap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate secured debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.

The following table summarizes the Company’s interest rate cap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Strike Rate	Index	June 30, 2022		December 31, 2021
April 2021(2)	May 2024	Non-designated	$	142,100	2.00 %	1 mo. USD-LIBOR-BBA	$	—	$	397

_____________________________

(1)At December 31, 2021, the interest rate cap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents two interest rate cap instruments that manage the Company’s exposure to variable cash flows on certain mortgage debt borrowings by limiting interest rates. These interest rate cap instruments were terminated in April 2022.

During the three and six months ended June 30, 2022, the Company recognized a $0.1 million and $2 million increase, respectively, in the fair value of the interest rate cap instruments within other income (expense), net.

XML

Accounts Payable, Accrued Liabilities, and Other Liabilities

6 Months Ended

Jun. 30, 2022

Payables and Accruals [Abstract]

Accounts Payable, Accrued Liabilities, and Other Liabilities

Accounts Payable, Accrued Liabilities, and Other Liabilities

The following table summarizes the Company’s accounts payable, accrued liabilities, and other liabilities, excluding accounts payable, accrued liabilities, and other liabilities related to assets classified as discontinued operations (in thousands):

	June 30, 2022		December 31, 2021
Refundable entrance fees(1)	$	275,152	$	288,409
Accrued construction costs	163,391		179,995
Accrued interest	59,092		59,342
Other accounts payable and accrued liabilities	209,184		227,638
Accounts payable, accrued liabilities, and other liabilities	$	706,819	$	755,384

_______________________________________

(1)At June 30, 2022 and December 31, 2021, unamortized nonrefundable entrance fee liabilities were $508 million and $496 million, respectively, which are recorded within deferred revenue on the Consolidated Balance Sheets. During the three and six months ended June 30, 2022, the Company collected nonrefundable entrance fees of $29 million and $50 million, respectively, and recognized amortization of $19 million and $38 million, respectively. During the three and six months ended June 30, 2021, the Company collected nonrefundable entrance fees of $24 million and $38 million, respectively, and recognized amortization of $18 million and $38 million, respectively. The amortization of nonrefundable entrance fees is included within resident fees and services on the Consolidated Statements of Operations.

XML

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management’s estimates.

The consolidated financial statements include the accounts of Healthpeak Properties, Inc., its wholly-owned subsidiaries, joint ventures (“JVs”), and variable interest entities (“VIEs”) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. All adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations, and cash flows have been included. Operating results for the three and six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (“SEC”).

Government Grant Income

Government Grant Income

On March 27, 2020, the federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide financial aid to individuals, businesses, and state and local governments. During the three and six months ended June 30, 2022 and 2021, the Company received government grants under the CARES Act primarily to cover increased expenses and lost revenue during the coronavirus (“Covid”) pandemic. Grant income is recognized when there is reasonable assurance that the grant will be received and the Company will comply with all conditions attached to the grant. Additionally, grants are recognized over the periods in which the Company recognizes the increased expenses and lost revenue the grants are intended to defray. As of June 30, 2022, the amount of qualifying expenditures and lost revenue exceeded grant income recognized and the Company believes it has complied and will continue to comply with all grant conditions. In the event of non-compliance, all such amounts received are subject to recapture.

Discontinued Operations

Discontinued Operations

Senior Housing Triple-Net and Senior Housing Operating Portfolio Dispositions

During 2020, the Company established and began executing a plan to dispose of its senior housing triple-net and Senior Housing Operating Property (“SHOP”) properties and concluded that the planned dispositions represented a strategic shift that had and will have a major effect on the Company’s operations and financial results. Therefore, senior housing triple-net and SHOP assets meeting the held for sale criteria are classified as discontinued operations in all periods presented herein. In September 2021, the Company successfully completed the disposition of the remaining senior housing triple-net and SHOP properties. See Note 4 for further information.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Adopted

Government Assistance. In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which increases the transparency of government assistance including the disclosure of the types of assistance, an entity’s accounting for assistance, and the effect of the assistance on an entity’s financial statements. The adoption of ASU 2021-10 on January 1, 2022 did not have a material impact on the Company’s consolidated financial position, results of operations, cash flows, or disclosures.

Not Yet Adopted

Reference Rate Reform. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides optional guidance for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on financial reporting. In January 2021, the FASB issued ASU No. 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”), which amends the scope of ASU 2020-04 to include derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. The amendments in ASU 2020-04 and ASU 2021-01 were effective immediately and may be applied through December 31, 2022. The Company is evaluating whether the optional relief provided by ASU 2020-04 or ASU 2021-01 will be adopted but does not expect the adoption of these standards to have a material impact on its consolidated financial position, results of operations, cash flows, or disclosures.

XML

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Schedule of Government Grant Receivables, CARES Act

The following table summarizes information related to government grant income received and recognized by the Company (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Government grant income recorded in other income (expense), net	$	209	$	87	$	6,762	$	1,397
Government grant income recorded in equity income (loss) from unconsolidated joint ventures	—		584		648		1,010
Government grant income recorded in income (loss) from discontinued operations	—		428		206		3,660
Total government grants received	$	209	$	1,099	$	7,616	$	6,067

XML

Dispositions of Real Estate and Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Summary of Assets and Liabilities

The following summarizes the assets and liabilities classified as held for sale or as discontinued operations at June 30, 2022 and December 31, 2021, which are included in assets held for sale and discontinued operations, net and liabilities related to assets held for sale and discontinued operations, net, respectively, on the Consolidated Balance Sheets (in thousands):

	June 30, 2022		December 31, 2021
ASSETS
Accounts receivable, net of allowance of $990 and $4,138	$	761	$	2,446
Cash and cash equivalents	8,070		7,707
Right-of-use asset, net	19		26
Other assets, net	1,400		3,237
Total assets of discontinued operations, net	10,250		13,416
Assets held for sale, net(1)	56,397		23,774
Assets held for sale and discontinued operations, net	$	66,647	$	37,190
LIABILITIES
Lease liability	$	19	$	26
Accounts payable, accrued liabilities, and other liabilities	11,479		14,843
Deferred revenue	102		92
Total liabilities of discontinued operations, net	11,600		14,961
Liabilities related to assets held for sale, net(1)	4,269		95
Liabilities related to assets held for sale and discontinued operations, net	$	15,869	$	15,056

_______________________________________

(1)As of June 30, 2022, includes two life science assets and two MOBs primarily comprised of net real estate assets of $51 million. As of December 31, 2021, includes four MOBs and one life science facility primarily comprised of net real estate assets of $23 million.

The results of discontinued operations during the three and six months ended June 30, 2022 and 2021, or through the disposal date of each asset or portfolio of assets held within discontinued operations if sold during such periods, as applicable, are included in the consolidated results of operations for the three and six months ended June 30, 2022 and 2021. Summarized financial information for discontinued operations for the three and six months ended June 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues:
Rental and related revenues	$	—	$	1,613	$	—	$	6,841
Resident fees and services	2,825		30,273		5,480		103,270
Total revenues	2,825		31,886		5,480		110,111
Costs and expenses:
Interest expense	—		1,177		—		3,853
Operating	2,442		33,647		5,116		105,165
Transaction costs	—		—		—		76
Impairments and loan loss reserves (recoveries), net	—		10,995		—		10,995
Total costs and expenses	2,442		45,819		5,116		120,089
Other income (expense):
Gain (loss) on sales of real estate, net	2,563		122,238		2,492		381,900
Other income (expense), net	16		128		19		6,012
Total other income (expense), net	2,579		122,366		2,511		387,912
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	2,962		108,433		2,875		377,934
Income tax benefit (expense)	30		302		370		1,124
Equity income (loss) from unconsolidated joint ventures	—		5,225		64		4,910
Income (loss) from discontinued operations	$	2,992	$	113,960	$	3,309	$	383,968

XML

Leases (Tables)

6 Months Ended

Jun. 30, 2022

Leases [Abstract]

Schedule of Company's Lease Income

The following table summarizes the Company’s lease income, excluding discontinued operations (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Fixed income from operating leases	$	296,729	$	268,290	$	584,020	$	531,246
Variable income from operating leases	90,350		72,352		173,209		137,368
Interest income from direct financing leases	—		2,180		1,168		4,343

Schedule of Components of Net Investment in DFLs

Net investment in DFLs consists of the following (in thousands):

	June 30, 2022		December 31, 2021
Present value of minimum lease payments receivable	$	—	$	1,220
Present value of estimated residual value	—		44,706
Less deferred selling profits	—		(1,220)
Net investment in direct financing leases	$	—	$	44,706

XML

Loans Receivable (Tables)

6 Months Ended

Jun. 30, 2022

Receivables [Abstract]

Schedule of Loans Receivable

The following table summarizes the Company’s loans receivable (in thousands):

	June 30, 2022		December 31, 2021
Secured loans(1)	$	387,447	$	396,281
Mezzanine and other	31,098		25,529
Unamortized discounts, fees, and costs	(2,568)		(4,186)
Reserve for loan losses	(2,015)		(1,813)
Loans receivable, net	$	413,962	$	415,811

_______________________________________

(1)At June 30, 2022, the Company had $48 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects. At December 31, 2021, the Company had $58 million remaining of commitments to fund additional loans for senior housing redevelopment and capital expenditure projects.

Schedule of Financing Receivable Credit Quality Indicators and by Year of Origination

The following table summarizes, by year of origination, the Company’s internal ratings for loans receivable, net of unamortized discounts, fees, and reserves for loan losses, as of June 30, 2022 (in thousands):

Investment Type	Year of Origination												Total
	2022		2021		2020		2019		2018		Prior
Secured loans
Risk rating:
Performing loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total secured loans	$	—	$	302,665	$	80,205	$	—	$	—	$	—	$	382,870
Mezzanine and other
Risk rating:
Performing loans	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092
Watch list loans	—		—		—		—		—		—		—
Workout loans	—		—		—		—		—		—		—
Total mezzanine and other	$	23,239	$	6,635	$	1,218	$	—	$	—	$	—	$	31,092

Schedule of Financing Receivable, Allowance for Credit Loss

The following table summarizes the Company’s reserve for loan losses (in thousands):

	June 30, 2022						December 31, 2021
	Secured Loans		Mezzanine and Other		Total		Secured Loans		Mezzanine and Other		Total
Reserve for loan losses, beginning of period	$	1,804	$	9	$	1,813	$	3,152	$	7,128	$	10,280
Provision for expected loan losses	256		(3)		253		793		896		1,689
Expected loan losses related to loans sold or repaid(1)	(51)		—		(51)		(2,141)		(8,015)		(10,156)
Reserve for loan losses, end of period	$	2,009	$	6	$	2,015	$	1,804	$	9	$	1,813

_______________________________________

(1)Includes one loan repaid during the six months ended June 30, 2022 and six loans sold or repaid during the year ended December 31, 2021.

XML

Investments in and Advances to Unconsolidated Joint Ventures (Tables)

6 Months Ended

Jun. 30, 2022

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Equity Method Investments

The Company owns interests in the following entities that are accounted for under the equity method, excluding investments classified as discontinued operations (dollars in thousands): 

				Carrying Amount
				June 30,		December 31,
Entity(1)	Segment	Property Count(2)	Ownership %(2)	2022		2021
SWF SH JV	Other	19	54	$	351,686	$	355,394
Life Science JV	Life science	1	49	26,719		25,605
Needham Land Parcel JV(3)	Life science	—	38	14,831		13,566
Medical Office JVs(4)	Medical office	3	20 - 67	8,918		9,069
				$	402,154	$	403,634

_______________________________________

(1)These entities are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.

(2)Property counts and ownership percentages are as of June 30, 2022.

(3)In December 2021, the Company acquired a 38% interest in a life science development joint venture in Needham, Massachusetts for $13 million. Land held for development is excluded from the property count as of June 30, 2022.

(4)Includes two unconsolidated medical office joint ventures in which the Company holds an ownership percentage as follows: (i) Ventures IV (20%) and (ii) Suburban Properties, LLC (67%). During 2021, the Company also held a 30% interest in Ventures III, which issued its final distribution and was dissolved.

XML

Intangibles (Tables)

6 Months Ended

Jun. 30, 2022

Intangibles [Abstract]

Schedule of Intangible Lease Assets

Intangible assets primarily consist of lease-up intangibles and above market tenant lease intangibles. The following table summarizes the Company’s intangible lease assets (dollars in thousands):

Intangible lease assets	June 30, 2022		December 31, 2021
Gross intangible lease assets	$	802,180	$	797,675
Accumulated depreciation and amortization	(331,315)		(277,915)
Intangible assets, net(1)	$	470,865	$	519,760
Weighted average remaining amortization period in years	6		6

_______________________________________

(1)Excludes intangible assets reported in assets held for sale and discontinued operations, net of $2 million and zero as of June 30, 2022 and December 31, 2021, respectively.

Schedule of Intangible Lease Liabilities

Intangible liabilities consist of below market lease intangibles. The following table summarizes the Company’s intangible lease liabilities (dollars in thousands):

Intangible lease liabilities	June 30, 2022		December 31, 2021
Gross intangible lease liabilities	$	240,733	$	234,917
Accumulated depreciation and amortization	(71,111)		(57,685)
Intangible liabilities, net	$	169,622	$	177,232
Weighted average remaining amortization period in years	8		8

XML

Debt (Tables)

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Summary of Senior Notes Issuances

The following table summarizes the Company’s senior unsecured notes repurchases and redemptions during the year ended December 31, 2021 (dollars in thousands):

Payoff Date	Amount		Coupon Rate		Maturity Year
May 19, 2021(1)	$	251,806	3.40	%	2025
May 19, 2021(1)	298,194		4.00	%	2025
February 26, 2021(2)	188,000		4.25	%	2023
February 26, 2021(2)	149,000		4.20	%	2024
February 26, 2021(2)	331,000		3.88	%	2024
January 28, 2021(2)	112,000		4.25	%	2023
January 28, 2021(2)	201,000		4.20	%	2024
January 28, 2021(2)	469,000		3.88	%	2024

_______________________________________

(1)Upon repurchasing a portion of the 3.40% and 4.00% senior unsecured notes due 2025, the Company recognized a $61 million loss on debt extinguishment during the three and six months ended June 30, 2021.

(2)Upon completing the repurchases and redemptions of all outstanding 4.25%, 4.20%, and 3.88% senior unsecured notes due 2023 and 2024, the Company recognized a $164 million loss on debt extinguishment during the six months ended June 30, 2021.

(dollars in thousands):

Issue Date	Amount		Coupon Rate		Maturity Year
November 24, 2021	$	500,000	2.13	%	2028
July 12, 2021	450,000		1.35	%	2027

Summary of Debt Maturities and Schedule Principal Repayments

The following table summarizes the Company’s stated debt maturities and scheduled principal repayments at June 30, 2022 (dollars in thousands):

					Senior Unsecured Notes(2)				Mortgage Debt(3)
Year	Bank Line of Credit		Commercial Paper(1)		Amount		Interest Rate		Amount		Interest Rate		Total
2022	$	—	$	—	$	—	—	%	$	2,541	3.80	%	$	2,541
2023	—		—		—		—	%	90,089		3.80	%	90,089
2024	—		—		—		—	%	7,024		4.28	%	7,024
2025	—		—		800,000		3.93	%	3,209		3.80	%	803,209
2026	—		1,448,569		650,000		3.39	%	244,523		4.48	%	2,343,092
Thereafter	—		—		3,250,000		3.24	%	366		5.91	%	3,250,366
	—		1,448,569		4,700,000				347,752				6,496,321
(Discounts), premium and debt costs, net	—		—		(44,148)				1,577				(42,571)
	$	—	$	1,448,569	$	4,655,852			$	349,329			$	6,453,750

_______________________________________

(1)Commercial Paper Program borrowings are backstopped by the Revolving Facility. As such, the Company calculates the weighted average remaining term of its Commercial Paper Program borrowings using the maturity date of the Revolving Facility.

(2)Effective interest rates on the senior unsecured notes range from 1.54% to 6.91% with a weighted average effective interest rate of 3.39% and a weighted average maturity of 7 years.

(3)Effective interest rates on the mortgage debt range from 3.42% to 5.91% with a weighted average effective interest rate of 4.28% and a weighted average maturity of 3 years. These interest rates include the impact of designated interest rate swap instruments, which effectively fix the interest rate on certain variable rate debt.

XML

Equity and Redeemable Noncontrolling Interests (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Schedule of Accumulated Other comprehensive Loss

The following table summarizes the Company’s accumulated other comprehensive income (loss) (in thousands):

	June 30, 2022		December 31, 2021
Unrealized gains (losses) on derivatives, net	$	1,629	$	—
Supplemental Executive Retirement Plan minimum liability	(2,947)		(3,147)
Total accumulated other comprehensive income (loss)	$	(1,318)	$	(3,147)

XML

Earnings Per Common Share (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Earnings per Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Numerator
Income (loss) from continuing operations	$	69,301	$	168,065	$	144,327	$	47,480
Noncontrolling interests' share in continuing operations	(3,955)		(3,535)		(7,685)		(6,841)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	65,346		164,530		136,642		40,639
Less: Participating securities' share in continuing operations	(281)		(287)		(2,258)		(2,732)
Income (loss) from continuing operations applicable to common shares	65,065		164,243		134,384		37,907
Income (loss) from discontinued operations	2,992		113,960		3,309		383,968
Noncontrolling interests' share in discontinued operations	—		(2,210)		—		(2,539)
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Numerator - Dilutive
Net income (loss) applicable to common shares	$	68,057	$	275,993	$	137,693	$	419,336
Add: distributions on dilutive convertible units and other	—		1,540		—		—
Dilutive net income (loss) available to common shares	$	68,057	$	277,533	$	137,693	$	419,336
Denominator
Basic weighted average shares outstanding	539,558		538,929		539,456		538,805
Dilutive potential common shares - equity awards(1)	257		264		245		276
Dilutive potential common shares - DownREIT conversions	—		5,501		—		—
Diluted weighted average common shares	539,815		544,694		539,701		539,081
Basic earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78
Diluted earnings (loss) per common share
Continuing operations	$	0.12	$	0.30	$	0.25	$	0.07
Discontinued operations	0.01		0.21		0.01		0.71
Net income (loss) applicable to common shares	$	0.13	$	0.51	$	0.26	$	0.78

_______________________________________

(1)For all periods presented, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options).

For the three and six months ended June 30, 2022, the 9.1 million shares under forward sales agreements that have not been settled as of June 30, 2022 were anti-dilutive. For the three and six months ended June 30, 2021, forward sales agreements had no dilutive impact as no shares remained outstanding under ATM forward contracts during the period.

XML

Segment Disclosures (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Summary of Financial Information of Reportable Segments

The following tables summarize information for the reportable segments (in thousands):

For the three months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	207,771	$	179,308	$	125,360	$	5,493	$	—	$	517,932
Government grant income(1)	—		—		209		—		—		209
Less: Interest income	—		—		—		(5,493)		—		(5,493)
Healthpeak’s share of unconsolidated joint venture total revenues	1,267		761		—		18,215		—		20,243
Noncontrolling interests’ share of consolidated joint venture total revenues	(62)		(8,943)		—		—		—		(9,005)
Operating expenses	(49,446)		(63,321)		(102,277)		—		—		(215,044)
Healthpeak’s share of unconsolidated joint venture operating expenses	(483)		(301)		—		(14,150)		—		(14,934)
Noncontrolling interests’ share of consolidated joint venture operating expenses	19		2,726		—		—		—		2,745
Adjustments to NOI(2)	(21,644)		(2,949)		—		54		—		(24,539)
Adjusted NOI	137,422		107,281		23,292		4,119		—		272,114
Plus: Adjustments to NOI(2)	21,644		2,949		—		(54)		—		24,539
Interest income	—		—		—		5,493		—		5,493
Interest expense	—		(1,930)		(1,876)		—		(38,061)		(41,867)
Depreciation and amortization	(79,673)		(68,873)		(31,943)		—		—		(180,489)
General and administrative	—		—		—		—		(24,781)		(24,781)
Transaction costs	(35)		(70)		(64)		—		(443)		(612)
Impairments and loan loss reserves	—		—		—		(139)		—		(139)
Gain (loss) on sales of real estate, net	—		10,340		—		—		—		10,340
Other income (expense), net	29		1,264		630		18		920		2,861
Less: Government grant income	—		—		(209)		—		—		(209)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(784)		(460)		—		(4,065)		—		(5,309)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	43		6,217		—		—		—		6,260
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	78,646		56,718		(10,170)		5,372		(62,365)		68,201
Income tax benefit (expense)	—		—		—		—		718		718
Equity income (loss) from unconsolidated joint ventures	148		211		—		23		—		382
Income (loss) from continuing operations	78,794		56,929		(10,170)		5,395		(61,647)		69,301
Income (loss) from discontinued operations	—		—		—		—		2,992		2,992
Net income (loss)	$	78,794	$	56,929	$	(10,170)	$	5,395	$	(58,655)	$	72,293

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the three months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	177,527	$	165,295	$	117,308	$	16,108	$	—	$	476,238
Government grant income(1)	—		—		87		—		—		87
Less: Interest income	—		—		—		(16,108)		—		(16,108)
Healthpeak’s share of unconsolidated joint venture total revenues	1,412		710		2,415		16,740		—		21,277
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		—		583		—		583
Noncontrolling interests’ share of consolidated joint venture total revenues	(75)		(8,825)		—		—		—		(8,900)
Operating expenses	(40,724)		(54,648)		(94,760)		—		—		(190,132)
Healthpeak’s share of unconsolidated joint venture operating expenses	(428)		(317)		(2,208)		(12,451)		—		(15,404)
Noncontrolling interests’ share of consolidated joint venture operating expenses	21		2,552		—		—		—		2,573
Adjustments to NOI(2)	(12,366)		(2,003)		1,226		(27)		—		(13,170)
Adjusted NOI	125,367		102,764		24,068		4,845		—		257,044
Plus: Adjustments to NOI(2)	12,366		2,003		(1,226)		27		—		13,170
Interest income	—		—		—		16,108		—		16,108
Interest expense	(48)		(786)		(1,924)		—		(35,923)		(38,681)
Depreciation and amortization	(76,955)		(63,371)		(31,133)		—		—		(171,459)
General and administrative	—		—		—		—		(24,088)		(24,088)
Transaction costs	21		35		(657)		(18)		—		(619)
Impairments and loan loss reserves	—		—		—		(931)		—		(931)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(60,865)		(60,865)
Other income (expense), net	28		(175)		165		—		1,716		1,734
Less: Government grant income	—		—		(87)		—		—		(87)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(984)		(393)		(207)		(4,872)		—		(6,456)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	54		6,273		—		—		—		6,327
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	59,849		221,588		(11,001)		15,159		(119,160)		166,435
Income tax benefit (expense)	—		—		—		—		763		763
Equity income (loss) from unconsolidated joint ventures	111		137		639		(20)		—		867
Income (loss) from continuing operations	59,960		221,725		(10,362)		15,139		(118,397)		168,065
Income (loss) from discontinued operations	—		—		—		—		113,960		113,960
Net income (loss)	$	59,960	$	221,725	$	(10,362)	$	15,139	$	(4,437)	$	282,025

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the six months ended June 30, 2022:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	401,826	$	356,571	$	246,920	$	10,987	$	—	$	1,016,304
Government grant income(1)	—		—		6,762		—		—		6,762
Less: Interest income	—		—		—		(10,987)		—		(10,987)
Healthpeak’s share of unconsolidated joint venture total revenues	2,698		1,493		—		36,260		—		40,451
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		333		315		—		648
Noncontrolling interests’ share of consolidated joint venture total revenues	(119)		(17,763)		—		—		—		(17,882)
Operating expenses	(97,635)		(124,491)		(200,165)		—		—		(422,291)
Healthpeak’s share of unconsolidated joint venture operating expenses	(966)		(600)		—		(28,205)		—		(29,771)
Noncontrolling interests’ share of consolidated joint venture operating expenses	38		5,328		—		—		—		5,366
Adjustments to NOI(2)	(35,756)		(6,495)		—		45		—		(42,206)
Adjusted NOI	270,086		214,043		53,850		8,415		—		546,394
Plus: Adjustments to NOI(2)	35,756		6,495		—		(45)		—		42,206
Interest income	—		—		—		10,987		—		10,987
Interest expense	—		(2,966)		(3,741)		—		(72,746)		(79,453)
Depreciation and amortization	(157,811)		(136,646)		(63,765)		—		—		(358,222)
General and administrative	—		—		—		—		(48,612)		(48,612)
Transaction costs	(327)		(74)		(64)		—		(443)		(908)
Impairments and loan loss reserves	—		—		—		(271)		—		(271)
Gain (loss) on sales of real estate, net	3,856		10,340		—		—		—		14,196
Other income (expense), net	20		12,201		7,141		(13)		1,828		21,177
Less: Government grant income	—		—		(6,762)		—		—		(6,762)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,732)		(893)		(333)		(8,370)		—		(11,328)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	81		12,435		—		—		—		12,516
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	149,929		114,935		(13,674)		10,703		(119,973)		141,920
Income tax benefit (expense)	—		—		—		—		(59)		(59)
Equity income (loss) from unconsolidated joint ventures	1,114		411		539		402		—		2,466
Income (loss) from continuing operations	151,043		115,346		(13,135)		11,105		(120,032)		144,327
Income (loss) from discontinued operations	—		—		—		—		3,309		3,309
Net income (loss)	$	151,043	$	115,346	$	(13,135)	$	11,105	$	(116,723)	$	147,636

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

For the six months ended June 30, 2021:

	Life Science		Medical Office		CCRC		Other Non-reportable		Corporate Non-segment		Total
Total revenues	$	347,461	$	325,496	$	233,436	$	25,121	$	—	$	931,514
Government grant income(1)	—		—		1,397		—		—		1,397
Less: Interest income	—		—		—		(25,121)		—		(25,121)
Healthpeak’s share of unconsolidated joint venture total revenues	2,749		1,425		6,903		33,493		—		44,570
Healthpeak’s share of unconsolidated joint venture government grant income	—		—		199		810		—		1,009
Noncontrolling interests’ share of consolidated joint venture total revenues	(140)		(17,751)		—		—		—		(17,891)
Operating expenses	(80,185)		(105,769)		(185,939)		—		—		(371,893)
Healthpeak’s share of unconsolidated joint venture operating expenses	(853)		(611)		(6,953)		(25,046)		—		(33,463)
Noncontrolling interests’ share of consolidated joint venture operating expenses	41		5,056		—		—		—		5,097
Adjustments to NOI(2)	(24,176)		(3,926)		1,246		85		—		(26,771)
Adjusted NOI	244,897		203,920		50,289		9,342		—		508,448
Plus: Adjustments to NOI(2)	24,176		3,926		(1,246)		(85)		—		26,771
Interest income	—		—		—		25,121		—		25,121
Interest expense	(150)		(881)		(3,842)		—		(80,651)		(85,524)
Depreciation and amortization	(145,388)		(121,326)		(62,283)		—		—		(328,997)
General and administrative	—		—		—		—		(48,990)		(48,990)
Transaction costs	(11)		(295)		(1,090)		(21)		—		(1,417)
Impairments and loan loss reserves	—		—		—		(4,173)		—		(4,173)
Gain (loss) on sales of real estate, net	—		175,238		—		—		—		175,238
Gain (loss) on debt extinguishments	—		—		—		—		(225,157)		(225,157)
Other income (expense), net	33		(2,454)		2,341		482		3,532		3,934
Less: Government grant income	—		—		(1,397)		—		—		(1,397)
Less: Healthpeak’s share of unconsolidated joint venture NOI	(1,896)		(814)		(149)		(9,257)		—		(12,116)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI	99		12,695		—		—		—		12,794
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	121,760		270,009		(17,377)		21,409		(351,266)		44,535
Income tax benefit (expense)	—		—		—		—		755		755
Equity income (loss) from unconsolidated joint ventures	18		328		639		1,205		—		2,190
Income (loss) from continuing operations	121,778		270,337		(16,738)		22,614		(350,511)		47,480
Income (loss) from discontinued operations	—		—		—		—		383,968		383,968
Net income (loss)	$	121,778	$	270,337	$	(16,738)	$	22,614	$	33,457	$	431,448

______________________________________________________________________________

(1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2).

(2)Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures.

See Notes 3, 4, and 5 for significant transactions impacting the Company’s segment assets during the periods presented.

XML

Supplemental Cash Flow Information (Tables)

6 Months Ended

Jun. 30, 2022

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

	Six Months Ended June 30,
	2022		2021
Supplemental cash flow information:
Interest paid, net of capitalized interest	$	74,327	$	109,277
Income taxes paid (refunded)	(612)		4,026
Capitalized interest	16,320		10,867
Supplemental schedule of non-cash investing and financing activities:
Increase in ROU asset in exchange for new lease liability related to operating leases	508		13,157
Seller financing provided on disposition of real estate asset	—		559,745
Accrued construction costs	163,391		113,221
Vesting of restricted stock units and conversion of non-managing member units into common stock	803		900
Carrying value of mortgages assumed by buyer in real estate dispositions	—		106,632

The following table summarizes certain cash flow information related to assets classified as discontinued operations (in thousands):

	Six Months Ended June 30,
	2022		2021
Leasing costs, tenant improvements, and recurring capital expenditures	$	21	$	2,349
Development, redevelopment, and other major improvements of real estate	18		4,569
Depreciation and amortization of real estate, in-place lease, and other intangibles	—		—

Schedule of Cash, Cash Equivalents and Restricted Cash

The following table summarizes cash, cash equivalents and restricted cash (in thousands):

	Six Months Ended June 30,
	2022		2021		2022		2021		2022		2021
	Continuing operations				Discontinued operations				Total
Beginning of period:
Cash and cash equivalents	$	158,287	$	44,226	$	7,707	$	53,085	$	165,994	$	97,311
Restricted cash	53,454		67,206		—		17,168		53,454		84,374
Cash, cash equivalents and restricted cash	$	211,741	$	111,432	$	7,707	$	70,253	$	219,448	$	181,685
End of period:
Cash and cash equivalents	$	73,013	$	96,923	$	8,070	$	17,354	$	81,083	$	114,277
Restricted cash	54,815		129,052		—		974		54,815		130,026
Cash, cash equivalents and restricted cash	$	127,828	$	225,975	$	8,070	$	18,328	$	135,898	$	244,303

XML

Variable Interest Entities (Tables)

6 Months Ended

Jun. 30, 2022

Variable Interest Entities [Abstract]

Schedule of Variable Interest Entities

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company’s involvement with these VIEs at June 30, 2022 was as follows (in thousands):

VIE Type	Asset Type	Maximum Loss Exposure and Carrying Amount(1)
Continuing operations:
CMBS and LLC investment	Other assets, net	$	36,599
Needham Land Parcel JV	Investments in and advances to unconsolidated joint ventures	14,831

_______________________________________

(1)The Company’s maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).

Consolidated Assets and Liabilities of Variable Interest Entities

Total assets and total liabilities include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Buildings and improvements	$	2,331,975	$	2,303,920
Development costs and construction in progress	138,655		82,303
Land	510,096		548,168
Accumulated depreciation and amortization	(592,488)		(551,097)
Net real estate	2,388,238		2,383,294
Accounts receivable, net	3,933		5,455
Cash and cash equivalents	37,274		22,295
Restricted cash	211		114
Intangible assets, net	106,855		117,180
Assets held for sale and discontinued operations, net	216		754
Right-of-use asset, net	108,390		107,993
Other assets, net	66,610		62,886
Total assets	$	2,711,727	$	2,699,971
Liabilities
Mortgage debt	$	144,451	$	144,350
Intangible liabilities, net	27,410		23,909
Liabilities related to assets held for sale and discontinued operations, net	1,668		1,677
Lease liability	98,666		99,213
Accounts payable, accrued liabilities, and other liabilities	69,143		58,440
Deferred revenue	25,431		21,546
Total liabilities	$	366,769	$	349,135

Total assets and liabilities related to assets held for sale and discontinued operations include VIE assets and liabilities as follows (in thousands):

	June 30, 2022		December 31, 2021
Assets
Accounts receivable, net	$	—	$	62
Cash and cash equivalents	153		59
Other assets, net	63		633
Total assets	$	216	$	754
Liabilities
Accounts payable, accrued liabilities, and other liabilities	$	1,668	$	1,677
Total liabilities	$	1,668	$	1,677

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Summary of Carry Amounts and Fair Value of Financial Instruments

The table below summarizes the carrying amounts and fair values of the Company’s financial instruments (in thousands):

	June 30, 2022(3)				December 31, 2021(3)
	Carrying Value		Fair Value		Carrying Value		Fair Value
Loans receivable, net(2)	$	413,962	$	432,914	$	415,811	$	437,607
Marketable debt securities(2)	21,345		21,345		21,003		21,003
Interest rate swap instruments(2)	1,629		1,629		—		—
Interest rate cap instruments(2)	—		—		397		397
Bank line of credit and commercial paper(2)	1,448,569		1,448,569		1,165,975		1,165,975
Senior unsecured notes(1)	4,655,852		4,360,241		4,651,933		5,054,747
Mortgage debt(2)	349,329		339,356		352,081		352,800

_______________________________________

(1)Level 1: Fair value calculated based on quoted prices in active markets.

(2)Level 2: Fair value based on (i) for marketable debt securities, quoted prices for similar or identical instruments in active or inactive markets, respectively, or (ii) for loans receivable, net, mortgage debt, interest rate swap instruments, and interest rate cap instruments, standardized pricing models in which significant inputs or value drivers are observable in active markets. For bank line of credit and commercial paper, the carrying values are a reasonable estimate of fair value because the borrowings are primarily based on market interest rates and the Company’s credit rating.

(3)During the six months ended June 30, 2022 and year ended December 31, 2021, there were no material transfers of financial assets or liabilities within the fair value hierarchy.

XML

Derivative Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments

The following table summarizes the Company’s interest rate swap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Pay Rate	Receive Rate	June 30, 2022		December 31, 2021
April 2022(2)	May 2026	Cash flow	$	51,100	5.08 %	1 mo. USD-LIBOR-BBA + 2.50%	$	586	$	—
April 2022(2)	May 2026	Cash flow	91,000		4.63 %	1 mo. USD-LIBOR-BBA + 2.05%	1,043		—

_____________________________

(1)At June 30, 2022, the interest rate swap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents interest rate swap instruments that hedge fluctuations in interest payments on variable rate secured debt by converting the interest rates to fixed interest rates. The changes in fair value of designated derivatives that qualify as cash flow hedges are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets.

The following table summarizes the Company’s interest rate cap instruments as of June 30, 2022 (in thousands):

							Fair Value(1)
Date Entered	Maturity Date	Hedge Designation	Notional Amount		Strike Rate	Index	June 30, 2022		December 31, 2021
April 2021(2)	May 2024	Non-designated	$	142,100	2.00 %	1 mo. USD-LIBOR-BBA	$	—	$	397

_____________________________

(1)At December 31, 2021, the interest rate cap instruments were in an asset position. Derivative assets are recorded in other assets, net on the Consolidated Balance Sheets.

(2)Represents two interest rate cap instruments that manage the Company’s exposure to variable cash flows on certain mortgage debt borrowings by limiting interest rates. These interest rate cap instruments were terminated in April 2022.

XML

Accounts Payable, Accrued Liabilities, and Other Liabilities (Tables)

6 Months Ended

Jun. 30, 2022

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

The following table summarizes the Company’s accounts payable, accrued liabilities, and other liabilities, excluding accounts payable, accrued liabilities, and other liabilities related to assets classified as discontinued operations (in thousands):

	June 30, 2022		December 31, 2021
Refundable entrance fees(1)	$	275,152	$	288,409
Accrued construction costs	163,391		179,995
Accrued interest	59,092		59,342
Other accounts payable and accrued liabilities	209,184		227,638
Accounts payable, accrued liabilities, and other liabilities	$	706,819	$	755,384

_______________________________________

(1)At June 30, 2022 and December 31, 2021, unamortized nonrefundable entrance fee liabilities were $508 million and $496 million, respectively, which are recorded within deferred revenue on the Consolidated Balance Sheets. During the three and six months ended June 30, 2022, the Company collected nonrefundable entrance fees of $29 million and $50 million, respectively, and recognized amortization of $19 million and $38 million, respectively. During the three and six months ended June 30, 2021, the Company collected nonrefundable entrance fees of $24 million and $38 million, respectively, and recognized amortization of $18 million and $38 million, respectively. The amortization of nonrefundable entrance fees is included within resident fees and services on the Consolidated Statements of Operations.

XML

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment	$ (6,840,388)	$ (6,947,722)	$ (7,058,760)	$ (7,351,410)	$ (7,241,139)	$ (7,289,950)
Redeemable noncontrolling interests	115,877		87,344
Accounts payable, accrued liabilities, and other liabilities	$ (706,819)		$ (755,384)
Revision of Prior Period, Error Correction, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment				82,319
Redeemable noncontrolling interests				85,367
Accounts payable, accrued liabilities, and other liabilities				$ 3,048

XML

Summary of Significant Accounting Policies - Government Grant Income (Details) - Government Assistance, CARES Act - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Unusual or Infrequent Item, or Both [Line Items]
Government grant income received	$ 209	$ 1,099	$ 7,616	$ 6,067
Government grant income recorded in other income (expense), net
Unusual or Infrequent Item, or Both [Line Items]
Government grant income received	209	87	6,762	1,397
Government grant income recorded in equity income (loss) from unconsolidated joint ventures
Unusual or Infrequent Item, or Both [Line Items]
Government grant income received	0	584	648	1,010
Government grant income recorded in income (loss) from discontinued operations
Unusual or Infrequent Item, or Both [Line Items]
Government grant income received	$ 0	$ 428	$ 206	$ 3,660

XML

Real Estate Transactions - Real Estate Investments (Details) $ in Millions	1 Months Ended			3 Months Ended		12 Months Ended
	May 31, 2022 USD ($) property	Mar. 31, 2022 USD ($) property	Jan. 31, 2022 USD ($)	Jun. 30, 2022 property	Mar. 31, 2022 property	Dec. 31, 2021 USD ($) a property	Apr. 30, 2021 USD ($)
MASSACHUSETTS
Real Estate [Line Items]
Payments to acquire real estate						$ 498
Number of properties acquired | property						8
CALIFORNIA
Real Estate [Line Items]
Area of land (in acres) | a						12
Payments to acquire land						$ 128
Life Science | MASSACHUSETTS
Real Estate [Line Items]
Payments to acquire real estate			$ 72
Life Science | CALIFORNIA
Real Estate [Line Items]
Payments to acquire real estate			$ 24			$ 20
Number of properties acquired | property						1
Medical Office Buildings
Real Estate [Line Items]
Number of properties acquired | property				1	2	2
Medical Office Buildings | Mortgage Debt
Real Estate [Line Items]
Debt instrument, face amount						$ 142	$ 142
Medical Office Buildings | MASSACHUSETTS
Real Estate [Line Items]
Payments to acquire real estate						$ 55
Number of properties acquired | property						1
Medical Office Buildings | TEXAS
Real Estate [Line Items]
Payments to acquire real estate		$ 43				$ 60
Number of properties acquired | property		2				2
Medical Office Buildings | ARKANSAS
Real Estate [Line Items]
Payments to acquire real estate	$ 26
Number of properties acquired | property	1
Medical Office Buildings | TENNESSEE
Real Estate [Line Items]
Payments to acquire real estate						$ 13
Number of properties acquired | property						1
Medical Office Buildings | COLORADO
Real Estate [Line Items]
Payments to acquire real estate						$ 38
Number of properties acquired | property						1
Medical Office Buildings | UNITED STATES
Real Estate [Line Items]
Payments to acquire real estate						$ 371
Number of properties acquired | property						14
Medical Office Buildings | FLORIDA
Real Estate [Line Items]
Payments to acquire real estate						$ 16
Number of properties acquired | property						1
Medical Office Buildings | KANSAS
Real Estate [Line Items]
Payments to acquire real estate						$ 50
Number of properties acquired | property						1
Medical Office Buildings | NEW JERSEY
Real Estate [Line Items]
Payments to acquire real estate						$ 155
Number of properties acquired | property						3
Medical Office Buildings | WASHINGTON
Real Estate [Line Items]
Payments to acquire real estate						$ 43
Number of properties acquired | property						1
Medical Office Buildings | LOUISIANA
Real Estate [Line Items]
Payments to acquire real estate						$ 34
Number of properties acquired | property						1

XML

Real Estate Transactions - Development Activities (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Real Estate [Abstract]
Development and redevelopment projects, amount decrease	$ 16
Development commitments	$ 454

XML

Dispositions of Real Estate and Discontinued Operations - Narrative (Details)	1 Months Ended									3 Months Ended				6 Months Ended			12 Months Ended	18 Months Ended
	Jul. 31, 2022 USD ($) property	Feb. 28, 2022 USD ($)	Jan. 31, 2022 USD ($) property	Jun. 30, 2021 USD ($) property	May 31, 2021 USD ($) property	Apr. 30, 2021 USD ($) property	Mar. 31, 2021 USD ($) property	Feb. 28, 2021 USD ($) property	Jan. 31, 2021 USD ($) property	Jun. 30, 2022 USD ($) property	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($) property	Mar. 31, 2021 USD ($) property	Jun. 30, 2022 USD ($) loan	Dec. 31, 2021 loan	Jun. 30, 2021 USD ($) property	Dec. 31, 2021 loan	Jun. 30, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sales of real estate, net										$ 10,340,000		$ 175,238,000		$ 14,196,000		$ 175,238,000
Carrying value of mortgages assumed by buyer in real estate dispositions														$ 0		106,632,000
Number of loans sold | loan														1	2		6
Impairment of real estate										$ 0				$ 0
Goodwill, impairment loss												0				0
Planned MOB Demolition, Tenant Relocation and Other Costs
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Expense on other											$ 14,000,000
Mortgage Debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of assets classified as discontinued operations | property					6	2	2						2
Repayments of secured debt						$ 64,000,000	$ 39,000,000
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sales of real estate, net												7,000,000				32,000,000
Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations, Abandonment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (loss) on sales of real estate, net												10,000,000				48,000,000
Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill, impairment loss												7,000,000				7,000,000
Sunrise Senior Housing Portfolio | SHOP
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditure funding, amount committed		$ 47,000,000		$ 56,000,000					$ 92,000,000
Capital expenditure funding, amount funded																		$ 400,000
Sunrise Senior Housing Portfolio | SHOP | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditure funding, amount committed	$ 40,000,000
Oakmont SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Carrying value of mortgages assumed by buyer in real estate dispositions						$ 107,000,000
Oakmont SHOP Portfolio | Mortgage Debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties disposed | property						4
Other Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Carrying value of mortgages assumed by buyer in real estate dispositions																$ 36,000,000
Other Dispositions | Mortgage Debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties disposed | property																1
SHOP
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings									230,000,000
Gain (loss) on sales of real estate, net									59,000,000				$ 16,000,000
Payments to acquire finance receivables									150,000,000
SHOP | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property													1
Proceeds from sale of buildings													$ 5,000,000
SHOP | Oakmont SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings						$ 564,000,000
Gain (loss) on sales of real estate, net						80,000,000
SHOP | Discovery SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings						334,000,000
Gain (loss) on sales of real estate, net						9,000,000
Proceeds from sale of loans and preferred equity method investments						21,000,000
SHOP | Sonata SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings						64,000,000
Gain (loss) on sales of real estate, net						$ 3,000,000
SHOP | Other Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings												44,000,000				$ 120,000,000
Senior Housing Triple Net
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings												$ 12,000,000				$ 12,000,000
Senior Housing Triple Net | Brookdale Triple Net Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings									510,000,000
Gain (loss) on sales of real estate, net									$ 169,000,000
Senior Housing Triple Net | HRA Triple Net Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings								$ 132,000,000
Gain (loss) on sales of real estate, net								$ 33,000,000
Life Science
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property			1
Proceeds from sale of buildings			$ 14,000,000
Gain (loss) on sales of real estate, net			$ 4,000,000
Medical Office Buildings
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property										3		4				6
Proceeds from sale of buildings										$ 27,000,000		$ 21,000,000				$ 47,000,000
Gain (loss) on sales of real estate, net										$ 10,000,000
Medical Office Buildings | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property	2
Proceeds from sale of buildings	$ 9,000,000
MOB Land Parcels
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property										1						1
SHOP
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property									16			6				8
Impairment of real estate												$ 4,000,000				$ 4,000,000
Number of real estate properties impaired | property												1				1
Real estate investment property, aggregate carrying value before impairment				20,000,000								$ 20,000,000				$ 20,000,000
Real estate held-for-sale				16,000,000								$ 16,000,000				$ 16,000,000
SHOP | Sunrise Senior Housing Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property									32
Proceeds from sale of buildings									$ 664,000,000
Gain (loss) on sales of real estate, net				$ 7,000,000
Payments to acquire finance receivables									$ 410,000,000
SHOP | Oakmont SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property						12
SHOP | Discovery SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property						10
Gain (loss) on sales of real estate, net						$ 0
Number of preferred equity method investments sold | property						2
SHOP | Discovery SHOP Portfolio | Mezzanine and Other
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of loans sold | property						2
SHOP | Sonata SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property						5
SHOP | SLC SHOP Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property					7
Repayments of secured debt					$ 70,000,000
SHOP | SLC SHOP Portfolio | Definitive Agreement Four
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of buildings					113,000,000
Gain (loss) on sales of real estate, net					$ 1,000,000
Senior Housing Triple Net
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property												3				4
Senior Housing Triple Net | Sunrise Senior Housing Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property				2
Proceeds from sale of buildings				$ 80,000,000
Gain (loss) on sales of real estate, net				$ 22,000,000
Senior Housing Triple Net | Brookdale Triple Net Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property									24
Senior Housing Triple Net | HRA Triple Net Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property								8
Medical Office, Hospital
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of properties sold | property					1
Proceeds from sale of buildings					$ 226,000,000
Gain (loss) on sales of real estate, net					$ 172,000,000

XML

Dispositions of Real Estate and Discontinued Operations - Assets and Liabilities for Discontinued Operations (Details) $ in Thousands	Jun. 30, 2022 USD ($) property	Dec. 31, 2021 USD ($) property	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
ASSETS
Cash and cash equivalents	$ 8,070	$ 7,707	$ 17,354	$ 53,085
Total assets of discontinued operations, net	66,647	37,190
LIABILITIES
Total liabilities of discontinued operations, net	15,869	15,056
Allowance for doubtful accounts receivable	990	4,138
Held-for-sale
ASSETS
Accounts receivable, net of allowance of $990 and $4,138	761	2,446
Cash and cash equivalents	8,070	7,707
Right-of-use asset, net	19	26
Other assets, net	1,400	3,237
Total assets of discontinued operations, net	10,250	13,416
Assets held for sale, net	56,397	23,774
Assets held for sale and discontinued operations, net	66,647	37,190
LIABILITIES
Lease liability	19	26
Accounts payable, accrued liabilities, and other liabilities	11,479	14,843
Deferred revenue	102	92
Total liabilities of discontinued operations, net	11,600	14,961
Liabilities related to assets held for sale, net	4,269	95
Liabilities related to assets held for sale and discontinued operations, net	$ 15,869	15,056
Net real estate assets		$ 23,000
Held-for-sale | Life Science
LIABILITIES
Number of properties classified as held for sale | property	2	1
Held-for-sale | Medical Office Buildings
LIABILITIES
Number of properties classified as held for sale | property	2	4
Held-for-sale | Life Science and Medical Office
LIABILITIES
Net real estate assets	$ 51,000

XML

Dispositions of Real Estate and Discontinued Operations - Schedule of Results of Discontinued Operations (Details) - Held-for-sale - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Rental and related revenues	$ 0	$ 1,613	$ 0	$ 6,841
Resident fees and services	2,825	30,273	5,480	103,270
Total revenues	2,825	31,886	5,480	110,111
Interest expense	0	1,177	0	3,853
Operating	2,442	33,647	5,116	105,165
Transaction costs	0	0	0	76
Impairments and loan loss reserves (recoveries), net	0	10,995	0	10,995
Total costs and expenses	2,442	45,819	5,116	120,089
Gain (loss) on sales of real estate, net	2,563	122,238	2,492	381,900
Other income (expense), net	16	128	19	6,012
Total other income (expense), net	2,579	122,366	2,511	387,912
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures	2,962	108,433	2,875	377,934
Income tax benefit (expense)	30	302	370	1,124
Equity income (loss) from unconsolidated joint ventures	0	5,225	64	4,910
Income (loss) from discontinued operations	$ 2,992	$ 113,960	$ 3,309	$ 383,968

XML

Leases - Lease Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Interest and Other Income [Abstract]
Fixed income from operating leases	$ 296,729	$ 268,290	$ 584,020	$ 531,246
Variable income from operating leases	90,350	72,352	173,209	137,368
Interest income from direct financing leases	$ 0	$ 2,180	$ 1,168	$ 4,343

XML

Leases - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Leases [Abstract]
Proceeds from sale of lease receivable	$ 68
Gain on sale of direct financing lease	$ 23

XML

Leases - Direct Financing Leases (Details) $ in Thousands	Jun. 30, 2022 USD ($) property	Dec. 31, 2021 USD ($) property
Leases [Abstract]
Present value of minimum lease payments receivable	$ 0	$ 1,220
Present value of estimated residual value	0	44,706
Less deferred selling profits	0	(1,220)
Net investment in direct financing leases	$ 0	$ 44,706
Number of properties classified as DFL | property	0	1

XML

Loans Receivable - Schedule of Loans Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing Receivable, Allowance for Credit Loss [Line Items]
Unamortized discounts, fees, and costs	$ (2,568)	$ (4,186)
Reserve for loan losses	(2,015)	(1,813)	$ (10,280)
Loans receivable, net	413,962	415,811
Remaining loans receivable commitments	48,000	58,000
Secured mortgage loans
Financing Receivable, Allowance for Credit Loss [Line Items]
Financing receivable, gross	387,447	396,281
Mezzanine and other
Financing Receivable, Allowance for Credit Loss [Line Items]
Financing receivable, gross	$ 31,098	$ 25,529

XML

Loans Receivable - Narrative (Details)	1 Months Ended									3 Months Ended				6 Months Ended			12 Months Ended	18 Months Ended
	Jul. 31, 2022 USD ($)	May 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jul. 31, 2021 USD ($)	Jun. 30, 2021 USD ($) loan	May 31, 2021 USD ($) loan	Apr. 30, 2021 USD ($) loan property	Jan. 31, 2021 USD ($) facility	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($) loan	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($) loan	Dec. 31, 2021 USD ($) loan	Jun. 30, 2021 USD ($) loan	Dec. 31, 2021 USD ($) loan	Jun. 30, 2022 USD ($)	Dec. 31, 2020 USD ($)
Loans Receivable:
Net cash provided by financing activities														$ (72,082,000)		$ (2,009,272,000)
Gain (loss) on sales of real estate, net										$ 10,340,000		$ 175,238,000		14,196,000		175,238,000
Financing receivable, after allowance for credit loss										413,962,000				413,962,000	$ 415,811,000		$ 415,811,000	$ 413,962,000
Reserves for loans receivable										2,015,000				$ 2,015,000	$ 1,813,000		$ 1,813,000	2,015,000	$ 10,280,000
Gain (loss) on sale of financing receivable											$ 23,000,000
Number of loans sold | loan														1	2		6
Proceeds from sale of receivables															$ 53,000,000
Credit loss reserve on unfunded loan commitments										400,000				$ 400,000	300,000		$ 300,000	400,000
Sunrise Senior Housing Portfolio | SHOP
Loans Receivable:
Net cash provided by financing activities									$ 410,000,000
Capital expenditure funding, amount committed			$ 47,000,000			$ 56,000,000			$ 92,000,000
Capital expenditure funding, cost of capital, percent committed									65.00%
Capital expenditure funding, amount funded																		400,000
Sunrise Senior Housing Portfolio | SHOP | Subsequent Event
Loans Receivable:
Capital expenditure funding, amount committed	$ 40,000,000
Secured mortgage loans
Loans Receivable:
Financing receivable, gross										387,447,000				387,447,000	396,281,000		396,281,000	387,447,000
Mezzanine and Other
Loans Receivable:
Reserves for loans receivable										6,000				6,000	9,000		9,000	6,000	$ 7,128,000
SHOP
Loans Receivable:
Number of assets to be sold | facility									16
SHOP | Sunrise Senior Housing Portfolio
Loans Receivable:
Number of assets to be sold | facility									32
Proceeds from sale of property									$ 664,000,000
Proceeds from the collection of loans receivable			$ 8,000,000			246,000,000
Gain (loss) on sales of real estate, net						7,000,000
Financing receivable, after allowance for credit loss										157,000,000				157,000,000	165,000,000		165,000,000	157,000,000
SHOP | Sunrise Senior Housing Portfolio | Subsequent Event
Loans Receivable:
Proceeds from the collection of loans receivable	27,000,000
Capital expenditure funding, decrease in amount	$ 7,000,000
SHOP | Discovery SHOP Portfolio
Loans Receivable:
Gain (loss) on sales of real estate, net								$ 0
SHOP | Mezzanine and Other | Discovery SHOP Portfolio
Loans Receivable:
Number of loans held for sale | loan								2
Gain (loss) on sale of financing receivable								$ 0
Number of loans sold | property								2
Secured mortgage loans
Loans Receivable:
Financing receivable, after allowance for credit loss						$ 53,000,000						$ 53,000,000				$ 53,000,000
Principal repayments received		$ 2,000,000		$ 15,000,000	$ 8,000,000		$ 10,000,000
Number of loans held for sale | loan						2						2				2
Financing receivable, gross						$ 64,000,000						$ 64,000,000				$ 64,000,000
Decrease in financing receivable												11,000,000
Reserves for loans receivable						$ 8,000,000						8,000,000				8,000,000
Gain (loss) on sale of financing receivable												(3,000,000)				(3,000,000)
Number of loans receivable | loan							1
SHOP
Loans Receivable:
Proceeds from sale of property									230,000,000
Net cash provided by financing activities									150,000,000
Gain (loss) on sales of real estate, net									$ 59,000,000				$ 16,000,000
Loans receivable, market rate													5.25%
Non-cash interest income										1,000,000		9,000,000		2,000,000		10,000,000
Noncash interest income, acceleration recognition												$ 7,000,000				$ 7,000,000
SHOP | Minimum
Loans Receivable:
Loans receivable, stated interest rate													3.50%
Interest income, amortization period (in years)													1 year
SHOP | Maximum
Loans Receivable:
Loans receivable, stated interest rate													4.50%
Interest income, amortization period (in years)													3 years
SHOP | Discovery SHOP Portfolio
Loans Receivable:
Proceeds from sale of property								$ 334,000,000
Gain (loss) on sales of real estate, net								$ 9,000,000
CCRC JV | Brookedale MTCA | Other Non-Reporting Segment | Lessor Asset Under Operating Lease
Loans Receivable:
Financing receivable, after allowance for credit loss										$ 30,000,000				$ 30,000,000	$ 24,000,000		$ 24,000,000	$ 30,000,000

XML

Loans Receivable - Schedule of Loans Receivable by Origination Year (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Secured Mortgage Loans
Loans receivable
2022	$ 0
2021	302,665
2020	80,205
2019	0
2018	0
Prior	0
Total	382,870
Mezzanine and other
Loans receivable
2022	23,239
2021	6,635
2020	1,218
2019	0
2018	0
Prior	0
Total	31,092
Performing loans | Secured Mortgage Loans
Loans receivable
2022	0
2021	302,665
2020	80,205
2019	0
2018	0
Prior	0
Total	382,870
Performing loans | Mezzanine and other
Loans receivable
2022	23,239
2021	6,635
2020	1,218
2019	0
2018	0
Prior	0
Total	31,092
Watch list loans | Secured Mortgage Loans
Loans receivable
2022	0
2021	0
2020	0
2019	0
2018	0
Prior	0
Total	0
Watch list loans | Mezzanine and other
Loans receivable
2022	0
2021	0
2020	0
2019	0
2018	0
Prior	0
Total	0
Workout loans | Secured Mortgage Loans
Loans receivable
2022	0
2021	0
2020	0
2019	0
2018	0
Prior	0
Total	0
Workout loans | Mezzanine and other
Loans receivable
2022	0
2021	0
2020	0
2019	0
2018	0
Prior	0
Total	$ 0

XML

Loans Receivable - Schedule of Reserve for Loan Losses (Details) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($) loan	Dec. 31, 2021 USD ($) loan	Dec. 31, 2021 USD ($) loan
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Reserve for loan losses, beginning of period	$ 1,813		$ 10,280
Provision for expected loan losses	253		1,689
Expected loan losses related to loans sold and repaid	(51)		(10,156)
Reserve for loan losses, end of period	$ 2,015	$ 1,813	$ 1,813
Number of loans sold | loan	1	2	6
Secured Loans
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Reserve for loan losses, beginning of period	$ 1,804		$ 3,152
Provision for expected loan losses	256		793
Expected loan losses related to loans sold and repaid	(51)		(2,141)
Reserve for loan losses, end of period	2,009	$ 1,804	1,804
Mezzanine and Other
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Reserve for loan losses, beginning of period	9		7,128
Provision for expected loan losses	(3)		896
Expected loan losses related to loans sold and repaid	0		(8,015)
Reserve for loan losses, end of period	$ 6	$ 9	$ 9

XML

Investments in and Advances to Unconsolidated Joint Ventures (Details) $ in Thousands	1 Months Ended						3 Months Ended		6 Months Ended
	Aug. 31, 2022 USD ($) property	Jul. 31, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 31, 2021 USD ($) property	Jan. 31, 2021 facility	Jun. 30, 2022 USD ($) property joint_venture	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Apr. 30, 2021 property	Mar. 31, 2021 joint_venture
Schedule of Equity Method Investments [Line Items]
Investments in and advances to unconsolidated joint ventures				$ 403,634			$ 402,154
Discovery Naples JV
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage											41.00%
Discovery Sarasota JV
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage											47.00%
Medical Office JVs
Schedule of Equity Method Investments [Line Items]
Number of unconsolidated joint ventures (in joint ventures) | joint_venture							2
HCP Ventures IV, LLC
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage							20.00%
Suburban Properties, LLC
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage							67.00%
HCP Ventures III, LLC
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage				30.00%
Discovery Naples JV and Discovery Sarasota JV
Schedule of Equity Method Investments [Line Items]
Number of unconsolidated joint ventures (in joint ventures) | joint_venture											2
CCRC JV
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage					49.00%
Proceeds from sale of property					$ 19,000
Brookedale MTCA | CCRC JV
Schedule of Equity Method Investments [Line Items]
Number of assets to be sold | property					2
Proceeds from sale of property					$ 38,000
Other Non-Reporting Segment | SWF SH JV
Schedule of Equity Method Investments [Line Items]
Property count | property							19
Investment ownership percentage							54.00%
Equity method investments				$ 355,394			$ 351,686
Life Science
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of property			$ 14,000
Life Science | Life Science JV
Schedule of Equity Method Investments [Line Items]
Property count | property							1
Investment ownership percentage							49.00%
Equity method investments				$ 25,605			$ 26,719
Life Science | Needham Land Parcel JV
Schedule of Equity Method Investments [Line Items]
Property count | property							0
Investment ownership percentage				38.00%			38.00%
Equity method investments				$ 13,566			$ 14,831
Payments to acquire equity method investment				13,000
Life Science | Life Science JV in San Francisco, California | Subsequent Event
Schedule of Equity Method Investments [Line Items]
Property count | property	7
Investment ownership percentage	70.00%
Life Science | Life Science JV in San Francisco, California | Life Science JV in San Francisco, California | Subsequent Event
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage	30.00%
Cash proceeds	$ 126,000
Medical Office
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of property							$ 27,000	$ 21,000	$ 47,000
Medical Office | Subsequent Event
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of property		$ 9,000
Medical Office | Medical Office JVs
Schedule of Equity Method Investments [Line Items]
Property count | property							3
Equity method investments				$ 9,069			$ 8,918
Medical Office | Medical Office JVs | Minimum
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage							20.00%
Medical Office | Medical Office JVs | Maximum
Schedule of Equity Method Investments [Line Items]
Investment ownership percentage							67.00%
SHOP
Schedule of Equity Method Investments [Line Items]
Number of assets to be sold | facility						16
SHOP | Discovery SHOP Portfolio
Schedule of Equity Method Investments [Line Items]
Number of preferred equity method investments sold | property										2

XML

Intangibles - Intangibles Lease Assets (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Intangibles [Abstract]
Gross intangible lease assets	$ 802,180,000	$ 797,675,000
Accumulated depreciation and amortization	(331,315,000)	(277,915,000)
Intangible assets, net	$ 470,865,000	$ 519,760,000
Weighted average remaining amortization period in years	6 years	6 years
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 470,865,000	$ 519,760,000
Discontinued Operations, Held-for-sale or Disposed of by Sale
Intangibles [Abstract]
Intangible assets, net	2,000,000	0
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 2,000,000	$ 0

XML

Intangibles - Intangibles Lease Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Intangibles [Abstract]
Gross intangible lease liabilities	$ 240,733	$ 234,917
Accumulated depreciation and amortization	(71,111)	(57,685)
Intangible liabilities, net	$ 169,622	$ 177,232
Weighted average remaining amortization period in years	8 years	8 years

XML

Intangibles - Narrative (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Weighted average remaining amortization period in years	6 years	6 years
Weighted average remaining amortization period, liabilities	8 years	8 years
Other Property
Finite-Lived Intangible Assets [Line Items]
Intangible assets acquired	$ 7	$ 109
Intangible liabilities acquired	$ 6	$ 57
Weighted average remaining amortization period in years	7 years	9 years
Weighted average remaining amortization period, liabilities	11 years	9 years

XML

Debt - Bank Line of Credit and Term Loans (Details)		1 Months Ended		6 Months Ended
	May 23, 2019 USD ($) renewal_option	Sep. 30, 2021 USD ($) renewal_option	Jul. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	May 31, 2019 USD ($)
Debt Instrument
Balance outstanding				$ 1,448,569,000	$ 1,165,975,000
Line of Credit and Term Loan
Debt Instrument
Debt instrument, covenant debt to assets (as a percent)		60.00%
Debt instrument, covenant secured debt to assets (as a percent)		40.00%
Debt instrument, covenant unsecured debt to unencumbered assets (as a percent)		60.00%
Debt instrument, covenant minimum fixed charge coverage ratio		1.5
Debt instrument, covenant net worth		$ 7,700,000,000
Bank Line of Credit | Revolving Credit Facility
Debt Instrument
Line of credit facility, maximum borrowing capacity	$ 2,500,000,000	$ 3,000,000,000
Number of extensions | renewal_option	2	2
Length of debt instrument extension period (in months)	6 months	6 months
Debt instrument, facility fee (as a percent)				0.15%
Balance outstanding				$ 0	$ 0
Line of credit facility additional aggregate amount, maximum		$ 750,000,000
Debt Instrument, interest rate, reduction available for sustainability metrics		0.00025
Bank Line of Credit | Revolving Credit Facility | LIBOR
Debt Instrument
Debt instrument, basis spread on variable rate (as a percent)				0.78%
Bank Line of Credit | 2019 Term Loan
Debt Instrument
Amount						$ 250,000,000
Repayment of 2019 term loan			$ 250,000,000

XML

Debt - Commercial Paper Program (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Jul. 31, 2022
Debt Instrument
Debt instrument, term (in months)	45 days	2 months
Weighted-average interest rate (as a percent)	1.95%	0.32%
Commercial Paper Program
Debt Instrument
Maximum outstanding amount capacity	$ 1,500,000,000	$ 1,500,000,000
Borrowings	$ 1,450,000,000	$ 1,170,000,000
Commercial Paper Program | Subsequent Event
Debt Instrument
Maximum outstanding amount capacity			$ 2,000,000,000

XML

Debt - Senior Unsecured Notes (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) bond	Nov. 24, 2021 USD ($)	Jul. 12, 2021 USD ($)	May 19, 2021 USD ($)	Feb. 26, 2021 USD ($)	Jan. 28, 2021 USD ($)
Debt Instrument
Principal balance on debt	$ 6,496,321,000		$ 6,496,321,000
Loss on extinguishment of debt	0	$ 60,865,000	0	$ 225,157,000
Number of bond offerings | bond					2
Senior Unsecured Note
Debt Instrument
Principal balance on debt	$ 4,700,000,000		$ 4,700,000,000		$ 4,700,000,000
Senior Unsecured Note | Unsecured Note 3.400 Percent
Debt Instrument
Amount								$ 251,806,000
Coupon Rate								3.40%
Senior Unsecured Note | Unsecured Note 4.000 Percent
Debt Instrument
Amount								$ 298,194,000
Coupon Rate								4.00%
Senior Unsecured Note | Unsecured Note 4.250 Percent
Debt Instrument
Amount									$ 188,000,000	$ 112,000,000
Coupon Rate									4.25%	4.25%
Senior Unsecured Note | Unsecured Note 4.200 Percent
Debt Instrument
Amount									$ 149,000,000	$ 201,000,000
Coupon Rate									4.20%	4.20%
Senior Unsecured Note | Unsecured Note 3.880 Percent
Debt Instrument
Amount									$ 331,000,000	$ 469,000,000
Coupon Rate									3.88%	3.88%
Senior Unsecured Note | Senior Notes Due 2025
Debt Instrument
Loss on extinguishment of debt		$ 61,000,000		61,000,000
Senior Unsecured Note | Senior Notes Due 2023 and 2024
Debt Instrument
Loss on extinguishment of debt				$ 164,000,000
Senior Unsecured Note | Unsecured Note 2.13 Percent
Debt Instrument
Amount						$ 500,000,000
Coupon Rate						2.13%
Senior Unsecured Note | Unsecured Note 1.35 Percent
Debt Instrument
Amount							$ 450,000,000
Coupon Rate							1.35%

XML

Debt - Mortgage Debt (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) facility	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) facility	Jun. 30, 2021 USD ($)	Apr. 30, 2022 derivativeHeld	Dec. 31, 2021 USD ($) derivativeHeld facility	Apr. 30, 2021 USD ($)
Debt Instrument
Principal balance on debt	$ 6,496,321		$ 6,496,321
Interest rate swap instruments
Debt Instrument
Number of interest-rate contracts held | derivativeHeld						0
Interest rate swap instruments | Cash Flow Hedging | Designated as Hedging Instrument
Debt Instrument
Number of interest-rate contracts held | derivativeHeld					2
Medical Office Buildings | Mortgage Debt
Debt Instrument
Amount						$ 142,000	$ 142,000
Mortgage Debt
Debt Instrument
Principal balance on debt	$ 347,752		$ 347,752			$ 350,000
Number of healthcare facilities used to secure debt (in facilities) | facility	18		18			18
Debt instrument, collateral, healthcare facilities carrying value	$ 799,000		$ 799,000			$ 811,000
Debt instrument, periodic payment	$ 1,000	$ 1,000	$ 3,000	$ 3,000

XML

Debt - Debt Maturities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument
2022	$ 2,541
2023	90,089
2024	7,024
2025	803,209
2026	2,343,092
Thereafter	3,250,366
Total debt before discount, net	6,496,321
(Discounts), premium and debt costs, net	(42,571)
Long-term debt	$ 6,453,750
Weighted-average interest rate (as a percent)	1.95%	0.32%
Bank Line of Credit
Debt Instrument
2022	$ 0
2023	0
2024	0
2025	0
2026	0
Thereafter	0
Total debt before discount, net	0
(Discounts), premium and debt costs, net	0
Long-term debt	0
Commercial Paper
Debt Instrument
2022	0
2023	0
2024	0
2025	0
2026	1,448,569
Thereafter	0
Total debt before discount, net	1,448,569
(Discounts), premium and debt costs, net	0
Long-term debt	1,448,569
Senior Unsecured Note
Debt Instrument
2022	0
2023	0
2024	0
2025	800,000
2026	650,000
Thereafter	3,250,000
Total debt before discount, net	4,700,000	$ 4,700,000
(Discounts), premium and debt costs, net	(44,148)
Long-term debt	$ 4,655,852
Weighted-average interest rate (as a percent)	3.39%
Weighted-average maturity (in years)	7 years
Senior Unsecured Note | Interest Rate 2022
Debt Instrument
Interest Rate	0.00%
Senior Unsecured Note | Interest Rate 2023
Debt Instrument
Interest Rate	0.00%
Senior Unsecured Note | Interest Rate 2024
Debt Instrument
Interest Rate	0.00%
Senior Unsecured Note | Interest Rate 2025
Debt Instrument
Interest Rate	3.93%
Senior Unsecured Note | Interest Rate 2026
Debt Instrument
Interest Rate	3.39%
Senior Unsecured Note | Interest Rate Thereafter
Debt Instrument
Interest Rate	3.24%
Senior Unsecured Note | Minimum
Debt Instrument
Interest Rate	1.54%
Senior Unsecured Note | Maximum
Debt Instrument
Interest Rate	6.91%
Mortgage Debt
Debt Instrument
2022	$ 2,541
2023	90,089
2024	7,024
2025	3,209
2026	244,523
Thereafter	366
Total debt before discount, net	347,752	$ 350,000
(Discounts), premium and debt costs, net	1,577
Long-term debt	$ 349,329
Weighted-average interest rate (as a percent)	4.28%
Weighted-average maturity (in years)	3 years
Mortgage Debt | Interest Rate 2022
Debt Instrument
Interest Rate	3.80%
Mortgage Debt | Interest Rate 2023
Debt Instrument
Interest Rate	3.80%
Mortgage Debt | Interest Rate 2024
Debt Instrument
Interest Rate	4.28%
Mortgage Debt | Interest Rate 2025
Debt Instrument
Interest Rate	3.80%
Mortgage Debt | Interest Rate 2026
Debt Instrument
Interest Rate	4.48%
Mortgage Debt | Interest Rate Thereafter
Debt Instrument
Interest Rate	5.91%
Mortgage Debt | Minimum
Debt Instrument
Interest Rate	3.42%
Mortgage Debt | Maximum
Debt Instrument
Interest Rate	5.91%

XML

Commitments and Contingencies (Details)	Jun. 30, 2022 property
Life Science JV | Life Science
Loss Contingencies [Line Items]
Investment ownership percentage	49.00%
Indemnification Agreement
Loss Contingencies [Line Items]
Number of properties may be contributed in the agreement	29

XML

Equity and Redeemable Noncontrolling Interests - Additional Information (Details)			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended		24 Months Ended
	Jul. 28, 2022 $ / shares	Apr. 30, 2021 USD ($)	May 31, 2021 USD ($)	Jun. 30, 2022 $ / shares shares	Jun. 30, 2021 $ / shares shares	Jun. 30, 2022 USD ($) interest $ / shares shares	Jun. 30, 2021 $ / shares shares	Dec. 31, 2022 interest	Dec. 31, 2021 USD ($) interest $ / shares shares	Dec. 31, 2024 interest	Aug. 01, 2022 USD ($)
Class of Stock [Line Items]
Dividends declared (in dollars per share) | $ / shares				$ 0.30	$ 0.30	$ 0.60	$ 0.60
Dividends paid (in dollars per share) | $ / shares				$ 0.30	$ 0.30	$ 0.60	$ 0.60
Number of redeemable noncontrolling interest redemptions | interest									1
Payments for repurchase of redeemable noncontrolling interest | $									$ 60,000,000
Number of interests redeemable over time | interest						3
Forecast
Class of Stock [Line Items]
Number of interests redeemable over time | interest								1		2
Subsequent Event
Class of Stock [Line Items]
Dividends declared (in dollars per share) | $ / shares	$ 0.30
Stock repurchase program, authorized amount | $											$ 500,000,000
2020 ATM Program
Class of Stock [Line Items]
ATM aggregate amount authorized | $		$ 1,250,000,000	$ 1,500,000,000
ATM aggregate amount remaining | $						$ 1,180,000,000
Maximum shares issuable under forward equity sales agreement (in shares) | shares									9,100,000
Forward equity sales agreement, initial net price (in usd per share) | $ / shares									$ 35.25
At-The-Market Program | Minimum
Class of Stock [Line Items]
Option indexed to issuers equity, term (in years)						1 year
At-The-Market Program | Maximum
Class of Stock [Line Items]
Option indexed to issuers equity, term (in years)						2 years
2020 ATM Program, Settled
Class of Stock [Line Items]
Share settlement (in shares) | shares				0		0
Remainder outstanding (in shares) | shares				9,100,000		9,100,000
ATM Direct Issuances | Common Stock
Class of Stock [Line Items]
Issuance of common stock, net (in shares) | shares				0	0	0	0

XML

Equity and Redeemable Noncontrolling Interests - AOCI (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Loss
Unrealized gains (losses) on derivatives, net	$ 1,629	$ 0
Supplemental Executive Retirement Plan minimum liability	(2,947)	(3,147)
Total accumulated other comprehensive income (loss)	$ (1,318)	$ (3,147)

XML

Earnings Per Common Share - Narrative (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares - forward equity agreements (in shares)	0	0	0	0
Shares of anti-dilutive securities excluded from earnings per share calculation (in shares)	9,100,000		9,100,000
Down REIT
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares of anti-dilutive securities excluded from earnings per share calculation (in shares)	7,000,000		7,000,000	7,000,000

XML

Earnings Per Common Share - Computation of EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator
Income (loss) from continuing operations	$ 69,301	$ 168,065	$ 144,327	$ 47,480
Noncontrolling interests' share in continuing operations	(3,955)	(3,535)	(7,685)	(6,841)
Income (loss) from continuing operations attributable to Healthpeak Properties, Inc.	65,346	164,530	136,642	40,639
Less: Participating securities' share in continuing operations	(281)	(287)	(2,258)	(2,732)
Income (loss) from continuing operations applicable to common shares	65,065	164,243	134,384	37,907
Income (loss) from discontinued operations	2,992	113,960	3,309	383,968
Noncontrolling interests' share in discontinued operations	0	(2,210)	0	(2,539)
Net income (loss) applicable to common shares	68,057	275,993	137,693	419,336
Add: distributions on dilutive convertible units and other	0	1,540	0	0
Dilutive net income (loss) available to common shares	$ 68,057	$ 277,533	$ 137,693	$ 419,336
Denominator
Basic weighted average shares outstanding (in shares)	539,558,000	538,929,000	539,456,000	538,805,000
Dilutive potential common shares - equity awards (in shares)	257,000	264,000	245,000	276,000
Dilutive potential common shares - DownREIT conversions (in shares)	0	5,501,000	0	0
Diluted weighted average common shares (in shares)	539,815,000	544,694,000	539,701,000	539,081,000
Basic earnings (loss) per common share
Continuing operations (in dollars per share)	$ 0.12	$ 0.30	$ 0.25	$ 0.07
Discontinued operations (in dollars per share)	0.01	0.21	0.01	0.71
Net income (loss) applicable to common shares (in dollars per share)	0.13	0.51	0.26	0.78
Diluted earnings (loss) per common share
Continuing operations (in dollars per share)	0.12	0.30	0.25	0.07
Discontinued operations (in dollars per share)	0.01	0.21	0.01	0.71
Net income (loss) applicable to common shares (in dollars per share)	$ 0.13	$ 0.51	$ 0.26	$ 0.78
Outstanding equity awards (in shares)	1,000,000	1,000,000	1,000,000	1,000,000
Shares of anti-dilutive securities excluded from earnings per share calculation (in shares)	9,100,000		9,100,000
Forward sales agreements that have been settled (in shares)		0		0
Total common shares attributable to REIT conversions		7,000,000

XML

Segment Disclosures - Summary Information for the Reportable Segments (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) property	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) property	Jun. 30, 2021 USD ($)
Segment Disclosure
Number of facilities owned by unconsolidated joint venture | property		19		19
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		$ 517,932	$ 476,238	$ 1,016,304	$ 931,514
Government grant income		209	87	6,762	1,397
Less: Interest income		(5,493)	(16,108)	(10,987)	(25,121)
Healthpeak’s share of unconsolidated joint venture total revenues		20,243	21,277	40,451	44,570
Healthpeak’s share of unconsolidated joint venture government grant income			583	648	1,009
Noncontrolling interests’ share of consolidated joint venture total revenues		(9,005)	(8,900)	(17,882)	(17,891)
Operating expenses		(215,044)	(190,132)	(422,291)	(371,893)
Healthpeak’s share of unconsolidated joint venture operating expenses		(14,934)	(15,404)	(29,771)	(33,463)
Noncontrolling interests’ share of consolidated joint venture operating expenses		2,745	2,573	5,366	5,097
Adjustments to NOI		(24,539)	(13,170)	(42,206)	(26,771)
Adjusted NOI		272,114	257,044	546,394	508,448
Plus: Adjustments to NOI		24,539	13,170	42,206	26,771
Interest income		5,493	16,108	10,987	25,121
Interest expense		(41,867)	(38,681)	(79,453)	(85,524)
Depreciation and amortization		(180,489)	(171,459)	(358,222)	(328,997)
General and administrative		(24,781)	(24,088)	(48,612)	(48,990)
Transaction costs		(612)	(619)	(908)	(1,417)
Impairments and loan loss reserves		(139)	(931)	(271)	(4,173)
Gain (loss) on sales of real estate, net		10,340	175,238	14,196	175,238
Gain (loss) on debt extinguishments		0	(60,865)	0	(225,157)
Other income (expense), net		2,861	1,734	21,177	3,934
Less: Government grant income		(209)	(87)	(6,762)	(1,397)
Less: Healthpeak’s share of unconsolidated joint venture NOI		(5,309)	(6,456)	(11,328)	(12,116)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		6,260	6,327	12,516	12,794
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		68,201	166,435	141,920	44,535
Income tax benefit (expense)		718	763	(59)	755
Equity income (loss) from unconsolidated joint ventures		382	867	2,466	2,190
Income (loss) from continuing operations		69,301	168,065	144,327	47,480
Income (loss) from discontinued operations		2,992	113,960	3,309	383,968
Net income (loss)		72,293	282,025	147,636	431,448
Corporate Non-segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		0	0	0	0
Government grant income		0	0	0	0
Less: Interest income		0	0	0	0
Healthpeak’s share of unconsolidated joint venture total revenues		0	0	0	0
Healthpeak’s share of unconsolidated joint venture government grant income			0	0	0
Noncontrolling interests’ share of consolidated joint venture total revenues		0	0	0	0
Operating expenses		0	0	0	0
Healthpeak’s share of unconsolidated joint venture operating expenses		0	0	0	0
Noncontrolling interests’ share of consolidated joint venture operating expenses		0	0	0	0
Adjustments to NOI		0	0	0	0
Adjusted NOI		0	0	0	0
Plus: Adjustments to NOI		0	0	0	0
Interest income		0	0	0	0
Interest expense		(38,061)	(35,923)	(72,746)	(80,651)
Depreciation and amortization		0	0	0	0
General and administrative		(24,781)	(24,088)	(48,612)	(48,990)
Transaction costs		(443)	0	(443)	0
Impairments and loan loss reserves		0	0	0	0
Gain (loss) on sales of real estate, net		0	0	0	0
Gain (loss) on debt extinguishments			(60,865)		(225,157)
Other income (expense), net		920	1,716	1,828	3,532
Less: Government grant income		0	0	0	0
Less: Healthpeak’s share of unconsolidated joint venture NOI		0	0	0	0
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		0	0	0	0
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		(62,365)	(119,160)	(119,973)	(351,266)
Income tax benefit (expense)		718	763	(59)	755
Equity income (loss) from unconsolidated joint ventures		0	0	0	0
Income (loss) from continuing operations		(61,647)	(118,397)	(120,032)	(350,511)
Income (loss) from discontinued operations		2,992	113,960	3,309	383,968
Net income (loss)		(58,655)	(4,437)	(116,723)	33,457
Life Science
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Gain (loss) on sales of real estate, net	$ 4,000
Life Science | Operating Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		207,771	177,527	401,826	347,461
Government grant income		0	0	0	0
Less: Interest income		0	0	0	0
Healthpeak’s share of unconsolidated joint venture total revenues		1,267	1,412	2,698	2,749
Healthpeak’s share of unconsolidated joint venture government grant income			0	0	0
Noncontrolling interests’ share of consolidated joint venture total revenues		(62)	(75)	(119)	(140)
Operating expenses		(49,446)	(40,724)	(97,635)	(80,185)
Healthpeak’s share of unconsolidated joint venture operating expenses		(483)	(428)	(966)	(853)
Noncontrolling interests’ share of consolidated joint venture operating expenses		19	21	38	41
Adjustments to NOI		(21,644)	(12,366)	(35,756)	(24,176)
Adjusted NOI		137,422	125,367	270,086	244,897
Plus: Adjustments to NOI		21,644	12,366	35,756	24,176
Interest income		0	0	0	0
Interest expense		0	(48)	0	(150)
Depreciation and amortization		(79,673)	(76,955)	(157,811)	(145,388)
General and administrative		0	0	0	0
Transaction costs		(35)	21	(327)	(11)
Impairments and loan loss reserves		0	0	0	0
Gain (loss) on sales of real estate, net		0	0	3,856	0
Gain (loss) on debt extinguishments			0		0
Other income (expense), net		29	28	20	33
Less: Government grant income		0	0	0	0
Less: Healthpeak’s share of unconsolidated joint venture NOI		(784)	(984)	(1,732)	(1,896)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		43	54	81	99
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		78,646	59,849	149,929	121,760
Income tax benefit (expense)		0	0	0	0
Equity income (loss) from unconsolidated joint ventures		148	111	1,114	18
Income (loss) from continuing operations		78,794	59,960	151,043	121,778
Income (loss) from discontinued operations		0	0	0	0
Net income (loss)		78,794	59,960	151,043	121,778
Medical Office
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Gain (loss) on sales of real estate, net		10,000
Medical Office | Operating Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		179,308	165,295	356,571	325,496
Government grant income		0	0	0	0
Less: Interest income		0	0	0	0
Healthpeak’s share of unconsolidated joint venture total revenues		761	710	1,493	1,425
Healthpeak’s share of unconsolidated joint venture government grant income			0	0	0
Noncontrolling interests’ share of consolidated joint venture total revenues		(8,943)	(8,825)	(17,763)	(17,751)
Operating expenses		(63,321)	(54,648)	(124,491)	(105,769)
Healthpeak’s share of unconsolidated joint venture operating expenses		(301)	(317)	(600)	(611)
Noncontrolling interests’ share of consolidated joint venture operating expenses		2,726	2,552	5,328	5,056
Adjustments to NOI		(2,949)	(2,003)	(6,495)	(3,926)
Adjusted NOI		107,281	102,764	214,043	203,920
Plus: Adjustments to NOI		2,949	2,003	6,495	3,926
Interest income		0	0	0	0
Interest expense		(1,930)	(786)	(2,966)	(881)
Depreciation and amortization		(68,873)	(63,371)	(136,646)	(121,326)
General and administrative		0	0	0	0
Transaction costs		(70)	35	(74)	(295)
Impairments and loan loss reserves		0	0	0	0
Gain (loss) on sales of real estate, net		10,340	175,238	10,340	175,238
Gain (loss) on debt extinguishments			0		0
Other income (expense), net		1,264	(175)	12,201	(2,454)
Less: Government grant income		0	0	0	0
Less: Healthpeak’s share of unconsolidated joint venture NOI		(460)	(393)	(893)	(814)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		6,217	6,273	12,435	12,695
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		56,718	221,588	114,935	270,009
Income tax benefit (expense)		0	0	0	0
Equity income (loss) from unconsolidated joint ventures		211	137	411	328
Income (loss) from continuing operations		56,929	221,725	115,346	270,337
Income (loss) from discontinued operations		0	0	0	0
Net income (loss)		56,929	221,725	115,346	270,337
CCRC | Operating Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		125,360	117,308	246,920	233,436
Government grant income		209	87	6,762	1,397
Less: Interest income		0	0	0	0
Healthpeak’s share of unconsolidated joint venture total revenues		0	2,415	0	6,903
Healthpeak’s share of unconsolidated joint venture government grant income			0	333	199
Noncontrolling interests’ share of consolidated joint venture total revenues		0	0	0	0
Operating expenses		(102,277)	(94,760)	(200,165)	(185,939)
Healthpeak’s share of unconsolidated joint venture operating expenses		0	(2,208)	0	(6,953)
Noncontrolling interests’ share of consolidated joint venture operating expenses		0	0	0	0
Adjustments to NOI		0	1,226	0	1,246
Adjusted NOI		23,292	24,068	53,850	50,289
Plus: Adjustments to NOI		0	(1,226)	0	(1,246)
Interest income		0	0	0	0
Interest expense		(1,876)	(1,924)	(3,741)	(3,842)
Depreciation and amortization		(31,943)	(31,133)	(63,765)	(62,283)
General and administrative		0	0	0	0
Transaction costs		(64)	(657)	(64)	(1,090)
Impairments and loan loss reserves		0	0	0	0
Gain (loss) on sales of real estate, net		0	0	0	0
Gain (loss) on debt extinguishments			0		0
Other income (expense), net		630	165	7,141	2,341
Less: Government grant income		(209)	(87)	(6,762)	(1,397)
Less: Healthpeak’s share of unconsolidated joint venture NOI		0	(207)	(333)	(149)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		0	0	0	0
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		(10,170)	(11,001)	(13,674)	(17,377)
Income tax benefit (expense)		0	0	0	0
Equity income (loss) from unconsolidated joint ventures		0	639	539	639
Income (loss) from continuing operations		(10,170)	(10,362)	(13,135)	(16,738)
Income (loss) from discontinued operations		0	0	0	0
Net income (loss)		(10,170)	(10,362)	(13,135)	(16,738)
Other Non-reportable | Operating Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Total revenues		5,493	16,108	10,987	25,121
Government grant income		0	0	0	0
Less: Interest income		(5,493)	(16,108)	(10,987)	(25,121)
Healthpeak’s share of unconsolidated joint venture total revenues		18,215	16,740	36,260	33,493
Healthpeak’s share of unconsolidated joint venture government grant income			583	315	810
Noncontrolling interests’ share of consolidated joint venture total revenues		0	0	0	0
Operating expenses		0	0	0	0
Healthpeak’s share of unconsolidated joint venture operating expenses		(14,150)	(12,451)	(28,205)	(25,046)
Noncontrolling interests’ share of consolidated joint venture operating expenses		0	0	0	0
Adjustments to NOI		54	(27)	45	85
Adjusted NOI		4,119	4,845	8,415	9,342
Plus: Adjustments to NOI		(54)	27	(45)	(85)
Interest income		5,493	16,108	10,987	25,121
Interest expense		0	0	0	0
Depreciation and amortization		0	0	0	0
General and administrative		0	0	0	0
Transaction costs		0	(18)	0	(21)
Impairments and loan loss reserves		(139)	(931)	(271)	(4,173)
Gain (loss) on sales of real estate, net		0	0	0	0
Gain (loss) on debt extinguishments			0		0
Other income (expense), net		18	0	(13)	482
Less: Government grant income		0	0	0	0
Less: Healthpeak’s share of unconsolidated joint venture NOI		(4,065)	(4,872)	(8,370)	(9,257)
Plus: Noncontrolling interests’ share of consolidated joint venture NOI		0	0	0	0
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		5,372	15,159	10,703	21,409
Income tax benefit (expense)		0	0	0	0
Equity income (loss) from unconsolidated joint ventures		23	(20)	402	1,205
Income (loss) from continuing operations		5,395	15,139	11,105	22,614
Income (loss) from discontinued operations		0	0	0	0
Net income (loss)		$ 5,395	$ 15,139	$ 11,105	$ 22,614

XML

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Supplemental cash flow information:
Interest paid, net of capitalized interest	$ 74,327	$ 109,277
Income taxes paid (refunded)	(612)	4,026
Capitalized interest	16,320	10,867
Supplemental schedule of non-cash investing and financing activities:
Increase in ROU asset in exchange for new lease liability related to operating leases	508	13,157
Seller financing provided on disposition of real estate asset	0	559,745
Accrued construction costs	163,391	113,221
Vesting of restricted stock units and conversion of non-managing member units into common stock	803	900
Carrying value of mortgages assumed by buyer in real estate dispositions	$ 0	$ 106,632

XML

Supplemental Cash Flow Information - Summary of Cash Flow Information Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Leasing costs, tenant improvements, and recurring capital expenditures			$ 50,745	$ 43,132
Development, redevelopment, and other major improvements of real estate			366,404	281,829
Depreciation and amortization of real estate, in-place lease, and other intangibles	$ 180,489	$ 171,459	358,222	328,997
Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Leasing costs, tenant improvements, and recurring capital expenditures			21	2,349
Development, redevelopment, and other major improvements of real estate			18	4,569
Depreciation and amortization of real estate, in-place lease, and other intangibles			$ 0	$ 0

XML

Supplemental Cash Flow Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Continuing operations
Cash and cash equivalents	$ 73,013	$ 158,287	$ 96,923	$ 44,226
Restricted cash	54,815	53,454	129,052	67,206
Cash, cash equivalents and restricted cash	127,828	211,741	225,975	111,432
Discontinued operations
Cash and cash equivalents	8,070	7,707	17,354	53,085
Restricted cash	0	0	974	17,168
Cash, cash equivalents and restricted cash	8,070	7,707	18,328	70,253
Cash and cash equivalents, total	81,083	165,994	114,277	97,311
Restricted cash, total	54,815	53,454	130,026	84,374
Cash, cash equivalents and restricted cash, total	$ 135,898	$ 219,448	$ 244,303	$ 181,685

XML

Variable Interest Entities - Narrative (Details) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended
	Dec. 31, 2021 USD ($) joint_venture	Jun. 30, 2022 USD ($) joint_venture property	Mar. 31, 2022 property	Jun. 30, 2022 USD ($) joint_venture	Dec. 31, 2021 USD ($) joint_venture property
Variable Interest Entity [Line Items]
Exchange accommodation titleholder, real estate, carrying value | $	$ 77	$ 66		$ 66	$ 77
Unconsolidated Variable Interest Entities
Variable Interest Entity [Line Items]
Number of unconsolidated joint ventures (in joint ventures)	2	2		2	2
Number of VIE borrowers with marketable debt securities (in joint ventures)	1	1		1	1
Ventures V
Variable Interest Entity [Line Items]
VIE ownership percentage				51.00%
Life Science JV
Variable Interest Entity [Line Items]
VIE ownership percentage				99.00%
MSREI JV
Variable Interest Entity [Line Items]
VIE ownership percentage				51.00%
DownREIT Partnerships
Variable Interest Entity [Line Items]
Number of controlling ownership interest entities as a managing member				7
Life Science | Needham Land Parcel JV
Variable Interest Entity [Line Items]
Investment ownership percentage	38.00%	38.00%		38.00%	38.00%
Payments to acquire equity method investment | $	$ 13
Medical Office Buildings
Variable Interest Entity [Line Items]
Number of properties acquired | property		1	2		2

XML

Variable Interest Entities - Schedule of Variable Interest Entities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
CMBS and LLC investment
Variable Interest Entity [Line Items]
Maximum Loss Exposure and Carrying Amount	$ 36,599
Needham Land Parcel JV
Variable Interest Entity [Line Items]
Maximum Loss Exposure and Carrying Amount	$ 14,831

XML

Variable Interest Entities - Consolidated Assets and Liabilities of VIEs (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
ASSETS
Buildings and improvements	$ 12,590,403	$ 12,025,271
Development costs and construction in progress	675,713	877,423
Land	2,705,260	2,603,964
Accumulated depreciation and amortization	(3,097,748)	(2,839,229)
Net real estate	12,873,628	12,667,429
Accounts receivable, net	47,340	48,691
Cash and cash equivalents	73,013	158,287	$ 96,923	$ 44,226
Intangible assets, net	470,865	519,760
Assets held for sale and discontinued operations, net	66,647	37,190
Right-of-use asset, net	233,391	233,942
Other assets, net	682,388	674,615
Total assets	15,318,203	15,257,519
Liabilities
Mortgage debt	349,329	352,081
Intangible liabilities, net	169,622	177,232
Liabilities related to assets held for sale and discontinued operations, net	15,869	15,056
Lease liability	201,124	204,547
Accounts payable, accrued liabilities, and other liabilities	706,819	755,384
Deferred revenue	814,754	789,207
Total liabilities	8,361,938	8,111,415
Consolidated Lessees VIE
ASSETS
Buildings and improvements	2,331,975	2,303,920
Development costs and construction in progress	138,655	82,303
Land	510,096	548,168
Accumulated depreciation and amortization	(592,488)	(551,097)
Net real estate	2,388,238	2,383,294
Accounts receivable, net	3,933	5,455
Cash and cash equivalents	37,274	22,295
Restricted cash	211	114
Intangible assets, net	106,855	117,180
Assets held for sale and discontinued operations, net	216	754
Right-of-use asset, net	108,390	107,993
Other assets, net	66,610	62,886
Total assets	2,711,727	2,699,971
Liabilities
Mortgage debt	144,451	144,350
Intangible liabilities, net	27,410	23,909
Liabilities related to assets held for sale and discontinued operations, net	1,668	1,677
Lease liability	98,666	99,213
Accounts payable, accrued liabilities, and other liabilities	69,143	58,440
Deferred revenue	25,431	21,546
Total liabilities	366,769	349,135
Consolidated Lessees VIE | Discontinued Operations
ASSETS
Accounts receivable, net	0	62
Cash and cash equivalents	153	59
Other assets, net	63	633
Total assets	216	754
Liabilities
Liabilities related to assets held for sale and discontinued operations, net	1,668	1,677
Total liabilities	$ 1,668	$ 1,677

XML

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Summary of financial instruments
Bank line of credit and commercial paper	$ 1,448,569	$ 1,165,975
Senior unsecured notes	4,655,852	4,651,933
Mortgage debt	349,329	352,081
Carrying Value
Summary of financial instruments
Loans receivable, net	413,962	415,811
Marketable debt securities	21,345	21,003
Bank line of credit and commercial paper	1,448,569	1,165,975
Senior unsecured notes	4,655,852	4,651,933
Mortgage debt	349,329	352,081
Carrying Value | Interest rate swap instruments
Summary of financial instruments
Interest rate cap assets	1,629	0
Carrying Value | Interest rate cap instruments
Summary of financial instruments
Interest rate cap assets	0	397
Fair Value | Level 1
Summary of financial instruments
Senior unsecured notes	4,360,241	5,054,747
Fair Value | Level 2
Summary of financial instruments
Loans receivable, net	432,914	437,607
Marketable debt securities	21,345	21,003
Bank line of credit and commercial paper	1,448,569	1,165,975
Mortgage debt	339,356	352,800
Fair Value | Level 2 | Interest rate swap instruments
Summary of financial instruments
Interest rate cap assets	1,629	0
Fair Value | Level 2 | Interest rate cap instruments
Summary of financial instruments
Interest rate cap assets	$ 0	$ 397

XML

Derivative Financial Instruments - Narrative (Details) $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended
	Apr. 30, 2021 USD ($) property	Mar. 31, 2021 USD ($) derivativeHeld property	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Apr. 30, 2022 derivativeHeld	Dec. 31, 2021 derivativeHeld	May 31, 2021 property	Apr. 30, 2021 USD ($)	Apr. 30, 2021 derivativeHeld	Apr. 30, 2021 instrument
Derivative [Line Items]
Asset at fair value, changes in fair value resulting from changes in assumptions				$ 5.0
Interest rate swap instruments
Derivative [Line Items]
Number of interest-rate contracts held | derivativeHeld						0
Interest rate swap instruments | Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Number of interest-rate contracts held | derivativeHeld					2
Interest rate cap instruments | Not Designated as Hedging Instrument
Derivative [Line Items]
Number of interest-rate contracts held									2	2
Increase in the fair value of the interest rate cap agreements			$ 0.1	$ 2.0
Derivative amount terminated								$ 142.0
Mortgage Debt
Derivative [Line Items]
Repayments of secured debt	$ 64.0	$ 39.0
Number of assets classified as discontinued operations | property	2	2					6
Mortgage Debt | Interest rate swap instruments
Derivative [Line Items]
Number of interest rate derivatives terminated | derivativeHeld		2

XML

Derivative Financial Instruments - Schedule of Derivative Instruments (Details)	Jun. 30, 2022 USD ($)	Apr. 30, 2022 derivativeHeld	Dec. 31, 2021 USD ($) derivativeHeld	Apr. 30, 2021 derivativeHeld	Apr. 30, 2021 instrument
Interest rate swap instruments
Derivative [Line Items]
Number of interest-rate contracts held | derivativeHeld			0
Interest rate swap instruments | Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Number of interest-rate contracts held | derivativeHeld		2
Interest Rate Swap, 5.08% Pay Rate | Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Notional Amount	$ 51,100,000
Pay Rate	5.08%
Receive Rate	2.50%
Fair Value	$ 586,000		$ 0
Interest Rate Swap, 4.63% Pay Rate | Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Notional Amount	$ 91,000,000
Pay Rate	4.63%
Receive Rate	2.05%
Fair Value	$ 1,043,000		0
Interest rate cap instruments | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount			$ 142,100,000
Pay Rate			2.00%
Fair Value	$ 0		$ 397,000
Number of interest-rate contracts held				2	2

XML

Accounts Payable, Accrued Liabilities, and Other Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Payables and Accruals [Abstract]
Refundable entrance fees	$ 275,152		$ 275,152		$ 288,409
Accrued construction costs	163,391		163,391		179,995
Accrued interest	59,092		59,092		59,342
Other accounts payable and accrued liabilities	209,184		209,184		227,638
Accounts payable, accrued liabilities, and other liabilities	706,819		706,819		755,384
Unamortized nonrefundable entrance fee	508,000		508,000		$ 496,000
Proceeds from collection of nonrefundable entrance fees	29,000	$ 24,000	50,000	$ 38,000
Amortization of nonrefundable entrance fee	$ 19,000	$ 18,000	$ 38,000	$ 38,000